



STIC Search Report

EIC 1700

STIC Database Tracking Number: 145771

TO: Ben Sackey
Location: rem 5b31
Art Unit : 1626
March 4, 2005

Case Serial Number: 10/737210

From: Kathleen Fuller
Location: EIC 1700
REMSEN 4B28
Phone: 571/272-2505
Kathleen.Fuller@uspto.gov

Search Notes

Don't be frightened by this stack. There were 679 structures but only 13 CA references from the structures. Most of the structures are to your applicant.



STIC Search Results Feedback Form

EIC17000

Questions about the scope or the results of the search? Contact *the EIC searcher* or contact:

Kathleen Fuller, EIC 1700 Team Leader
571/272-2505 REMSEN 4B28

Voluntary Results Feedback Form

➤ I am an examiner in Workgroup: Example: 1713

➤ Relevant prior art **found**, search results used as follows:

- ☐ 102 rejection
- ☐ 103 rejection
- ☐ Cited as being of interest.
- ☐ Helped examiner better understand the invention.
- ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
(journal articles, conference proceedings, new product announcements etc.)

➤ Relevant prior art **not found**:

- ☐ Results verified the lack of relevant prior art (helped determine patentability).
- ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to EIC1700 REMSEN 4B28



Ms Fuller

Access DB# 145771

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: BEN LACEY Examiner #: 13499 Date: 2/18/05
Art Unit: 1626 Phone Number 202-6704 Serial Number: 10/737,210
Mail Box and Bldg/Room Location: REM 5B31 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc. if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.


Title of Invention: Substituted acid derivatives useful as antidiabetic ^{agents} & anti-obesity

Inventors (please provide full names): Peter Cheng et al.

Earliest Priority Filing Date: 09/22/99

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

A method for lowering blood glucose levels or for treating diabetes or treating an early malignant and malignant disease, dysplastic condition, compound of structure:



Substituents are as defined in claim 36.

② Also pharmaceutical combination of claim 37 employing additional agents.

Thanks

STAFF USE ONLY		Type of Search	Vendors and cost where applicable
Searcher: <u>A. Fuller</u>	NA Sequence (#) _____	STN <input checked="" type="checkbox"/>	
Searcher Phone #: _____	AA Sequence (#) _____	Dialog _____	
Searcher Location: _____	Structure (#) <u>1</u>	Questel/Orbit _____	
Date Searcher Picked Up: _____	Bibliographic _____	Dr.Link _____	
Date Completed: <u>3/4/05</u>	Litigation _____	Lexis/Nexis _____	
Searcher Prep & Review Time: <u>30</u>	Fulltext _____	Sequence Systems _____	
Clerical Prep Time: _____	Patent Family _____	WWW/Internet _____	
Online Time: <u>30</u>	Other _____	Other (specify) _____	

=> FILE REG

FILE 'REGISTRY' ENTERED AT 15:32:14 ON 04 MAR 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 MAR 2005 HIGHEST RN 841200-41-7

DICTIONARY FILE UPDATES: 2 MAR 2005 HIGHEST RN 841200-41-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> FILE HCAPLU

FILE 'HCAPLU' ENTERED AT 15:32:18 ON 04 MAR 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Mar 2005 VOL 142 ISS 11



FILE LAST UPDATED: 3 Mar 2005 (20050303/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> D QUE

L8

STR



VAR G1=C/N
 VAR G2=O/S
 VAR G3=3/4/5
 REP G4=(0-1) O
 NODE ATTRIBUTES:
 NSPEC IS RC AT 22
 DEFAULT MLEVEL IS ATOM
 GGCAT IS MCY UNS AT 15
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE

L11 679 SEA FILE=REGISTRY SSS FUL L8
 L13 13 SEA FILE=HCAPLUS ABB=ON L11

*679 structures from
 this query*

*13 CA references
 from the structures*

=> D L13 BIB ABS IND HITSTR 1-13

L13 ANSWER 1 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2005:14148 HCAPLUS
 DN 142:107413
 TI Combination therapy for the treatment of dyslipidemia
 IN Erond, Ngozi E.; Fong, Tung M.; MacNeil, Douglas J.; Van Der Ploeg,
 Leonardus H. T.
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 106 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005000217	A2	20050106	WO 2004-US17120	20040602
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,				

SN, TD, TG

PRAI US 2003-476387P P 20030606

AB The invention relates to compns. comprising an anti-obesity agent and an anti-dyslipidemic agent useful for the treatment of dyslipidemia, dyslipidemia associated with obesity and dyslipidemia-related disorders. The invention further relates to methods of treating or preventing obesity, and obesity-related disorders, in a subject in need thereof by administering a composition of the present invention. The invention further provides pharmaceutical compns., medicaments, and kits useful in carrying out these methods.

IC ICM A61K

CC 1-10 (Pharmacology)
Section cross-reference(s): 2, 15, 63

ST antiobesity antidyslipidemic antihistamine antidiabetic ghrelin antibody
obesity dyslipidemia disease

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(melanin-concentrating hormone 2 receptor) MCH-2R; combination therapy for treatment of dyslipidemia)

IT Uncoupling protein
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(1; combination therapy for treatment of dyslipidemia)

IT Uncoupling protein
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(2; combination therapy for treatment of dyslipidemia)

IT Uncoupling protein
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(3; combination therapy for treatment of dyslipidemia)

IT Adenosine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(A2; combination therapy for treatment of dyslipidemia)

IT Cholecystokinin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CCKA; combination therapy for treatment of dyslipidemia)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FLAP (arachidonate lipooxygenase-activating protein); combination therapy for treatment of dyslipidemia)

IT Nuclear receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FXR (farnesoid X receptor); combination therapy for treatment of dyslipidemia)

IT Histamine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(H3, inverse agonist; combination therapy for treatment of dyslipidemia)

IT Lipoprotein receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(LDL; combination therapy for treatment of dyslipidemia)

IT Nuclear receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(LXR; combination therapy for treatment of dyslipidemia)

IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MCH-1R (melanin concentrating hormone receptor 1); combination therapy for treatment of dyslipidemia)

IT VIP receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(VIP2; combination therapy for treatment of dyslipidemia)

IT Neuropeptide receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Y5; combination therapy for treatment of dyslipidemia)

IT Neuropeptide Y receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Y1; combination therapy for treatment of dyslipidemia)

IT Neuropeptide Y receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Y2; combination therapy for treatment of dyslipidemia)

IT Estrogens
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(acyl-; combination therapy for treatment of dyslipidemia)

IT Angiotensin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(angiotensin II; combination therapy for treatment of dyslipidemia)

IT Heart, disease
(attack; combination therapy for treatment of dyslipidemia)

IT Ion channel blockers
(calcium; combination therapy for treatment of dyslipidemia)

IT Drug delivery systems
(carriers; combination therapy for treatment of dyslipidemia)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cholesterol ester-exchanging; combination therapy for treatment of
dyslipidemia)

IT Antidiabetic agents
Antihistamines
Antihypertensives
Antiobesity agents
Antioxidants
Atherosclerosis
Blood serum
Body weight
Diabetes mellitus
Diet
Diuretics
Drug interactions
Feeding
Human
Hypercholesterolemia
Hypertension
Hypertriglyceridemia
Hypolipemic agents
Obesity
Opioid antagonists
Oxidative stress, biological
Platelet aggregation inhibitors
Renin-angiotensin system
Transcription, genetic
Vasodilators
(combination therapy for treatment of dyslipidemia)

IT Bile acids
Endothelin receptors
Fatty acids, biological studies
Glucagon-like peptide-1 receptors
Glucocorticoid receptors
Lipoproteins
Monoamines

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(combination therapy for treatment of dyslipidemia)

IT Ciliary neurotrophic factor
Sulfonylureas
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(combination therapy for treatment of dyslipidemia)

IT Artery, disease
(coronary; combination therapy for treatment of dyslipidemia)

IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dicarboxylate transporter; combination therapy for treatment of
dyslipidemia)

IT Lipids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dyslipidemia; combination therapy for treatment of dyslipidemia)

IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(fatty acid transporter; combination therapy for treatment of
dyslipidemia)

IT Antibodies and Immunoglobulins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(ghrelin; combination therapy for treatment of dyslipidemia)

IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(glucose transporter; combination therapy for treatment of
dyslipidemia)

IT Lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(high-d.; combination therapy for treatment of dyslipidemia)

IT Lipids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hyperlipidemia; combination therapy for treatment of dyslipidemia)

IT Heart, disease
(left ventricle, hypertrophy; combination therapy for treatment of
dyslipidemia)

IT Hypertrophy
(left ventricular; combination therapy for treatment of dyslipidemia)

IT Diuretics
(loop; combination therapy for treatment of dyslipidemia)

IT Lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(low-d.; combination therapy for treatment of dyslipidemia)

IT Pituitary hormone receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(melanocortin receptor 3; combination therapy for treatment of
dyslipidemia)

IT Pituitary hormone receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(melanocortin receptor 4; combination therapy for treatment of
dyslipidemia)

IT Biological transport
(microsomal triglyceride; combination therapy for treatment of
dyslipidemia)

IT Glycerides, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(microsomal; combination therapy for treatment of dyslipidemia)

IT Transport proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(norepinephrine transporter; combination therapy for treatment of
dyslipidemia)

IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(phosphate transporter; combination therapy for treatment of
dyslipidemia)

IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(serotonin transporter; combination therapy for treatment of
dyslipidemia)

IT Brain, disease
(stroke; combination therapy for treatment of dyslipidemia)

IT Drug delivery systems
(suspensions; combination therapy for treatment of dyslipidemia)

IT Microsome
(triglyceride transport; combination therapy for treatment of
dyslipidemia)

IT 5-HT receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type 5-HT₂, c; combination therapy for treatment of dyslipidemia)

IT Bombesin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type BB₃; combination therapy for treatment of dyslipidemia)

IT Pituitary adenylate cyclase-activating polypeptide receptor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type III; combination therapy for treatment of dyslipidemia)

IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α ; combination therapy for treatment of dyslipidemia)

IT Adrenoceptor antagonists
(β -; combination therapy for treatment of dyslipidemia)

IT Thyroid hormone receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β ; combination therapy for treatment of dyslipidemia)

IT Adrenoceptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β ₃; combination therapy for treatment of dyslipidemia)

IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(δ ; combination therapy for treatment of dyslipidemia)

IT 9014-34-0, Stearoyl CoA desaturase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(1; combination therapy for treatment of dyslipidemia)

IT 9023-93-2, Acetyl-CoA carboxylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(2; combination therapy for treatment of dyslipidemia)

IT 141869-53-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(Pradimicin Q; combination therapy for treatment of dyslipidemia)

IT 50-99-7, D-Glucose, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(blood; combination therapy for treatment of dyslipidemia)

IT 50-67-9, Serotonin, biological studies 51-41-2, Norepinephrine
52-39-1, Aldosterone 57-88-5, Cholesterol, biological studies 59-67-6,
Niacin, biological studies 7440-09-7, Potassium, biological studies
9000-90-2 9001-42-7, α Glucoside hydrolase 9001-51-8,
Glucokinase 9001-62-1, Lipase 9004-10-8, Insulin, biological studies

9025-82-5, Phosphodiesterase 9027-44-5, HMG-CoA synthase 9027-63-8, Acyl coenzyme A -cholesterol acyl transferase 9028-35-7, HMG-CoA reductase 9029-62-3, Squalene epoxidase 9041-46-7, 11.β-Hydroxysteroid dehydrogenase, type 1 9045-77-6, Fatty-acid synthase 9077-14-9, Squalene synthetase 54249-88-6, Dipeptidyl peptidase-IV 80619-02-9, 5-Lipoxygenase 82707-54-8, Neutral endopeptidase 116243-73-3, Endothelin 245359-74-4, Orexin 300865-11-6, Protein tyrosine phosphatase 1B 304853-26-7, Ghrelin RL: BSU (Biological study, unclassified); BIOL (Biological study)

(combination therapy for treatment of dyslipidemia)

IT 51-64-9, Dextroamphetamine 52-01-7, Spironolactone 52-53-9, Verapamil 54-31-9, Furosemide 58-54-8, Ethacrynic acid 58-93-5, Hydrochlorothiazide 58-94-6, Chlorothiazide 58-94-6D, Thiazide, compds. 64-77-7, Tolbutamide 77-36-1, Chlorothalidone 83-46-5, β-Sitosterol 86-54-4, Hydralazine 90-84-6, Diethylpropion 94-20-2, Diabinese 100-55-0, Nicotiny alcohol 114-86-3, Phenformin 120-97-8, Dichlorophenamide 122-09-8, Phentermine 134-49-6, Phenmetrazine 135-09-1, Hydroflumethiazide 156-08-1, Benzphetamine; 156-34-3, Levamfetamine 300-62-9, Amphetamine 396-01-0, Triamterene 434-43-5, Pentorex 457-87-4, N-Ethylamphetamine 458-24-2, Fenfluramine 461-78-9 525-66-6, Propranolol 532-52-5, Cyclexedrine 537-46-2, Methamphetamine 634-03-7, Phendimetrazine 657-24-9, Metformin 692-13-7, Buformin 720-76-3, Fluminorex 968-81-0, Acetohexamide 1156-19-0, Tolazamide 2207-50-3, Aminorex 2609-46-3, Amiloride 3239-44-9, Dexfenfluramine 3876-10-6, Clominorex 3930-20-9, Sotalol 4205-90-7, Clonidine 4378-36-3, Fenbutrazate 5051-62-7, Guanabenz 8049-62-5, Insulin zinc suspension 9004-10-8D, Insulin, derivs. 9035-55-6, Adiposin 10238-21-8, Glibenclamide 10389-73-8, Clortermine 13364-32-4, Clobenzorex 13445-60-8, Furfurylmethylamphetamine 13523-86-9, Pindolol 13862-07-2, Diphemethoxidine 14261-75-7, Cloforex 14838-15-4, Phenylpropanolamine 15221-81-5, Fludorex 15351-09-4, Metamfepramone 16397-28-7, Fenproporex 16662-47-8, Gallopamil 17243-57-1, Mefenorex 19216-56-9, Prazosin 21187-98-4, Gliclazide 21829-25-4, Nifedipine 22232-71-9, Mazindol 24477-37-0, Glisolamide 24558-01-8, Levophacetoperane 26807-65-8, Indapamide 26839-75-8, Timolol 26844-12-2, Indoramin 28395-03-1 29094-61-9, Glipizide 29122-68-7, Atenolol 31036-80-3, Lofexidine 31428-61-2, Tiamenidine 32797-92-5, Glipentide 33342-05-1, Gliquidone 34661-75-1, Urapidil 34887-52-0, Fenisorex 35795-16-5, Trimazosin 36393-56-3, Norpseudoephedrine 37517-30-9, Acebutolol 38304-91-5, Minoxidil 38363-40-5, Penbutolol 39562-70-4, Nitrendipine 42200-33-9, Nadolol 42399-41-7, Diltiazem 51384-51-1 51781-06-7, Carteolol 54187-04-1, Rilmidenidine 55985-32-5, Nicardipine 56180-94-0, Acarbose 56211-40-6, Torsemide 56980-93-9, Celiprolol 57149-07-2, Naftopidil 59170-23-9, Bevantolol 60607-68-3, Indenolol 62510-56-9, Picilorex 62571-86-2, Captopril 62658-63-3, Bopindolol 63590-64-7, Terazosin 63659-18-7, Betaxolol 63675-72-9, Nisoldipine 64706-54-3, Bepridil 66085-59-4, Nimodipine 66529-17-7, Midaglizole 66722-44-9, Bisoprolol 68291-97-4, Zonisamide 68377-92-4, Arotinolol 69567-10-8, MOR 14 72432-03-2, Miglitol 72509-76-3, Felodipine 72956-09-3, Carvedilol 74191-85-8, Doxazosin 74772-77-3, Ciglitazone 75330-75-5, Lovastatin 75358-37-1, Linoglriride 75438-57-2, Moxonidine 75530-68-6, Nilvadipine 75695-93-1, Isradipine 75847-73-3, Enalapril 76547-98-3, Lisinopril 79902-63-9, Simvastatin 79944-58-4, Idazoxan 80755-51-7, Bunazosin 80879-63-6, Emiglitate 81093-37-0, Pravastatin 81147-92-4, Esmolol 81486-22-8, Nipradilol 81872-10-8, Zofenopril 82768-85-2, Quinaprilat 82834-16-0, Perindopril 83435-66-9, Delapril 83480-29-9, Voglibose 83647-97-6, Spirapril 83688-84-0, Tertatolol 85136-71-6, Tilisolol 85320-68-9, Amosulalol 85441-61-8, Quinapril 86541-75-5, Benazepril

86596-25-0, Tendamistat 86596-26-1, Trestatin 86780-90-7, Aranidipine
 87333-19-5, Ramipril 87679-37-6, Trandolapril 88150-42-9, Amlodipine
 88431-47-4, Clomoxir 88768-40-5, Cilazapril 89197-32-0, Efaroxan
 89226-50-6, Manidipine 89371-37-9, Imidapril 93479-97-1, Glimepiride
 93957-54-1, Fluvastatin 94739-29-4, Lemildipine 97240-79-4, Topiramate
 97322-87-7, Troglitazone 98048-97-6, Fosinopril 99522-79-9,
 Pranidipine 99759-19-0, Tiqueside 100427-26-7, Lercanidipine
 103775-10-6, Moexipril 103890-78-4, Lacidipine 104343-33-1, MDL-25637
 104713-75-9, Barnidipine 105182-45-4, Fluparoxan 105816-04-4,
 Nateglinide 105979-17-7, Benidipine 106612-94-6, 7-37-Glucagon-like
 peptide I (human) 107444-51-9 107724-20-9, Eplerenone 109229-58-5,
 Englitazone 110605-64-6, Isaglidole 111011-63-3, Efonidipine
 111025-46-8, Pioglitazone 111902-57-9, Temocapril 112573-73-6,
 Ecadotril 114798-26-4, Losartan 116094-23-6, Novorapid 116372-01-1,
 LG-100641 118457-14-0, Nebivolol 122320-73-4, Rosiglitazone
 122830-14-2, Deriglidole 123122-55-4, Candoxatril 123524-52-7,
 Azelnidipine 124083-20-1, Etomoxir 127214-23-7, Camiglibose
 128826-89-1, Salbostatin 129981-36-8, Sampatrilat 132203-70-4
 133040-01-4, Eprosartan 133107-64-9, Insulin lispro 134523-00-5,
 Atorvastatin 135038-57-2, Fasidotril 135062-02-1, Repaglinide
 137862-53-4, Valsartan 138402-11-6, Irbesartan 139481-59-7,
 Candesartan 141200-24-0, Darglitazone 143201-11-0, Rivastatin
 144689-24-7, RNH6270 144701-48-4, Telmisartan 145599-86-6,
 Cerivastatin 145733-36-4, Tasosartan 147511-69-1 153804-05-8,
 Pratosartan 160337-95-1, Insulin glargine 161600-01-7, Isaglitazone
 163222-33-1, Ezetimibe 167221-71-8, Clevidipine 167305-00-2,
 Omapatrilat 169148-63-4, Insulin detemir 169494-85-3, Leptin
 170861-63-9, JT 501 177785-17-0, SB 219994 180384-57-0, Tezosentan
 194608-80-5, L-796449 196808-24-9, GW1929 196808-45-4, Farglitazar
 213252-19-8, KRP-297 227941-61-9, GW-2433 249886-47-3, CLX 0921
 256532-03-3, WHIP 164 287714-41-4, ZD 4522 328231-96-5 328231-97-6
 328231-98-7 328231-99-8 328232-00-4 328232-01-5 328232-02-6
 328232-03-7 328232-04-8 328232-05-9 328232-07-1 328232-08-2
 328232-09-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(combination therapy for treatment of dyslipidemia)

IT 328232-10-6 328232-11-7 328232-12-8 328232-13-9 328232-14-0
 328232-16-2 328232-17-3 328232-18-4 328232-19-5 328232-20-8
 328232-21-9 328232-22-0 328232-23-1 328232-25-3 328232-26-4
 328232-27-5 328232-28-6 328232-30-0 328232-31-1 328232-32-2
 328232-33-3 328232-34-4 328232-35-5 328232-36-6 328232-37-7
 328232-38-8 328232-39-9 328232-40-2 328232-41-3 328232-42-4
 328232-43-5 328232-44-6 328232-45-7 328232-46-8 328232-47-9
 328232-48-0 328232-49-1 328232-50-4 328232-51-5 328232-52-6
 328232-53-7 328232-54-8 328232-55-9 328232-56-0 328232-57-1
 328232-58-2 328232-59-3 328232-60-6 328232-61-7 328232-62-8
 328232-63-9 328232-64-0 328232-65-1 328232-66-2 328232-67-3
 328232-68-4 328232-69-5 328232-70-8 328232-71-9 328232-72-0
 328232-73-1 328232-74-2 328232-75-3 328232-76-4 328232-77-5
 328232-78-6 328232-79-7 328232-80-0 328232-81-1 328232-82-2
 328232-83-3 328232-84-4 328232-85-5 328232-86-6 328232-87-7
 328232-88-8 328232-89-9 328232-90-2 328232-91-3 328232-92-4
 328232-93-5 328232-94-6 328232-95-7 328232-96-8 328232-97-9
 328232-98-0 328232-99-1 328233-00-7 331741-94-7,
 Muraglitazar 400607-95-6, GW 0207 445010-62-8, CKD-711 478014-42-5
 478014-43-6 478014-44-7 478014-45-8 540534-85-8, Amphechloral
 669764-02-7, AVE7688 812697-69-1, LY 300512 812697-77-1, LP 100
 812697-78-2, CLX 0940 812697-79-3, GW 1536 812697-87-3, ER 4030

812697-90-8, A 308165 812697-92-0, YM 62899 812697-93-1, EXP 3137
 812697-96-4, XEN 010 820234-09-1, 5BTZD 820234-13-7, Al 3688
 820234-31-9, FI 6828K

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(combination therapy for treatment of dyslipidemia)

IT 9015-82-1

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; combination therapy for treatment of dyslipidemia)

IT 9029-98-5, Acyl CoA:diacylglycerol acyltransferase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(isoforms 1 and 2; combination therapy for treatment of dyslipidemia)


IT 331741-94-7, Muraglitazar

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(combination therapy for treatment of dyslipidemia)

RN 331741-94-7 HCAPLUS

CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



L13 ANSWER 2 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:1124581 HCAPLUS

DN 142:69181

TI Combination therapy for the treatment of hypertension

IN Fong, Tung M.; Erondy, Ngozi E.; Macneil, Douglas J.; McIntyre, James H.;
 Van Der Ploeg, Leonardus H. T.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004110368	A2	20041223	WO 2004-US17090	20040602
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				
	EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,				
	SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,				
	SN, TD, TG				
PRAI	US 2003-476390P	P	20030606		

AB The present invention relates to compns. comprising an anti-obesity agent and an anti-hypertensive agent useful for the treatment of hypertension, hypertension associated with obesity, and hypertension-related disorders. The present invention further relates to methods of treating or preventing obesity, and obesity-related disorders, in a subject in need thereof by administering a composition of the present invention. The present invention further provides for pharmaceutical compns., medicaments, and kits useful in carrying out these methods.

IC ICM A61K

CC 1-8 (Pharmacology)

Section cross-reference(s): 2

ST hypertension combination treatment antiobesity antihypertensive agent

IT Uncoupling protein

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(1, activators; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)

IT Uncoupling protein

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(2, activators; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)

IT Uncoupling protein

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(3, activators; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)

IT 5-HT agonists

(5-HT_{2C}; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)

IT Purinoceptor antagonists

(A₂; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)

IT Cholecystokinin receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CCKA, agonists; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FLAP (arachidonate lipoxygenase-activating protein), inhibitors; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)

IT Nuclear receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FXR (farnesoid X receptor), modulators; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)

IT G protein-coupled receptors

Hormone receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(GHS-R (growth hormone secretagogue receptor), agonists; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)

IT Histamine receptors

- RL: BSU (Biological study, unclassified); BIOL (Biological study)
(H3, inverse agonists; combination therapy of hypertension and
hypertension-related disorders using antiobesity agent and
antihypertensive agent and other agents and antihypertensive agent)
- IT Antihistamines
(H3; combination therapy of hypertension and hypertension-related
disorders using antiobesity agent and antihypertensive agent and other
agents and antihypertensive agent)
- IT Lipoprotein receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(LDL, inducers; combination therapy of hypertension and
hypertension-related disorders using antiobesity agent and
antihypertensive agent and other agents and antihypertensive agent)
- IT Steroid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(LXR (liver X receptor), modulators; combination therapy of
hypertension and hypertension-related disorders using antiobesity agent
and antihypertensive agent and other agents and antihypertensive agent)
- IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MCH-1R (melanin concentrating hormone receptor 1), antagonists; combination
therapy of hypertension and hypertension-related disorders using
antiobesity agent and antihypertensive agent and other agents and
antihypertensive agent)
- IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MCH-2R (melanin concentrating hormone receptor 2), agonists/antagonists;
combination therapy of hypertension and hypertension-related disorders
using antiobesity agent and antihypertensive agent and other agents and
antihypertensive agent)
- IT VIP receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(VIP1, agonists; combination therapy of hypertension and
hypertension-related disorders using antiobesity agent and
antihypertensive agent and other agents and antihypertensive agent)
- IT Neuropeptide Y receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Y1, antagonists; combination therapy of hypertension and
hypertension-related disorders using antiobesity agent and
antihypertensive agent and other agents and antihypertensive agent)
- IT Neuropeptide Y receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Y2, agonists; combination therapy of hypertension and
hypertension-related disorders using antiobesity agent and
antihypertensive agent and other agents and antihypertensive agent)
- IT Neuropeptide Y receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Y5, antagonists; combination therapy of hypertension and
hypertension-related disorders using antiobesity agent and
antihypertensive agent and other agents and antihypertensive agent)
- IT Angiotensin receptor antagonists
(angiotensin II; combination therapy of hypertension and
hypertension-related disorders using antiobesity agent and
antihypertensive agent and other agents and antihypertensive agent)
- IT Heart, disease
(attack; combination therapy of hypertension and hypertension-related
disorders using antiobesity agent and antihypertensive agent and other
agents and antihypertensive agent)
- IT Ion channel blockers

(calcium; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)

IT Hypertrophy
(cardiac; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)

IT Drug delivery systems
(carriers; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cholesterol ester-exchanging, inhibitors; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)

IT 5-HT reuptake inhibitors
Antidiabetic agents
Antihypertensives
Antiobesity agents
Antioxidants
Combination chemotherapy
Diuretics
Drug interactions
Heart, disease
Human
Hypertension
Obesity
Opioid antagonists
Platelet aggregation inhibitors
Vasodilators
(combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)

IT Ciliary neurotrophic factor
Sulfonylureas
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)

IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dicarboxylate transporter, inhibitors; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)

IT Lipids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dyslipidemia, inhibitors; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)

IT Heart, disease
Kidney, disease
(failure; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)

IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(fatty acid transporter, inhibitors; combination therapy of

- hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (for niacin, agonists; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (glucose transporter, inhibitors; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Estrogens
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (hydroxy, esters; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Heart, disease
(hypertrophy; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Renin-angiotensin system
(inhibitors; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Glucocorticoids
RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitors; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Heart, disease
(left ventricle, hypertrophy; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Hypertrophy
(left ventricular; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Pituitary hormone receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (melanocortin receptor 3, agonists; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Pituitary hormone receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (melanocortin receptor 4, agonists; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Disease, animal
(metabolic syndrome X; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Transcription, genetic
(modulators; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Nervous system agents
(noradrenaline reuptake inhibitors; combination therapy of hypertension

- and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (norepinephrine transporter, inhibitors; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Fatty acids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study) (oxidation inhibitors; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (phosphate transporter, inhibitors; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Monoamines
RL: BSU (Biological study, unclassified); BIOL (Biological study) (reuptake inhibitors; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Bile acids
RL: BSU (Biological study, unclassified); BIOL (Biological study) (sequestrants and absorption inhibitors; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (serotonin transporter, inhibitors; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Sterols
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (stanols, esters; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Glycosides
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (steroidal; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Brain, disease
(stroke; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Glycerides, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study) (synthesis and microsomal transport, inhibitors; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (synthesis, inhibitors; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Antibodies and Immunoglobulins

- RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(to ghrelin; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Bombesin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type BB3, agonists; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Cannabinoid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type CB1, agonists and inverse agonists; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Pituitary adenylate cyclase-activating polypeptide receptor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type II, agonists; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α , agonists; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Adrenoceptor antagonists
(α -; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Adrenoceptor antagonists
(α 1-; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Adrenoceptor agonists
(α 2-, α 2a; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Thyroid hormone receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β , agonists; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Adrenoceptor antagonists
(β -; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Adrenoceptor antagonists
(β 3-; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(γ , agonists; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)
- IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(δ , agonists and partial agonists; combination therapy of hypertension and hypertension-related disorders using antiobesity agent

and antihypertensive agent and other agents and antihypertensive agent)

IT 9029-98-5, Diacylglycerol acyltransferase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(1 and 2, inhibitors; combination therapy of hypertension and
hypertension-related disorders using antiobesity agent and
antihypertensive agent and other agents and antihypertensive agent)

IT 9014-34-0
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(1, inhibitors; combination therapy of hypertension and
hypertension-related disorders using antiobesity agent and
antihypertensive agent and other agents and antihypertensive agent)

IT 9023-93-2
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(2, inhibitors; combination therapy of hypertension and
hypertension-related disorders using antiobesity agent and
antihypertensive agent and other agents and antihypertensive agent)

IT 444313-53-5, Vytorin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(Mixt containing Ezetimibe/Simvastin; combination therapy of hypertension
and hypertension-related disorders using antiobesity agent and
antihypertensive agent and other agents and antihypertensive agent)

IT 141869-53-6, Pradimicin Q
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(Pradimicin Q; combination therapy of hypertension and
hypertension-related disorders using antiobesity agent and
antihypertensive agent and other agents and antihypertensive agent)

IT 57-88-5, Cholesterol, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(absorption inhibitors; combination therapy of hypertension and
hypertension-related disorders using antiobesity agent and
antihypertensive agent and other agents and antihypertensive agent)

IT 9001-51-8, Glucokinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(activators; combination therapy of hypertension and
hypertension-related disorders using antiobesity agent and
antihypertensive agent and other agents and antihypertensive agent)

IT 116243-73-3, Endothelin 245359-74-4, Orexin 304853-26-7, Ghrelin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; combination therapy of hypertension and
hypertension-related disorders using antiobesity agent and
antihypertensive agent and other agents and antihypertensive agent)

IT 328232-26-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(combination therapy of hypertension and hypertension-related disorders
using antiobesity agent and antihypertensive agent and other agents)

IT 51-64-9, Dextroamphetamine 56-03-1D, Biguanide, derivs. 59-67-6,
Niacin, biological studies 64-77-7, Tolbutamide 83-46-5,
 β -Sitosterol 90-84-6, Diethylpropion 94-20-2, Chloropropamide
114-86-3, Phenformin 122-09-8, Phentermine 134-49-6, Phenmetrazine
156-08-1, Benzphetamine 156-34-3, Levamfetamine 300-62-9, Amphetamine
434-43-5, Pentorex 457-87-4, N-Ethylamphetamine 458-24-2, Fenfluramine
461-78-9, Chlorphentermine 532-52-5, Cyclexedrine 537-46-2,
Methamphetamine 634-03-7, Phendimetrazine 637-07-0, Clofibrate
657-24-9, Metformin 692-13-7, Buformin 720-76-3, Fluminorex
943-45-3D, Fibrin acid, derivs. 968-81-0, Acetohexamide 1156-19-0,
Tolazamide 2207-50-3, Aminorex 2295-31-0D, Glitazone, derivs.

3239-44-9, Dexfenfluramine 3876-10-6, Clominoxone 4378-36-3,
Fenbutrazate 8049-62-5, Insulin zinc 8075-95-4, Atromid 9004-10-8,
Insulin, biological studies 9004-54-0D, Dextran, crosslinked,
dialkylaminoalkyl derivs., biological studies 9028-35-7, HMG-CoA
reductase 9035-55-6, Adiposin 10238-21-8, Glibenclamide 10389-73-8,
Clortermine 11041-12-6, Cholestyramine 13364-32-4, Clobenzorex
13445-60-8, Furfurylmethylamphetamine 13862-07-2, Diphenmethoxidine
14261-75-7, Cloforex 14838-15-4, Phenylpropanolamine 15221-81-5,
Fludorex 15351-09-4, Metamfepramone 16397-28-7, Fenproporex
17243-57-1, Mefenorex 21187-98-4, Gliclazide 22232-71-9, Mazindol
23288-49-5, Probucol 24477-37-0, Glisolamide 24558-01-8,
Levophacetoperane 25812-30-0, Gemfibrozil 29094-61-9, Glipizide
31637-97-5, Etofibrate 32797-92-5, Glipentide 33321-31-2 33342-05-1,
Gliquidone 34887-52-0, Fenisorex 36393-56-3, Norpseudoephedrine
37296-80-3, Colestid 41859-67-0 42017-89-0, Fenofibric acid
49562-28-9, Tricor 50925-79-6, Colestipol 52214-84-3, Ciprofibrate
54870-28-9D, Meglitinide, derivs. 55121-56-7D, Azetidinone, derivs.
56180-94-0, Acarbose 62510-56-9, Picilorex 66529-17-7, Midaglizole
68291-97-4, Zonisamide 69567-10-8, MOR 14 71548-66-8, Beclofibrate
72432-03-2, Miglitol 74772-77-3, Ciglitazone 75330-75-5, Lovastatin
75847-73-3, Enalapril 79902-63-9, Simvastatin 79944-58-4, Idazoxan
80879-63-6, Emiglitate 81093-37-0, Pravastatin 83480-29-9, Voglibose
86596-25-0, Tendamistat 86596-26-1, Trestatin 88431-47-4, Clomoxir
89197-32-0, Efaroxan 93479-97-1, Glimepiride 93957-54-1, Fluvastatin
97240-79-4, Topiramate 97322-87-7, Troglitazone 99759-19-0, Tiqueside
104343-33-1, MDL-25637 105182-45-4, Fluparoxan 105816-04-4,
Nateglinide 106612-94-6, 7-37-Glucagon-like peptide I (human)
107444-51-9 109229-58-5, Englitazone 110605-64-6, Isaglidole
111025-46-8, Pioglitazone 116094-23-6, Novorapid 116372-01-1,
LG-100641 122320-73-4, Rosiglitazone 122830-14-2, Deriglidole
124083-20-1, Etomoxir 127214-23-7, Camiglibose 128826-89-1,
Salbostatin 133107-64-9, Insulin lispro 134523-00-5, Atorvastatin
135062-02-1, Repaglinide 141200-24-0, Darglitazone 143201-11-0,
Rivastatin 147511-69-1 151165-96-7, S8921 160337-95-1, Insulin
glargine 161600-01-7, Isaglitazone 163222-33-1, Ezetimibe
166518-60-1, Avasimibe 169148-63-4, Insulin detemir 169494-85-3,
Leptin 169494-85-3D, Leptin, derivs. 170861-63-9, JT 501
177469-96-4, Implipapide 177785-17-0, SB 219994 182815-43-6,
Colesevelam 183293-82-5, Gemcabene 186390-48-7, CP346086
194608-80-5, L-796449 196808-24-9, GW1929 196808-45-4, Farglitazar
202340-45-2, Eflucimibe 211513-37-0, JTT 705 213252-19-8, KRP-297
221564-97-2, BM 170744 227941-61-9, GW-2433 245075-84-7, LR-90
249886-47-3, CLX 0921 256397-11-2, LAB 687 262352-17-0, Torcetrapib
265129-71-3, GW 7647 278779-30-9, GW 4064 287714-41-4, ZD 4522
289037-67-8, SC435 315229-16-4, SC 795 317318-70-0, GW 501516
331741-94-7, Muraglitazar 400607-95-6, GW 0207 405911-09-3, GW
3965 430433-43-5, CP 644673 445010-62-8, CKD-711 540534-85-8,
Amphechloral 622402-22-6, GW 590735 812696-88-1, KY 505 812697-02-2,
SMP 797 812697-40-8, CP 532632 812697-41-9, BAY 63-2149 812697-42-0,
SC 591 812697-51-1, LY 518674 812697-56-6, SR 103912 812697-59-9, T
9013137 812697-65-7, XTCO 179628 812697-66-8, BARI 1453 812697-67-9,
PHA 384640 812697-68-0, AZD 7706 812697-69-1, LY 300512 812697-76-0,
A 1-3688 812697-77-1, LP 100 812697-78-2, CLX 0940 812697-79-3, GW
1536

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(combination therapy of hypertension and hypertension-related disorders
using antiobesity agent and antihypertensive agent and other agents and
antihypertensive agent)

IT 52-39-1, Aldosterone 9000-90-2, α -Amylase 9001-42-7,
 α -Glucoside hydrolase 9001-62-1, Lipase 9015-82-1 9027-44-5,
HMG-CoA synthase 9027-63-8, Acyl coenzyme A-cholesterol acyl transferase
9029-62-3, Squalene epoxidase 9040-59-9, 3',5'-Cyclic nucleotide
phosphodiesterase 9041-46-7, 11 β Hydroxysteroid dehydrogenase 1
9045-77-6, Fatty acid synthase 9077-14-9, Squalene synthetase
80619-02-9, 5-Lipoxygenase 82707-54-8, Neutral endopeptidase
300865-11-6, Protein tyrosine phosphatase-1B

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibitors; combination therapy of hypertension and
hypertension-related disorders using antiobesity agent and
antihypertensive agent and other agents and antihypertensive agent)

IT 328231-96-5 328231-97-6 328231-98-7 328231-99-8 328232-00-4
328232-01-5 328232-02-6 328232-03-7 328232-04-8 328232-05-9
328232-07-1 328232-08-2 328232-09-3 328232-10-6 328232-11-7
328232-12-8 328232-13-9 328232-14-0 328232-16-2 328232-17-3
328232-18-4 328232-19-5 328232-20-8 328232-21-9 328232-22-0
328232-23-1 328232-25-3 328232-27-5 328232-28-6 328232-30-0
328232-31-1 328232-32-2 328232-33-3 328232-34-4 328232-35-5
328232-36-6 328232-37-7 328232-38-8 328232-39-9 328232-40-2
328232-41-3 328232-42-4 328232-43-5 328232-44-6 328232-45-7
328232-46-8 328232-47-9 328232-48-0 328232-49-1 328232-50-4
328232-53-7 328232-54-8 328232-55-9 328232-56-0 328232-57-1
328232-58-2 328232-59-3 328232-60-6 328232-61-7 328232-62-8
328232-63-9 328232-64-0 328232-65-1 328232-66-2 328232-67-3
328232-68-4 328232-69-5 328232-70-8 328232-71-9 328232-72-0
328232-73-1 328232-74-2 328232-75-3 328232-76-4 328232-77-5
328232-78-6 328232-79-7 328232-80-0 328232-81-1 328232-83-3
328232-84-4 328232-85-5 328232-86-6 328232-87-7 328232-88-8
328232-89-9 328232-90-2 328232-91-3 328232-92-4 328232-93-5
328232-94-6 328233-00-7 478014-42-5 478014-43-6 478014-44-7
478014-45-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(neuropeptide Y Y5 receptor antagonist; combination therapy of
hypertension and hypertension-related disorders using antiobesity agent
and antihypertensive agent and other agents)

IT 6508-43-6 328232-95-7 328232-96-8 328232-97-9 328232-98-0
328232-99-1 478014-55-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(neuropeptide Y Y5 receptor antagonist; combination therapy of
hypertension and hypertension-related disorders using antiobesity agent
and antihypertensive agent and other agents and antihypertensive agent)


IT 331741-94-7, Muraglitazar

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(combination therapy of hypertension and hypertension-related disorders
using antiobesity agent and antihypertensive agent and other agents and
antihypertensive agent)


RN 331741-94-7 HCAPLUS

CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



- L13 ANSWER 3 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:965989 HCAPLUS
 TI Design and Synthesis of N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a Novel Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist with Efficacious Glucose and Lipid-Lowering Activities
 AU Devasthale, Pratik V.; Chen, Sean; Jeon, Yoon; Qu, Fucheng; Shao, Chunnging; Wang, Wei; Zhang, Hao; Farrelly, Dennis; Golla, Rajasree; Grover, Gary; Harrity, Thomas; Ma, Zhengping; Moore, Lisa; Ren, Jimmy; Seethala, Ramakrishna; Cheng, Lin; Slep, Paul; Sun, Wei; Tieman, Aaron; Wetterau, John R.; Doweiko, Arthur; Chandrasena, Gamini; Chang, Shu Y.; Humphreys, W. Griffith; Sasseville, Vito G.; Biller, Scott A.; Ryono, Denis E.; Selan, Fred; Hariharan, Narayanan; Cheng, Peter T. W.
 CS Metabolic Diseases Chemistry, Metabolic Diseases Biology, Macromolecular Structure, Metabolism and Pharmacokinetics, Drug Safety Evaluation, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-5400, USA
 SO Journal of Medicinal Chemistry ACS ASAP
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 AB Muraglitazar/BMS-298585 (I) has been identified as a non-thiazolidinedione PPAR α/γ dual agonist that shows potent activity in vitro at human PPAR α (EC₅₀ = 240 nM) and PPAR γ (EC₅₀ = 120 nM). I shows excellent efficacy for lowering glucose, insulin, triglycerides, and free fatty acids in genetically obese, severely diabetic db/db mice and has a favorable ADME profile. I is currently in clin. development for the treatment of type 2 diabetes and dyslipidemia.
 CC 34-2 (Amino Acids, Peptides, and Proteins)
 Section cross-reference(s): 1
 ST muraglitazar BMS298585 prepn PPAR dual agonist antidiabetic lipid lowering
 IT Lipids
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (dyslipidemia; preparation of BMS-298585 as a peroxisome proliferator-activated receptor α/γ dual agonist with glucose- and lipid-lowering activities)
 IT Diabetes mellitus
 (non-insulin-dependent; preparation of BMS-298585 as a peroxisome proliferator-activated receptor α/γ dual agonist with glucose- and lipid-lowering activities)
 IT Antidiabetic agents
 Human
 Hypolipemic agents
 (preparation of BMS-298585 as a peroxisome proliferator-activated receptor α/γ dual agonist with glucose- and lipid-lowering

- activities)
- IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α ; preparation of BMS-298585 as a peroxisome proliferator-activated receptor α/γ dual agonist with glucose- and lipid-lowering activities)
- IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(δ ; preparation of BMS-298585 as a peroxisome proliferator-activated receptor α/γ dual agonist with glucose- and lipid-lowering activities)
- IT 42017-89-0, Fenofibric acid 50892-23-4, WY-14643 122320-73-4, Rosiglitazone 190844-95-2, GW-2331 **331739-67-4**
RL: PAC (Pharmacological activity); BIOL (Biological study)
(preparation of BMS-298585 as a peroxisome proliferator-activated receptor α/γ dual agonist with glucose- and lipid-lowering activities)
- IT **331741-94-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of BMS-298585 as a peroxisome proliferator-activated receptor α/γ dual agonist with glucose- and lipid-lowering activities)
- IT 123-08-0, 4-Hydroxybenzaldehyde 5680-79-5, Methyl glycinate hydrochloride 7693-41-6 103788-65-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of BMS-298585 as a peroxisome proliferator-activated receptor α/γ dual agonist with glucose- and lipid-lowering activities)
- IT 103788-59-6P 227029-27-8P 331746-65-7P **331746-67-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of BMS-298585 as a peroxisome proliferator-activated receptor α/γ dual agonist with glucose- and lipid-lowering activities)
- IT **331739-67-4**
RL: PAC (Pharmacological activity); BIOL (Biological study)
(preparation of BMS-298585 as a peroxisome proliferator-activated receptor α/γ dual agonist with glucose- and lipid-lowering activities)
- RN 331739-67-4 HCAPLUS
- CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




- IT **331741-94-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(preparation of BMS-298585 as a peroxisome proliferator-activated receptor α/γ dual agonist with glucose- and lipid-lowering activities)

RN 331741-94-7 HCAPLUS

CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




IT 331746-67-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of BMS-298585 as a peroxisome proliferator-activated receptor α/γ dual agonist with glucose- and lipid-lowering activities)

RN 331746-67-9 HCAPLUS

CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:799479 HCAPLUS

DN 141:289040

TI Concomitant drug as therapeutic agent for inflammatory bowel disease

IN Horizoe, Tatsuo

PA Eisai Co., Ltd., Japan

SO PCT Int. Appl., 51 pp.

CODEN: PIXXD2.

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004082715	A1	20040930	WO 2004-JP3662	20040318

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

PRAI JP 2003-77467

A 20030320

AB Disclosed is a drug having enhanced efficacy against inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. In particular, disclosed is a therapeutic agent for inflammatory bowel diseases comprising active ingredient (a) consisting of at least one compound having inflammation inhibiting activity selected from the group consisting of an aminosalicyclic acid derivative, an antiinflammatory glucocorticoid, an immunosuppressive compound, an anti-TNF α antibody, a neurohypophysial hormone and an antiinfective compound, combined with active ingredient (b) consisting of at least one compound having PPAR γ agonist activity. In the application of this therapeutic agent for inflammatory bowel diseases, compound (a) and compound (b) can be administered simultaneously, sep. or with intervals. Thus, a compound 3-[3-[(3-trifluoromethoxybenzyloxycarbonylamino)methyl]phenyl]-2(S)-isopropoxypropanoic acid (3 mg/kg/day) and sulphasalazine (100 mg/kg/day) were administered to inflammatory bowel disease model mice to examine the effect of the combination.

IC ICM A61K045-00

ICS A61P001-04

CC 1-7 (Pharmacology)

Section cross-reference(s): 2, 63

ST PPAR γ agonist antiinflammatory agent combination inflammatory bowel disease

IT Inflammation

(Crohn's disease; concomitant drugs consisting of antiinflammatory agents and PPAR γ agonists as therapeutic agents for inflammatory bowel disease)

IT Intestine, disease

(Crohn's; concomitant drugs consisting of antiinflammatory agents and PPAR γ agonists as therapeutic agents for inflammatory bowel disease)

IT Tumor necrosis factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (anti-TNF α antibody; concomitant drugs consisting of antiinflammatory agents and PPAR γ agonists as therapeutic agents for inflammatory bowel disease)

IT Antibodies and Immunoglobulins

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (anti-TNF α antibody; concomitant drugs consisting of antiinflammatory agents and PPAR γ agonists as therapeutic agents for inflammatory bowel disease)

IT Anti-inflammatory agents

Antimicrobial agents

Human

Immunosuppressants

(concomitant drugs consisting of antiinflammatory agents and PPAR γ agonists as therapeutic agents for inflammatory bowel disease)

IT Glucocorticoids
Pituitary hormones
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(concomitant drugs consisting of antiinflammatory agents and
PPARy agonists as therapeutic agents for inflammatory bowel
disease)

IT Intestine, disease
(inflammatory; concomitant drugs consisting of antiinflammatory agents
and PPARy agonists as therapeutic agents for inflammatory bowel
disease)

IT Inflammation
Intestine, disease
(ulcerative colitis; concomitant drugs consisting of antiinflammatory
agents and PPARy agonists as therapeutic agents for inflammatory
bowel disease)


IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(y, agonists; concomitant drugs consisting of antiinflammatory
agents and PPARy agonists as therapeutic agents for inflammatory
bowel disease)

IT 50-04-4, Cortisone acetate 50-23-7, Hydrocortisone 50-24-8,
Prednisolone 50-44-2, 6-Mercaptopurine 53-03-2, Prednisone 59-05-2,
Methotrexate 69-53-4, Ampicillin 83-43-2, MethylPrednisolone
89-57-6, Mesalazine 378-44-9, Betamethasone 443-48-1, Metronidazole
446-86-6, Azathioprine 599-79-1, Sulphasalazine 15722-48-2, Olsalazine
25953-19-9, Cefazolin 32986-56-4, Tobramycin 51333-22-3, Budesonide
60189-34-6, Tetracosactideacetate 79217-60-0, Cyclosporin 80573-04-2,
Balsalazide 81103-11-9, Clarithromycin 82419-36-1, Ofloxacin
93107-08-5, Ciprofloxacin hydrochloride 100986-85-4, Levofloxacin
104987-11-3, Tacrolimus 111025-46-8, Pioglitazone 161600-01-7,
Netoglitazone 170277-31-3, Infliximab 185243-69-0, Etanercept
213252-19-8 251565-85-2, Tesaglitazar 331731-18-1, Adalimumab
331741-94-7 334010-93-4 334010-94-5 334011-75-5
336128-48-4, CDP-571 428863-50-7, CDP 870 467236-05-1 467236-11-9
470668-07-6 470668-33-8 478923-80-7 478925-95-0 478926-13-5
478926-16-8 478926-30-6 478926-36-2 478926-37-3 478926-39-5
478926-42-0 478926-43-1 478926-45-3 478926-48-6 478926-49-7
478926-51-1 478926-60-2 478926-87-3 478926-92-0 478927-11-6
478927-20-7 478929-06-5 478929-12-3 499788-20-4 560131-16-0
765300-31-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(concomitant drugs consisting of antiinflammatory agents and
PPARy agonists as therapeutic agents for inflammatory bowel
disease)

IT **331741-94-7**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(concomitant drugs consisting of antiinflammatory agents and
PPARy agonists as therapeutic agents for inflammatory bowel
disease)

RN 331741-94-7 HCAPLUS

CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:818314 HCAPLUS
DN 139:297051
TI Medicinal composition comprising ACAT inhibitor and insulin resistance improving agent
IN Inaba, Toshimori; Fujiwara, Toshihiko
PA Sankyo Company, Limited, Japan
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003084572	A1	20031016	WO 2003-JP4296	20030403
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2481379	AA	20031016	CA 2003-2481379	20030403
BR 2003008871	A	20050104	BR 2003-8871	20030403
EP 1493448	A1	20050105	EP 2003-745697	20030403
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2004002365	A2	20040108	JP 2003-101076	20030404
PRAI JP 2002-103134	A	20020405		
WO 2003-JP4296	W	20030403		

AB It is intended to provide a medicinal composition for preventing or treating arteriosclerosis or diseases caused by arteriosclerosis which comprises an ACAT inhibitor and an insulin resistance improving agent. For example, tablets were formulated containing 5-[[4-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione hydrochloride 50, N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide hemisulfate 10, lactose 113, starch 25, and Mg stearate 2 mg/tablet.

IC ICM A61K045-06
ICS A61K031-404; A61K031-427; A61K031-357; A61K031-496; A61K031-4439; A61K031-421; A61K031-4245; A61K031-426; A61K031-4709; A61K031-538; A61P009-00; A61P009-10

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1

ST antiarteriosclerotic ACAT inhibitor insulin resistance enhancer;
arteriosclerosis tablet benzimidazolylthiazolidinedione
indolinylopropanamide

IT Ischemia
(cardiac; medicinal composition comprising ACAT inhibitor and insulin
resistance improving agent)

IT Ischemia
(cerebral; medicinal composition comprising ACAT inhibitor and insulin
resistance improving agent)

IT Brain, disease
Heart, disease
(ischemia; medicinal composition comprising ACAT inhibitor and insulin
resistance improving agent)

IT Antiartherosclerotics
Artherosclerosis
(medicinal composition comprising ACAT inhibitor and insulin resistance
improving agent)

IT Circulation
(peripheral, disorder; medicinal composition comprising ACAT inhibitor and
insulin resistance improving agent)

IT Drug delivery systems
(tablets; medicinal composition comprising ACAT inhibitor and insulin
resistance improving agent)


IT 9004-10-8, Insulin, biological studies 9027-63-8, ACAT
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(medicinal composition comprising ACAT inhibitor and insulin resistance
improving agent)

IT 111025-46-8, Pioglitazone 118384-10-4, T 174 122320-73-4,
Rosiglitazone 143895-84-5, FR 129169 144288-97-1, HL 004
161600-01-7, MCC 555 162490-89-3, F 1394 166518-60-1, CI 1011
166967-85-7, NTE 122 170861-63-9, JTT 501 178469-71-1 179053-90-8,
FR 186054 179068-64-5, NC 2100 185428-18-6 189198-30-9
195315-05-0, T 2591 196808-45-4, GI 262570 199914-96-0, YM 440
202340-45-2, F 12511 213252-19-8, KRP 297 217094-22-9, K 10085
222834-21-1, NN 622 251565-85-2, AZ 242 299176-11-7
331741-94-7, BMS 298585 460358-05-8, FCE 28654 608510-47-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(medicinal composition comprising ACAT inhibitor and insulin resistance
improving agent)

IT 331741-94-7, BMS 298585
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(medicinal composition comprising ACAT inhibitor and insulin resistance
improving agent)

RN 331741-94-7 HCAPLUS

CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:396869 HCAPLUS

DN 138:401724

TI Preparation of carboxylic acid derivatives as peroxisome proliferator
activated receptor regulators

IN Tajima, Hisao; Nakayama, Yoshisuke

PA Ono Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 86 pp.


CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2003042194	A1	20030522	WO 2002-JP11729	20021111	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	EP 1445256	A1	20040811	EP 2002-803104	20021111	
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK		
	BR 2002014049	A	20041013	BR 2002-14049	20021111	
	US 2004254370	A1	20041216	US 2004-495158	20040511	
PRAI	JP 2001-346583	A	20011112			
	WO 2002-JP11729	W	20021111			
OS	MARPAT 138:401724					
GI						



- AB The title compds. I [X, Y = alkylene; Z = O, S; R1 - R4 = H, alkyl; R5 = alkenyl; A = O, S; D = Q1, etc.; ring A1 = saturated heteroaryl; R6 = H, alkyl, etc.; m = 1 - 3] are prepared I are useful in the treatment of diabetes, obesity, syndrome X, hypercholesterolemia, etc. The peroxisome proliferator activated receptor regulating activity of one compound of this invention was demonstrated. Formulations are given.
- IC ICM C07D263-32
ICS C07D277-42; C07D413-04; C07D413-10; C07D417-10; A61K031-421; A61K031-422; A61K031-427; A61K031-433; A61K031-4439; A61K031-454; A61K031-4545; A61K031-496; A61K031-497; A61K031-5355; A61K031-5377; A61K031-55; A61P003-00; A61P003-04; A61P003-06
- CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
- ST carboxylic acid deriv PPAR regulator prepn; diabetes treatment carboxylic acid deriv prepn; syndrome X treatment carboxylic acid deriv prepn; hypercholesterolemia treatment carboxylic acid deriv prepn
- IT Heart, disease
(cardiac syndrome X; preparation and bioeffect of carboxylic acid derivs. as peroxisome proliferator activated receptor regulators)
- IT Ischemia
(cardiac; preparation and bioeffect of carboxylic acid derivs. as peroxisome proliferator activated receptor regulators)
- IT Lipids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hyperlipidemia; preparation and bioeffect of carboxylic acid derivs. as peroxisome proliferator activated receptor regulators)
- IT Lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hyperlipoproteinemia; preparation and bioeffect of carboxylic acid derivs. as peroxisome proliferator activated receptor regulators)
- IT Appetite
(hyperphagia; preparation and bioeffect of carboxylic acid derivs. as peroxisome proliferator activated receptor regulators)
- IT Heart, disease
(ischemia; preparation and bioeffect of carboxylic acid derivs. as peroxisome proliferator activated receptor regulators)
- IT Anticholesteremic agents
Antidiabetic agents
Antihypertensives
Antiobesity agents
Arteriosclerosis
Cardiovascular agents
Cardiovascular system, disease
Diabetes mellitus
Human
Hypercholesterolemia
Hypertension

Obesity

- (preparation and bioeffect of carboxylic acid derivs. as peroxisome proliferator activated receptor regulators)
- IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation and bioeffect of carboxylic acid derivs. as peroxisome proliferator activated receptor regulators)
- IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α ; preparation and bioeffect of carboxylic acid derivs. as peroxisome proliferator activated receptor regulators)
- IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(γ ; preparation and bioeffect of carboxylic acid derivs. as peroxisome proliferator activated receptor regulators)
- IT 57-88-5, Cholesterol, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HDL cholesterol-elevating agents, LDL cholesterol and VLDL cholesterol-lowering agents; preparation and bioeffect of carboxylic acid derivs. as peroxisome proliferator activated receptor regulators)
- IT 530130-12-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and bioeffect of carboxylic acid derivs. as peroxisome proliferator activated receptor regulators)
- IT 530129-59-0P 530129-60-3P 530129-61-4P 530129-62-5P
530129-63-6P 530129-64-7P 530129-65-8P
530129-66-9P 530129-67-0P 530129-68-1P
530129-69-2P 530129-70-5P 530129-71-6P
530129-72-7P 530129-73-8P 530129-74-9P
530129-75-0P 530129-76-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of carboxylic acid derivs. as peroxisome proliferator activated receptor regulators)
- IT 530129-77-2P 530129-78-3P 530129-79-4P 530129-81-8P
530129-83-0P 530129-85-2P 530129-86-3P 530129-87-4P
530129-88-5P 530129-89-6P 530129-90-9P
530129-91-0P 530129-92-1P 530129-93-2P
530129-95-4P 530129-96-5P 530129-97-6P
530129-98-7P 530129-99-8P 530130-00-8P
530130-01-9P 530130-02-0P 530130-03-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of carboxylic acid derivs. as peroxisome proliferator activated receptor regulators)
- IT 98-59-9, Tosyl chloride 100-83-4, 3-Hydroxybenzaldehyde 107-30-2, Methoxymethyl chloride 108-24-7, Acetic anhydride 3182-79-4, N-Allylglycine ethyl ester 5326-23-8, 6-Chloronicotinic acid 100483-42-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of carboxylic acid derivs. as peroxisome proliferator activated receptor regulators)
- IT 13709-05-2P 81245-32-1P 530130-04-2P 530130-05-3P 530130-06-4P
530130-07-5P 530130-08-6P 530130-09-7P 530130-10-0P 530130-11-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation of carboxylic acid derivs. as peroxisome proliferator activated receptor regulators)


IT 530130-12-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and bioeffect of carboxylic acid derivs. as peroxisome proliferator activated receptor regulators)

RN 530130-12-2 HCAPLUS

CN Glycine, N-[[3-[2-[5-methyl-2-[4-(1,2,3-thiadiazol-4-yl)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]-N-2-propenyl- (9CI) (CA INDEX NAME)



IT 530129-59-0P 530129-62-5P 530129-63-6P

530129-64-7P 530129-66-9P 530129-67-0P

530129-68-1P 530129-69-2P 530129-70-5P

530129-71-6P 530129-72-7P 530129-73-8P


530129-74-9P 530129-76-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of carboxylic acid derivs. as peroxisome proliferator activated receptor regulators)


RN 530129-59-0 HCAPLUS

CN Glycine, N-[[3-[2-[2-[6-(hexahydro-1H-azepin-1-yl)-3-pyridinyl]-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-2-propenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 530129-62-5 HCAPLUS

CN Glycine, N-[[3-[2-[5-methyl-2-[4-(1,2,3-thiadiazol-4-yl)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]-N-2-propenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 530129-63-6 HCAPLUS

CN Glycine, N-[[3-[2-[2-(4-cyclohexylphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-2-propenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 530129-64-7 HCAPLUS

CN Glycine, N-[[3-[2-[5-methyl-2-[4-(tetrahydro-2H-pyran-4-yl)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]-N-2-propenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 530129-66-9 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-2-propenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 530129-67-0 HCAPLUS

CN Glycine, N-[[3-[2-[2-[6-(dimethylamino)-3-pyridinyl]-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-2-propenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 530129-68-1 HCAPLUS

CN Glycine, N-[[3-[2-[2-[4-(dimethylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-2-propenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 530129-69-2 HCAPLUS

CN Alanine, 2-methyl-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-2-propenyl-, methyl ester (9CI) (CA INDEX NAME)




RN 530129-70-5 HCAPLUS

CN Glycine, N-[[3-[2-[5-methyl-2-[6-(4-morpholinyl)-3-pyridinyl]-4-oxazolyl]ethoxy]phenyl]methyl]-N-2-propenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 530129-71-6 HCAPLUS

CN Glycine, N-[[3-[2-[5-methyl-2-[6-(1-piperidinyl)-3-pyridinyl]-4-oxazolyl]ethoxy]phenyl]methyl]-N-2-propenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 530129-72-7 HCAPLUS

CN Glycine, N-[[3-[2-[2-[6-(diethylamino)-3-pyridinyl]-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-2-propenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 530129-73-8 HCAPLUS

CN Glycine, N-[[3-[2-[5-methyl-2-[6-(1-pyrrolidinyl)-3-pyridinyl]-4-oxazolyl]ethoxy]phenyl]methyl]-N-2-propenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 530129-74-9 HCAPLUS

CN Glycine, N-[[3-[2-[5-methyl-2-[4-(4-morpholinyl)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]-N-2-propenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 530129-76-1 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-2-propenyl-, ethyl ester (9CI) (CA INDEX NAME)



IT 530129-77-2P 530129-81-8P 530129-83-0P

530129-85-2P 530129-88-5P 530129-89-6P

530129-90-9P 530129-91-0P 530129-92-1P

530129-93-2P 530129-95-4P 530129-96-5P

530129-97-6P 530129-98-7P 530129-99-8P

530130-00-8P 530130-03-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of carboxylic acid derivs. as peroxisome proliferator activated receptor regulators)

RN 530129-77-2 HCAPLUS


CN Glycine, N-[[3-[2-[2-[6-(hexahydro-1H-azepin-1-yl)-3-pyridinyl]-5-methyl-4-

oxazolyl]ethoxy]phenyl]methyl]-N-2-propenyl- (9CI) (CA INDEX NAME)



RN 530129-81-8 HCAPLUS


CN Glycine, N-[[3-[2-[5-methyl-2-[4-(1,2,3-thiadiazol-4-yl)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]-N-2-propenyl-, sodium salt (9CI) (CA INDEX NAME)



● Na


RN 530129-83-0 HCAPLUS

CN Glycine, N-[[3-[2-[2-(4-cyclohexylphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 530129-85-2 HCAPLUS

CN Glycine, N-[[3-[2-[5-methyl-2-[4-(tetrahydro-2H-pyran-4-yl)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 530129-88-5 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-2-propenyl- (9CI) (CA INDEX NAME)



RN 530129-89-6 HCAPLUS


CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-2-propenyl-, sodium salt (9CI) (CA INDEX NAME)



● Na


RN 530129-90-9 HCAPLUS

CN Glycine, N-[[3-[2-[2-[6-(dimethylamino)-3-pyridinyl]-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 530129-91-0 HCAPLUS

CN Glycine, N-[[3-[2-[2-[4-(dimethylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 530129-92-1 HCAPLUS

CN Alanine, 2-methyl-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-2-propenyl- (9CI) (CA INDEX NAME)



RN 530129-93-2 HCAPLUS


CN Alanine, 2-methyl-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-2-propenyl-, sodium salt (9CI) (CA INDEX NAME)



● Na


RN 530129-95-4 HCAPLUS

CN Glycine, N-[[3-[2-[5-methyl-2-[6-(4-morpholinyl)-3-pyridinyl]-4-oxazolyl]ethoxy]phenyl]methyl]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 530129-96-5 HCAPLUS

CN Glycine, N-[[3-[2-[5-methyl-2-[6-(1-piperidinyl)-3-pyridinyl]-4-oxazolyl]ethoxy]phenyl]methyl]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 530129-97-6 HCAPLUS

CN Glycine, N-[[3-[2-[2-[6-(diethylamino)-3-pyridinyl]-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 530129-98-7 HCAPLUS

CN Glycine, N-[[3-[2-[5-methyl-2-[6-(1-pyrrolidinyl)-3-pyridinyl]-4-oxazolyl]ethoxy]phenyl]methyl]-N-2-propenyl- (9CI) (CA INDEX NAME)



RN 530129-99-8 HCAPLUS


CN Glycine, N-[[3-[2-[5-methyl-2-[4-(4-morpholinyl)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]-N-2-propenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 530130-00-8 HCAPLUS

CN Glycine, N-[[3-[2-[5-methyl-2-[4-(4-morpholinyl)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]-N-2-propenyl- (9CI) (CA INDEX NAME)



RN 530130-03-1 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-2-propenyl- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 7 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:173582 HCAPLUS

DN 138:221586

TI Preparation of azoles as oral antidiabetic agents.

IN Bigge, Christopher Franklin; Bridges, Alesander James; Casimiro-Garcia, Augustin; Fakhoury, Stephen Alan; Lee, Helen Tsenwhei; Reed, Jessica Elizabeth; Schaum, Robert Philipp; Schlosser, Kevin Matthew; Sexton, Karen Elaine; Zhou, Hairong

PA Warner Lambert Co., USA

SO PCT Int. Appl., 333 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003018553	A1	20030306	WO 2002-IB2843	20020715
	WO 2003018553	C1	20040408		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1423363	A1	20040602	EP 2002-745739	20020715
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

BR 2002012069	A	20040720	BR 2002-12069	20020715
EE 200400075	A	20040816	EE 2004-75	20020715
JP 2005504778	T2	20050217	JP 2003-523217	20020715
US 2003171377	A1	20030911	US 2002-225716	20020822

PRAI US 2001-315728P P 20010829
 US 2001-322123P P 20010914
 US 2002-369788P P 20020403
 WO 2002-IB2843 W 20020715

OS MARPAT 138:221586

AB AXQYC(B)(D)ZE [A = (substituted) (fused) aryl, heteroaryl, cycloalkyl, heterocycloalkyl; X = CH₂O, CH₂CH₂O, (CH₂)₃, CH₂C.tplbond.C, CH₂CH:CH; Q = (substituted) (fused) aryl, heteroaryl; Y, Z = null, (CR₁R₂)_n, (CR₃R₄)_m; R₁-R₄ = H, halo, alkyl, OH, alkoxy; m, n = 1-3; B = H, halo, alkyl, haloalkyl, alkoxy; D = H, (substituted) arylamino, alkanoyl, PhCO, aryl, heteroaryl, cycloalkyl, heterocycloalkyl; E = COR₅; R₅ = alkyl, OH, alkoxy, amino, sulfonylamino, substituted heteroaryl, dioxothiazolyl, etc.; with provisos], were prepared Thus, (S)-tyrosine Me ester, 2,5-dimethoxytetrahydrofuran, and NaOAc were heated in aqueous HOAc at 100° for 20 min. to give 35% pyrrolotyrosine Me ester. This was stirred with 2-(5-methyl-2-phenyloxazol-4-yl)ethanol, Ph₃P, and di-Et azodicarboxylate in THF for 18 h to give 51% Me (S)-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-pyrrol-1-ylpropionate. The latter was stirred with LiOH in THF/H₂O to give 51% (S)-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-pyrrol-1-ylpropionic acid. In a 3T3-L1 adipocyte differentiation assay, title compds. at 5 µM showed 2-183% of the activity of BRL 49653 pos. control. A drug formulation is given.

IC C07D207-32; C07D263-32; C07D413-12; C07D403-12; C07D401-12

CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 27

ST azole prepn oral antidiabetic agent; PPAR modulator azole prepn; diabetes mellitus obesity hyperglycemia hyperlipidemia hypercholesteremia treatment azole prepn; fat cell differentiation modulator azole prepn

IT Adipose tissue
 (adipocyte, differentiation modulators; preparation of azoles as oral antidiabetic agents)

IT Antiarteriosclerotics
 (antiatherosclerotics; preparation of azoles as oral antidiabetic agents)

IT Lipids, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (hyperlipidemia, treatment; preparation of azoles as oral antidiabetic agents)

IT Disease, animal
 (metabolic syndrome X, treatment; preparation of azoles as oral antidiabetic agents)

IT Peroxisome proliferator-activated receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (modulators; preparation of azoles as oral antidiabetic agents)

IT Anticholesteremic agents
 Antidiabetic agents
 Antiobesity agents
 Human
 Hypolipemic agents
 (preparation of azoles as oral antidiabetic agents)

IT Atherosclerosis
 Diabetes mellitus
 Hypercholesterolemia
 Hyperglycemia
 Hypertriglyceridemia

Obesity

(treatment; preparation of azoles as oral antidiabetic agents)

IT Peroxisome proliferator-activated receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(γ, agonists; preparation of azoles as oral antidiabetic agents)

IT 331746-96-4P 501028-78-0P 501029-59-0P 501029-74-9P 501029-83-0P
 501029-89-6P 501029-91-0P 501030-05-3P 501030-10-0P 501030-33-7P
501030-36-0P 501030-37-1P 501030-38-2P 501030-52-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(claimed compound; preparation of azoles as oral antidiabetic agents)

IT 403986-40-3P 403986-43-6P 403986-50-5P 500996-17-8P 501027-46-9P
 501027-47-0P 501027-48-1P 501027-49-2P 501027-50-5P 501027-51-6P
 501027-52-7P 501027-53-8P 501027-54-9P 501027-55-0P 501027-56-1P
 501027-57-2P 501027-58-3P 501027-59-4P 501027-60-7P 501027-61-8P
 501027-62-9P 501027-63-0P 501027-64-1P 501027-65-2P 501027-66-3P
 501027-67-4P 501027-68-5P 501027-69-6P 501027-70-9P 501027-71-0P
 501027-72-1P 501027-73-2P 501027-74-3P 501027-75-4P 501027-76-5P
 501027-77-6P 501027-78-7P 501027-79-8P 501027-80-1P 501027-81-2P
 501027-82-3P 501027-83-4P 501027-84-5P 501027-85-6P 501027-86-7P
 501027-87-8P 501027-88-9P 501027-89-0P 501027-90-3P 501027-91-4P
 501027-92-5P 501027-93-6P 501027-94-7P 501027-95-8P 501027-96-9P
 501027-97-0P 501027-98-1P 501027-99-2P 501028-00-8P 501028-01-9P
 501028-02-0P 501028-03-1P 501028-04-2P 501028-05-3P 501028-06-4P
 501028-07-5P 501028-08-6P 501028-09-7P 501028-10-0P 501028-11-1P
 501028-12-2P 501028-13-3P 501028-14-4P 501028-15-5P 501028-16-6P
 501028-17-7P 501028-18-8P 501028-19-9P 501028-20-2P 501028-21-3P
 501028-22-4P 501028-23-5P 501028-24-6P 501028-25-7P 501028-26-8P
 501028-27-9P 501028-28-0P 501028-29-1P 501028-30-4P 501028-31-5P
 501028-32-6P 501028-33-7P 501028-34-8P 501028-35-9P 501028-36-0P
 501028-37-1P 501028-38-2P 501028-39-3P 501028-40-6P 501028-41-7P
 501028-42-8P 501028-43-9P 501028-44-0P 501028-45-1P 501028-46-2P
 501028-48-4P 501028-49-5P 501028-50-8P 501028-51-9P 501028-52-0P
 501028-53-1P 501028-54-2P 501028-55-3P 501028-56-4P 501028-57-5P
 501028-59-7P 501028-60-0P 501028-61-1P 501028-62-2P 501028-63-3P
 501028-64-4P 501028-65-5P 501028-66-6P 501028-67-7P 501028-68-8P
 501028-69-9P 501028-70-2P 501028-71-3P 501028-72-4P 501028-73-5P
 501028-74-6P 501028-76-8P 501028-77-9P 501028-79-1P 501028-81-5P
 501028-83-7P 501028-84-8P 501028-86-0P 501028-88-2P 501028-90-6P,
 2-(4-Benzoyloxyindol-1-yl)propionic acid 501028-92-8P 501028-95-1P
 501028-97-3P 501028-99-5P 501029-01-2P 501029-03-4P 501029-05-6P
 501029-06-7P 501029-07-8P 501029-09-0P 501029-13-6P 501029-16-9P
 501029-20-5P 501029-21-6P 501029-22-7P 501029-23-8P 501029-24-9P
 501029-25-0P 501029-26-1P **501029-27-2P** 501029-28-3P
 501029-29-4P 501029-30-7P 501029-31-8P 501029-32-9P 501029-33-0P
 501029-34-1P 501029-35-2P 501029-36-3P 501029-37-4P 501029-38-5P
 501029-39-6P 501029-40-9P 501029-41-0P 501029-42-1P 501029-43-2P
 501029-44-3P 501029-45-4P 501029-46-5P 501029-47-6P 501029-48-7P
 501029-49-8P 501029-50-1P 501029-51-2P 501029-52-3P 501029-53-4P
 501029-54-5P 501029-55-6P 501029-56-7P 501029-57-8P 501029-58-9P
 501029-60-3P 501029-61-4P 501029-62-5P 501029-63-6P 501029-64-7P
 501029-65-8P 501029-66-9P 501029-67-0P 501029-68-1P 501029-69-2P
 501029-70-5P 501029-71-6P 501029-72-7P 501029-73-8P 501029-75-0P
 501029-76-1P 501029-77-2P 501029-78-3P 501029-79-4P 501029-80-7P
 501029-82-9P 501029-85-2P 501029-86-3P 501029-87-4P 501029-88-5P
 501029-90-9P 501029-92-1P 501029-93-2P 501029-94-3P 501029-95-4P
 501029-96-5P 501029-97-6P 501029-98-7P 501029-99-8P 501030-00-8P
 501030-01-9P 501030-02-0P 501030-03-1P 501030-04-2P 501030-06-4P

501030-07-5P 501030-08-6P 501030-12-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of azoles as oral antidiabetic agents)

IT 501030-13-3P 501030-14-4P 501030-16-6P 501030-17-7P 501030-19-9P
501030-20-2P 501030-21-3P 501030-23-5P 501030-27-9P 501030-29-1P
501030-32-6P 501030-34-8P 501030-35-9P 501030-39-3P 501030-40-6P
501030-41-7P 501030-42-8P 501030-43-9P 501030-44-0P 501030-45-1P
501030-46-2P 501030-47-3P 501030-48-4P 501030-49-5P 501030-50-8P
501030-51-9P 501030-53-1P 501030-54-2P 501030-55-3P 501030-56-4P
501030-57-5P 501030-58-6P 501030-59-7P 501030-60-0P 501030-61-1P
501030-62-2P 501030-63-3P 501030-64-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of azoles as oral antidiabetic agents)

IT 9004-10-8, Insulin, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(hyperinsulinemia, treatment; preparation of azoles as oral antidiabetic agents)

IT 501031-17-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of azoles as oral antidiabetic agents)

IT 501031-06-7P 501031-07-8P 501031-08-9P 501031-09-0P 501031-14-7P
501031-15-8P 501031-18-1P 501031-21-6P 501031-22-7P 501031-23-8P
501031-68-1P 501031-69-2P 501031-70-5P 501031-71-6P 501031-72-7P
501031-73-8P 501031-74-9P 501031-75-0P 501031-76-1P 501031-77-2P
501031-78-3P 501031-79-4P 501031-80-7P 501031-83-0P 501031-84-1P
501031-85-2P 501031-86-3P 501031-87-4P 501031-88-5P 501031-89-6P
501031-90-9P 501031-94-3P 501031-95-4P 501031-96-5P 501031-97-6P
501031-98-7P 501031-99-8P 501032-00-4P 501032-01-5P 501032-02-6P
501032-03-7P 501032-04-8P 501032-05-9P 501074-68-6P 501074-70-0P
501074-72-2P 501074-74-4P 501074-76-6P 501074-78-8P 501074-80-2P
501074-82-4P 501074-84-6P 501074-87-9P 501074-89-1P 501074-91-5P
501074-93-7P 501074-95-9P 501074-97-1P 501074-99-3P 501075-01-0P
501075-03-2P 501075-05-4P 501075-07-6P 501075-09-8P 501075-96-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of azoles as oral antidiabetic agents)

IT 78-96-6, 1-Amino-2-propanol 96-48-0, γ -Butyrolactone 98-10-2, Benzenesulfonamide 98-80-6, Phenylboronic acid 98-88-4, Benzoyl chloride 100-52-7, Benzaldehyde, reactions 101-41-7, Methyl phenylacetate 103-82-2, Phenylacetic acid, reactions 105-36-2, Ethyl bromoacetate 106-95-6, Allyl bromide, reactions 106-96-7, Propargyl bromide 110-13-4, 2,5-Hexanedione 115-80-0, Triethyl orthopropionate 123-08-0, 4-Hydroxybenzaldehyde 288-13-1, Pyrazole 288-36-8, 1H-1,2,3-Triazole 288-88-0, 1H-1,2,4-Triazole 446-48-0, 2-Fluorobenzyl bromide 446-51-5, 2-Fluorobenzyl alcohol 539-74-2, Ethyl 3-bromopropionate 547-63-7, Methyl 2,2-dimethylacetate 583-05-1, 1-Phenyl-1,4-pentanedione 589-15-1, 4-Bromobenzyl bromide 622-95-7, 4-Chlorobenzyl bromide 672-87-7, α -Methyl-L-tyrosine 696-59-3, 2,5-Dimethoxytetrahydrofuran 836-42-0, 4-Benzyloxybenzyl chloride 1003-29-8, Pyrrole-2-carboxaldehyde 1080-06-4, L-Tyrosine methyl ester 1215-59-4, 5-Benzyloxyindole 1878-67-7, 2-(3-Bromophenyl)acetic acid 1912-48-7, 1-Methyl-3-indoleacetic acid 2208-07-3, Ethyl acetimidate

hydrochloride 2605-67-6, Methyl triphenylphosphoranylideneacetate
2719-27-9, Cyclohexanecarbonyl chloride 2835-06-5 3042-81-7, Methyl
 α -bromophenylacetate 3081-24-1, L-Phenylalanine ethyl ester
3289-19-8 4282-82-0, N-Methyl-N-propyn-2-ylaniline 4597-87-9,
2-Methylaminopyridine 4665-63-8 4946-06-9 5006-66-6,
6-Hydroxynicotinic acid 5445-17-0, Methyl 2-bromopropionate 5680-79-5,
Glycine methyl ester hydrochloride 6962-09-0 7423-96-3,
3-Fluoro-L-tyrosine 7486-35-3, Vinyltributylstannane 10068-07-2,
Methyl 3-hydroxy-5-isoxazolecarboxylate 13081-18-0 14062-23-8
16726-67-3, 5-Bromonaphthalene-1-carboxylic acid 17295-11-3
17841-30-4, Methyl 2-fluoro-2-phenylacetate 18282-51-4 19432-68-9
19668-85-0 20289-26-3, 4-Benzoyloxyindole 23786-14-3, Methyl
p-methoxyphenylacetate 31508-44-8, Methyl 2-methyl-2-phenylacetate
36245-26-8 37784-63-7 38002-45-8, 3-Bromo-1-(trimethylsilyl)-1-propyne
39931-77-6 39998-25-9 43083-12-1, Trimethyl orthobutyrate
54401-85-3, Ethyl 4-pyridylacetate 57382-97-5, Ethyl 2-thiopheneacetate
58185-48-1 59776-88-4 62451-84-7, Methyl 3-
trifluoromethylphenylacetate 63476-16-4 64099-82-7,
Tributylprop-1-ynylstannane 78148-37-5 86436-62-6 91721-19-6
94022-96-5, 2-(2-Trifluoromethylphenyl)ethanol 103788-64-3
103788-65-4, 2-(5-Methyl-2-phenyloxazol-4-yl)ethanol 107367-98-6
122320-77-8 128677-61-2 132646-28-7 141899-12-9 175136-30-8
207119-66-2, 3-Phenyl-2,5-dimethoxytetrahydrofuran 256925-70-9
501031-25-0 501031-60-3 501031-61-4 501031-62-5 501031-63-6
501031-64-7 501031-67-0 501031-92-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of azoles as oral antidiabetic agents)

IT 4314-21-0P 4320-90-5P 5544-60-5P 20366-57-8P, (5-Bromonaphthalen-1-
yl)methanol 23054-66-2P 26682-99-5P, Phenylglycine methyl ester
27349-40-2P 30057-79-5P 49616-56-0P 50966-72-8P 50996-03-7P
58665-00-2P 65592-02-1P 66171-50-4P 75852-28-7P 116763-11-2P
126535-90-8P 132451-32-2P 140130-10-5P 150529-73-0P 151109-14-7P,
1-Bromo-5-bromomethylnaphthalene 170861-68-4P 172374-54-8P
258346-54-2P 258346-55-3P 331745-78-9P 331746-72-6P 441357-21-7P
445490-43-7P 445490-44-8P 445492-18-2P 501030-65-5P 501030-66-6P
501030-67-7P 501030-68-8P 501030-69-9P 501030-70-2P 501030-71-3P
501030-72-4P 501030-73-5P 501030-74-6P 501030-75-7P 501030-76-8P
501030-77-9P 501030-78-0P 501030-79-1P 501030-80-4P 501030-81-5P
501030-82-6P 501030-83-7P 501030-84-8P 501030-85-9P 501030-86-0P
501030-87-1P 501030-88-2P 501030-89-3P 501030-90-6P 501030-91-7P
501030-92-8P 501030-93-9P 501030-95-1P 501030-97-3P 501030-99-5P
501031-00-1P 501031-02-3P 501031-03-4P 501031-05-6P 501031-11-4P
501031-12-5P 501031-13-6P 501031-16-9P 501031-19-2P 501031-20-5P
501031-24-9P 501031-26-1P 501031-27-2P 501031-28-3P 501031-29-4P
501031-30-7P 501031-31-8P 501031-32-9P 501031-33-0P 501031-34-1P
501031-35-2P 501031-36-3P 501031-37-4P 501031-38-5P 501031-39-6P
501031-40-9P 501031-41-0P 501031-42-1P 501031-43-2P 501031-44-3P
501031-45-4P 501031-46-5P 501031-47-6P 501031-48-7P 501031-49-8P
501031-50-1P 501031-51-2P 501031-52-3P 501031-53-4P 501031-54-5P
501031-55-6P 501031-56-7P 501031-57-8P 501031-58-9P 501031-59-0P
501031-65-8P 501031-66-9P 501031-81-8P **501031-82-9P**
501031-93-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)


(preparation of azoles as oral antidiabetic agents)

IT **501030-36-0P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)

(claimed compound; preparation of azoles as oral antidiabetic agents)

RN 501030-36-0 HCAPLUS


CN Benzeneacetic acid, α -[methyl[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

IT 501029-27-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of azoles as oral antidiabetic agents)

RN 501029-27-2 HCAPLUS


CN Benzeneacetic acid, α -[methyl[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

IT 501031-82-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of azoles as oral antidiabetic agents)

RN 501031-82-9 HCAPLUS

CN Benzeneacetic acid, α -[acetyl[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]-, methyl ester (9CI) (CA INDEX NAME)RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 8 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:927184 HCAPLUS

DN 138:14048

KATHLEEN FULLER EIC 1700 REMSEN 4B28 571/272-2505

TI Preparation of oxazolylethoxyphenylprolines and related compounds as antidiabetic and antiobesity agents.

IN Cheng, Peter T.; Jeon, Yoon; Wang, Wei

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 107 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002096357	A2	20021205	WO 2002-US16628	20020523
	WO 2002096357	A3	20030925		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2003092697	A1	20030515	US 2002-153342	20020522
	EP 1401433	A2	20040331	EP 2002-737192	20020523
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRAI	US 2001-294505P	P	20010530		
	WO 2002-US16628	W	20020523		
OS	MARPAT 138:14048				
GI					



I



II

AB Title compds. [I; m, n = 0-2; Q = C, N; A = (CH₂)_x, (CH₂)_{x1}, with an alkenyl or alkynyl bond in the chain, (CH₂)_{x2}(CH₂)_{x3}; x = 1-5; x₁ = 2-5; x₂, x₃ = 0-5; provided that ≥1 of x₂ and x₃ ≠ 0; X₁ = CH, N; X₂ = C, N, O, S; X₃ = C, N; X₄ = C, N, O, S provided that ≥1 of X₂,

X3, X4 = N; in each of X1-X4, C may include CH; R1 = H, alkyl; R2 = H, alkyl, alkoxy, halo, (substituted) amino; R2a, R2b R2c = H, alkyl, alkoxy, halo, (substituted) amino; R3 = H, alkyl, arylalkyl, aryloxy, carbonyl, alkyloxy, carbonyl, alkynyloxy, carbonyl, alkenyloxy, carbonyl, aryl, carbonyl, alkyl, carbonyl, aryl, heteroaryl, cycloheteroalkyl, heteroaryl, carbonyl, heteroaryl, heteroarylalkyl, alkyl, carbonyl, amino, aryl, carbonyl, amino, heteroaryl, carbonyl, amino, alkoxy, carbonyl, amino, aryloxy, carbonyl, amino, heteroaryl, oxy, carbonyl, amino, heteroaryl, heteroaryl, carbonyl, alkyl, sulfonyl, alkenyl, sulfonyl, heteroaryl, oxy, carbonyl, cycloheteroalkyl, oxy, carbonyl, aryloxy, heteroaryl, alkyl, heteroaryl, alkyl, oxy, aryl, alkyl, aryl, alkyl, aryl, amino, aryl, alkyl, etc.; Y = CO₂R₄, 1-tetrazolyl, P(O)(OR_{4a})R₅, P(O)(OR_{4a})₂; R₄ = H, alkyl, prodrug ester; R_{4a} = H, prodrug ester; R₅ = alkyl, aryl; Z = (CH₂)_{x4}, (CH₂)_{x5}, (CH₂)_{x6}(CH₂)_{x7}; x₄ = 1-5; x₅ = 2-5; x₆, x₇ = 0-4], were prepared as antidiabetic and antiobesity agents (no data). Thus, title compound (II) was prepared in 6 steps.

IC ICM A61K

CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 34

ST oxazolylethoxyphenylproline prepn antidiabetic antiobesity agent; proline oxazolylethoxyphenyl prepn antidiabetic antiobesity agent

IT Proteins

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (ALBP (adipocyte lipid-binding protein), inhibitors, coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)

IT. Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (AP-2 (activator protein 2), inhibitors, coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)

IT Inflammation

(Crohn's disease, treatment; preparation of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)

IT Intestine, disease

(Crohn's, treatment; preparation of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)

IT Lipoprotein receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (LDL, upregulators, coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)

IT Proteins

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (MTP (microsomal triglyceride-exchanging protein), inhibitors, coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)

IT Thyroid hormone receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (agonists, coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)

IT Angiotensin receptor antagonists

(angiotensin II, coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)

IT Antiarteriosclerotics

(antiatherosclerotics; preparation of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)

IT Osteoporosis

(antiosteoporotics, coadministration; preparation of

- oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)
- IT Ion channel blockers
(calcium, coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)
- IT Appetite depressants
Platelet aggregation inhibitors
(coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)
- IT Sulfonylureas
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)
- IT Intestine, neoplasm
(colon, treatment; preparation of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)
- IT Diabetes mellitus
(complication treatment; preparation of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)
- IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dopamine transporter, inhibitors, coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)
- IT Ulcer
(gastric, treatment; preparation of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)
- IT Lipids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hyperlipidemia, treatment; preparation of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)
- IT Intestine, disease
(irritable bowel syndrome, treatment; preparation of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)
- IT Adipose tissue, neoplasm
Sarcoma
(liposarcoma, treatment; preparation of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)
- IT Disease, animal
(metabolic syndrome X, treatment; preparation of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)
- IT Anti-inflammatory agents
Antihypertensives
Antiobesity agents
Antitumor agents
Human
Hypolipemic agents
(preparation of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)
- IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(serotonin transporter, inhibitors, coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)
- IT Atherosclerosis
Carcinoma
Hyperglycemia

Hypertriglyceridemia
Inflammation
Lung, neoplasm
Mammary gland, neoplasm
Neoplasm
Obesity
Ovary, neoplasm
Prostate gland, neoplasm
Psoriasis
Stomach, neoplasm
 (treatment; preparation of oxazolylethoxyphenylprolines and related compds.
 as antidiabetic and antiobesity agents)

IT Stomach, disease
 (ulcer, treatment; preparation of oxazolylethoxyphenylprolines and related
 compds. as antidiabetic and antiobesity agents)

IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (α , agonists, coadministration; preparation of
 oxazolylethoxyphenylprolines and related compds. as antidiabetic and
 antiobesity agents)

IT Adrenoceptor antagonists
 (β -, coadministration; preparation of oxazolylethoxyphenylprolines and
 related compds. as antidiabetic and antiobesity agents)

IT Adrenoceptors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (β 3, agonist coadministration; preparation of
 oxazolylethoxyphenylprolines and related compds. as antidiabetic and
 antiobesity agents)

IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (γ , agonists, coadministration; preparation of
 oxazolylethoxyphenylprolines and related compds. as antidiabetic and
 antiobesity agents)

IT 477719-09-8P 477719-10-1P 477719-11-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (claimed compound; preparation of oxazolylethoxyphenylprolines and related
 compds. as antidiabetic and antiobesity agents)

IT 89750-14-1, Glucagon-like peptide I
RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (coadministration; preparation of oxazolylethoxyphenylprolines and related
 compds. as antidiabetic and antiobesity agents)

IT 50-78-2, Aspirin 51-64-9, Dexamphetamine 52-53-9, Verapamil 58-32-2,
Dipyridamole 59-67-6, Niacin, biological studies 94-20-2,
Chlorpropamide 122-09-8, Phentermine 525-66-6, Propranolol 637-07-0,
Clofibrate 657-24-9, Metformin 4205-91-8, Clonidine hydrochloride
9004-10-8, Insulin, biological studies 10238-21-8, Glyburide
14838-15-4, Phenylpropanolamine 19237-84-4, Prazosin hydrochloride
21187-98-4, Gliclazide 21829-25-4, Nifedipine 22232-71-9, Mazindol
25812-30-0, Gemfibrozil 29094-61-9, Glipizide 42200-33-9, Nadolol
49562-28-9, Fenofibrate 54870-28-9, Meglitinide 55142-85-3,
Ticlopidine 56180-94-0, Acarbose 62571-86-2, Captopril 72432-03-2,
Miglitol 72956-09-3, Carvedilol 75330-75-5, Lovastatin 75847-73-3,
Enalapril 76547-98-3, Lisinopril 79902-63-9, Simvastatin 80830-42-8,
Fentiapril 81093-37-0, Pravastatin 85441-61-8, Quinapril 86541-75-5,
Benazepril 87333-19-5, Ramipril 93479-97-1, Glimepiride 93957-54-1,
Fluvastatin 96829-58-2, Orlistat 97240-79-4, Topiramate 97322-87-7,
Troglitazone 98048-97-6, Fosinopril 103775-10-6, Moexipril

105816-04-4, Nateglinide 106650-56-0, Sibutramine 111025-46-8,
 Pioglitazone 111470-99-6, Amlodipine besylate 113665-84-2, Clopidogrel
 114798-26-4, Losartan 122320-73-4, Rosiglitazone 134523-00-5,
 Atorvastatin 135062-02-1, Repaglinide 137862-53-4, Valsartan
 138402-11-6, Irbesartan 141758-74-9, AC 2993 143443-90-7, Ifetroban
 144288-97-1, TS-962 145599-86-6, Cerivastatin 147511-69-1
 152755-31-2, LY295427 159183-92-3, L750355 160135-92-2, Gemopatrilat
 161600-01-7, Isaglitazone 166518-60-1, Avasimibe 167305-00-2,
 Omapatrilat 169319-62-4, CGS 30440 170861-63-9, JTT-501 176435-10-2,
 LY315902 178759-95-0, MD 700 182815-44-7, Cholestagel 196808-45-4,
 GI 262570 199113-98-9, NN-2344 199914-96-0, YM-440 213252-19-8,
 KRP297 244081-42-3, AJ9677 251565-85-2, AR-H 039242 251572-86-8,
 P32/98 287714-41-4 335149-08-1, L895645 335149-14-9, R-119702
 335149-15-0, KAD1129 335149-19-4, GW-409544 335149-23-0, NVP-DPP-728A
 335149-24-1, ATL-962 335149-25-2, CP331648 430433-17-3, Glipryride
 444069-80-1, Axokine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (coadministration; preparation of oxazolyethoxyphenylprolines and related
 compds. as antidiabetic and antiobesity agents)

IT 943-45-3, Fibric acid

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (derivs., coadministration; preparation of oxazolyethoxyphenylprolines and
 related compds. as antidiabetic and antiobesity agents)

IT 107-66-4, DP 4 9001-62-1, Lipase 9015-82-1 9028-35-7, HMG-CoA
 reductase 9033-06-1, Glucosidase 9077-14-9, Squalene synthetase
 82707-54-8, Neutral endopeptidase 335197-46-1, SGLT2

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors, coadministration; preparation of oxazolyethoxyphenylprolines
 and related compds. as antidiabetic and antiobesity agents)

IT 9027-63-8, ACAT 9029-60-1, Lipoxxygenase

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (inhibitors, coadministration; preparation of oxazolyethoxyphenylprolines
 and related compds. as antidiabetic and antiobesity agents)

IT 50-99-7, Glucose, biological studies

RL: ADV (Adverse effect, including toxicity); BSU (Biological study,
 unclassified); BIOL (Biological study)
 (intolerance treatment; preparation of oxazolyethoxyphenylprolines and
 related compds. as antidiabetic and antiobesity agents)

IT 477719-12-3P 477719-13-4P 477719-14-5P 477719-15-6P 477719-16-7P
 477719-17-8P 477719-18-9P 477719-19-0P 477719-20-3P 477719-21-4P
 477719-22-5P 477719-23-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of oxazolyethoxyphenylprolines and related compds. as
 antidiabetic and antiobesity agents)

IT 67-36-7, 4-Phenoxybenzaldehyde 106-41-2, 4-Bromophenol 501-53-1,
 Benzyl chloroformate 591-20-8, 3-Bromophenol 1068-90-2, Diethyl
 acetamidomalonate 1137-42-4, 4'-Hydroxybenzophenone 7685-44-1,
 Allylglycine 7693-41-6, 4-Methoxyphenyl chloroformate 24277-39-2
 72086-72-7 73872-71-6 103788-65-4 227029-27-8

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of oxazolyethoxyphenylprolines and related compds. as
 antidiabetic and antiobesity agents)

IT 2847-87-2P 4006-70-6P 67963-68-2P 70837-19-3P 81323-62-8P
 103788-59-6P 147698-05-3P 197159-25-4P 208520-00-7P 477719-24-7P
 477719-25-8P 477719-26-9P 477719-27-0P 477719-28-1P 477719-29-2P
 477719-30-5P 477719-31-6P 477719-32-7P 477719-33-8P 477719-34-9P
 477719-35-0P 477719-36-1P 477719-37-2P 477719-38-3P 477719-39-4P

477719-40-7P 477719-41-8P 477719-42-9P 477719-43-0P 477719-44-1P
 477719-45-2P 477719-46-3P 477719-47-4P 477719-48-5P 477719-49-6P
 477719-50-9P 477719-51-0P 477719-52-1P 477719-53-2P 477719-54-3P
477719-55-4P 477719-56-5P 477719-57-6P 477719-58-7P
 477719-59-8P 477719-60-1P 477719-61-2P 477719-62-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)

IT **477719-55-4P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)

RN 477719-55-4 HCAPLUS

CN 4-Pentenoic acid, 2-[[[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-3-butenyl](trifluoroacetyl)amino]-, (2S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 9 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:504648 HCAPLUS

DN 137:83637

TI Medicinal compositions containing diuretic and insulin resistance-improving agent

IN Takaoka, Masaya; Araki, Kazushi; Kanda, Shoichi

PA Sankyo Company, Limited, Japan

SO PCT Int. Appl., 183 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002051441	A1	20020704	WO 2001-JP11296	20011221
	W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PH, PL, RU, SG, SK, US, VN, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	JP 2002255854	A2	20020911	JP 2001-386861	20011220
	EP 1354602	A1	20031022	EP 2001-271867	20011221
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	US 2004053974	A1	20040318	US 2003-606632	20030626
PRAI	JP 2000-394424	A	20001226		

WO 2001-JP11296 W 20011221
OS MARPAT 137:83637
AB Disclosed are medicinal compns. containing a diuretic and an insulin resistance-improving agent whereby side effects associating the administration of an insulin resistance-improving agent (for example, megalocardia, edema, body fluid retention, pleural effusion) can be prevented or treated. Oral administration of furosemide prevented increases of heart weight and blood plasma, and edema due to administration of 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione hydrochloride.
IC ICM A61K045-06
ICS A61P003-10; A61P043-00; A61K031-433; A61K031-343; A61K031-4965; A61K031-427; A61K031-4439; A61K031-421; A61K031-422; A61K031-4709
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
ST insulin resistance improving agent diuretic; diuretic antidiabetic side effect prevention
IT Hypertrophy
(cardiac, prevention of; medicinal compns. containing diuretics and insulin resistance-improving agents)
IT Body fluid
Pleura, disease
(effusion, prevention of; medicinal compns. containing diuretics and insulin resistance-improving agents)
IT Heart, disease
(hypertrophy, prevention of; medicinal compns. containing diuretics and insulin resistance-improving agents)
IT Antidiabetic agents
Diabetes mellitus
Diuretics
(medicinal compns. containing diuretics and insulin resistance-improving agents)
IT Antidiabetic agents
Drug delivery systems
(oral; medicinal compns. containing diuretics and insulin resistance-improving agents)
IT Edema
(prevention of; medicinal compns. containing diuretics and insulin resistance-improving agents)
IT 179068-64-5, NC 2100
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NC 2100; medicinal compns. containing diuretics and insulin resistance-improving agents)
IT 299176-11-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(medicinal compns. containing diuretics and insulin resistance-improving agents)
IT 54-31-9, Furosemide 2609-46-3, Amiloride
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicinal compns. containing diuretics and insulin resistance-improving agents)
IT 185428-18-6P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(medicinal compns. containing diuretics and insulin resistance-improving agents)

IT 52-01-7, Spironolactone 58-54-8, Ethacrynic acid 58-93-5, Hydrochlorothiazide 59-66-5, Acetazolamide 77-36-1, Chlortalidone 133-67-5, Trichlormethiazide 135-07-9, Methyclothiazide 135-09-1, Hydroflumethiazide 396-01-0, Triamterene 652-67-5, Isosorbide 742-20-1, Cyclopenthiazide 1766-91-2, Penflutizide 1824-50-6, Benzylhydrochlorothiazide 2181-04-6, Potassium canrenoate 7195-27-9, Mefruside 17560-51-9, Metolazone 27589-33-9, Azosemide 28395-03-1, Bumetanide 55837-27-9, Piretanide 56211-40-6, Torasemide 97322-87-7, Troglitazone 111025-46-8, Pioglitazone 118384-10-4, T-174 122320-73-4, Rosiglitazone 161600-01-7, MCC-555 170861-63-9, JTT-501 196808-45-4, GI 262570 199914-96-0, YM-440 213252-19-8, KRP-297 222834-21-1, NN 622 251565-85-2, AZ-242 331741-94-7, BMS 298585 406701-59-5 406701-61-9 406701-63-1 406701-66-4 406701-68-6 406701-70-0 406701-72-2 406701-74-4 406701-76-6
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (medicinal compns. containing diuretics and insulin resistance-improving agents)


IT 79-37-8, Oxalyl chloride 100-39-0, Benzylbromide 106-48-9, 4-Chlorophenol 124-63-0, Methanesulfonyl chloride 371-41-5, 4-Fluorophenol 405-79-8, 4-Fluorophenoxyacetic acid 725-15-5, 4'-(4-Fluorophenyl)acetophenone oxime 940-64-7 1798-04-5, 4-tert-Butylphenoxyacetic acid 4397-53-9, 4-Benzylloxybenzaldehyde 5470-11-1, Hydroxylamine chloride 13021-18-6 17739-45-6 62517-34-4, 3-(4-Hydroxyphenyl)lactic acid ethyl ester 90719-32-7, (S)-4-Benzyl-2-oxazolidinone 129139-48-6 178055-46-4 178055-58-8 185428-88-0 197298-91-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of medicinal compns. containing diuretics and insulin resistance-improving agents)

IT 15516-47-9P, 4-Methylphenoxyacetyl chloride 82827-69-8P 141109-83-3P, 3-(4-Benzylloxyphenyl)lactic acid ethyl ester 178055-70-4P 197299-17-5P, 223127-76-2P 223127-82-0P 223127-83-1P 406701-57-3P 406701-60-8P 406701-62-0P 406701-69-7P 406701-71-1P 406701-73-3P 406701-75-5P 406701-77-7P 406701-78-8P 406701-83-5P 406701-84-6P 406701-85-7P 406701-86-8P 406701-87-9P 406701-89-1P 406701-91-5P 406701-94-8P 406701-96-0P 406701-98-2P 406708-49-4P 406708-51-8P 406708-52-9P 406708-54-1P 406708-56-3P 439946-58-4P 439946-60-8P 439946-79-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of medicinal compns. containing diuretics and insulin resistance-improving agents)

IT 9004-10-8, Insulin, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (resistance-improving agents; medicinal compns. containing diuretics and insulin resistance-improving agents)

IT 331741-94-7, BMS 298585
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (medicinal compns. containing diuretics and insulin resistance-improving agents)

RN 331741-94-7 HCAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 10 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:502825 HCAPLUS

DN 137:63237

TI Preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compounds as antidiabetic and antiobesity agents

IN Cheng, Peter T.; Devasthale, Pratik; Jeon, Yoon; Chen, Sean; Zhang, Hao

PA Bristol-Myers Squibb Company, USA

SO U.S., 190 pp., Cont.-in-part of U.S. Ser. No. 664,598.

CODEN: USXXAM

DT Patent

LA English



FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6414002	B1	20020702	US 2001-812960	20010320
	US 2003069275	A1	20030410	US 2002-80965	20020222
	US 2003087935	A1	20030508	US 2002-81075	20020222
	US 6727271	B2	20040427		
	US 2003096846	A1	20030522	US 2002-80981	20020222
	US 6653314	B2	20031125		
	US 2004171644	A1	20040902	US 2003-655876	20030905
	US 2004147560	A1	20040729	US 2003-737210	20031216
PRAI	US 1999-155400P	P	19990922		
	US 2000-664598	A2	20000918		
	US 2001-812960	A3	20010320		
	US 2002-80981	A3	20020222		
	US 2002-81075	A3	20020222		

OS MARPAT 137:63237

GI

applicant



AB Title compds. I [wherein Q = C, N; A = O, S; B = (CH₂)_x; Z = O, bond; X = CH, N; R₁ = H, alkyl; R₂ = H, alkyl, alkoxy, halo, amino; R₃ = H, alkyl, aralkyl, aryloxyacarbonyl, alkoxyacarbonyl, arylcarbonyl, alkylcarbonyl, aryl, heteroaryl, hydroxyalkyl, aryloxyarylalkyl, etc.; R_{2a}, R_{2b}, R_{2c} = H, alkyl, alkoxy, halo, amino; Y = CO₂R₄, 1-tetrazolyl, PO(OR_{4a})R₅; R₄ = H, alkyl, prodrug or ester; R_{4a} = H, prodrug ester; R₅ = alkyl, aryl; x = 1-4; m, n = 1, 2] were prepared as modulators of blood glucose levels, triglyceride levels, insulin levels, and non-esterified fatty acid levels (no data). For example, 4-hydroxybenzaldehyde, 5-methyl-2-phenyloxazole-4-ethanol, Ph₃P, and DEAD were stirred in THF at 0°-room temperature to give 4-(5-methyl-2-phenyloxazole-4-ethyl)benzaldehyde (65%). Addition of N-benzylglycine Et ester and NaBH(OAc)₃ in 1,2-dichloroethane afforded the benzylamine derivative (55%), which was stirred with aqueous NaOH in MeOH for

14 h to give the title compound II (71%). I are useful for the treatment of diabetes, especially Type II diabetes, as well as hyperglycemia, hyperinsulinemia, hyperlipidemia, obesity, atherosclerosis, and related diseases (no data).

IC ICM A61K031-42

ICS A61K031-425; C07D277-30; C07D413-04

NCL 514374000

CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 34

ST oxazolylalkoxybenzylglycine thiazolylalkoxybenzylglycine prepn

antidiabetic antiobesity antiatherosclerosis agent

IT Antiarteriosclerotics

(antiatherosclerotics; preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

IT Lipids, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(hyperlipidemia; preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

IT Diabetes mellitus

(non-insulin-dependent; preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

IT Antidiabetic agents

Antiobesity agents

Atherosclerosis

Human

Hyperglycemia

Hypolipemic agents

(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

IT 9004-10-8, Insulin, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(hyperinsulinemia; preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

IT 331746-96-4P, Oxazole, 5-methyl-2-phenyl-4-(2-propenyl)-

RL: BYP (Byproduct); PREP (Preparation)

(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

IT 331739-69-6P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

IT 331739-67-4P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenylmethyl)- 331739-68-5P, Glycine, N,N-bis[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-70-9P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-2-propynyl- 331739-71-0P, Glycine, N-2-benzoxazolyl-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-72-1P, Glycine, N-2-benzoxazolyl-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-73-2P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- 331739-74-3P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-naphthalenylmethyl)- 331739-75-4P, Glycine, N-[[3-(4-chlorophenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-76-5P, Glycine, N-[[5-(4-chlorophenyl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-77-6P, Glycine, N-[[4-(3-fluorophenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-78-7P, Glycine, N-[[4-(3-methylphenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-79-8P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(3-pyridinyl)phenyl]methyl]- 331739-80-1P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenylmethyl)- 331739-81-2P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-phenylethyl)- 331739-82-3P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(3-phenylpropyl)- 331739-83-4P, Glycine, N-[[3-(3,4-dichlorophenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-84-5P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-phenoxyphenyl)methyl]- 331739-85-6P, Glycine, N-([1,1'-biphenyl]-4-ylmethyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-86-7P, Glycine, N-[[5-(2-chlorophenyl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-87-8P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-[3-(trifluoromethyl)phenoxy]phenyl]methyl]- 331739-88-9P, Glycine,

N-[[3-(4-methylphenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-89-0P, Glycine,
N-[[3-(4-methoxyphenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-90-3P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[(1E)-2-phenylethenyl]phenyl]methyl]- 331739-91-4P, Glycine,
N-[[4-[(2-chloro-6-fluorophenyl)methoxy]phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-92-5P,
Glycine, N-[(2E)-3,7-dimethyl-2,6-octadienyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-93-6P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylmethoxy)phenyl]methyl]- 331739-94-7P, Glycine,
N-[[4-[4-(1,1-dimethylethyl)-2-thiazolyl]phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-95-8P,
Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-phenoxy-2-thienyl]methyl]- 331739-96-9P, Glycine,
N-[(2Z)-3-(2-furanyl)-2-propenyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-97-0P, Glycine,
N-[[4-(4-fluorophenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-98-1P, Glycine,
N-[[2-[(4-chlorophenyl)thio]phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-99-2P, Glycine,
N-[[3-(3,5-dimethoxyphenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-00-2P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(1-naphthalenylmethyl)- 331740-01-3P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-naphthalenylmethyl)- 331740-02-4P, Glycine, N-(1H-indol-2-ylmethyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-03-5P,
Glycine, N-[(3-benzoyl-2,4-dichlorophenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-04-6P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-[2-(trifluoromethyl)phenyl]-2-furanyl]methyl]- 331740-05-7P,
Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-(3-nitrophenyl)-2-furanyl]methyl]- 331740-06-8P, Glycine,
N-[[5-[2-chloro-5-(trifluoromethyl)phenyl]-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-07-9P,
Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-[3-(trifluoromethyl)phenyl]-2-furanyl]methyl]- 331740-08-0P,
Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-(2-nitrophenyl)-2-furanyl]methyl]- 331740-09-1P,
1H-Pyrrole-2-carboxylic acid, 5-[[[(carboxymethyl)[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]methyl]-4-ethyl-3-methyl-,
2-(phenylmethyl) ester 331740-10-4P, Glycine,
N-[[5-(4-bromophenyl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-11-5P, Glycine,
N-[[5-(3-chlorophenyl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-12-6P, Glycine,
N-[[5-(1,3-dioxolan-2-yl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-13-7P, Glycine,
N-[[1-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-1H-indol-3-yl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-14-8P, Glycine, N-[[5-(2,4-dichlorophenyl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-15-9P, Glycine,
N-[[4-(2,6-difluorobenzoyl)-1-methyl-1H-pyrrol-2-yl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-16-0P,
Glycine, N-[(4-benzoyl-1-methyl-1H-pyrrol-2-yl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-17-1P,

Glycine, N-([2,2'-bithiophen]-5-ylmethyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- 331740-18-2P, Glycine, N-([5-bromo-3,4-dimethylthieno[2,3-b]thien-2-yl)methyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- 331740-19-3P, Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-[[5-(phenylethynyl)-2-thienyl]methyl)- 331740-20-6P, Glycine, N-([4-(2,4-dichlorobenzoyl)-1-methyl-1H-pyrrol-2-yl)methyl]-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- 331740-21-7P, Glycine, N-([1-(4-chlorophenyl)-1H-pyrrol-2-yl)methyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- 331740-22-8P, Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-[[4-(phenylethynyl)-2-thienyl]methyl)- 331740-23-9P, Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-[(3-nitro-4-phenoxyphenyl)methyl)- 331740-24-0P, Glycine, N-[(3-methyl-4-phenoxyphenyl)methyl]-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- 331740-25-1P, Glycine, N-[(3-chloro-4-phenoxyphenyl)methyl]-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- 331740-26-2P, Glycine, N-[(2-chloro-4-phenoxyphenyl)methyl]-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- 331740-27-3P, Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-[(4-nitro-3-phenoxyphenyl)methyl)- 331740-28-4P, Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-[(2-nitro-5-phenoxyphenyl)methyl)- 331740-29-5P, Glycine, N-[(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- 331740-30-8P, Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-[[5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-2-thienyl]methyl]- 331740-31-9P, Glycine, N-[(6-methoxy-2-naphthalenyl)methyl]-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- 331740-32-0P, Glycine, N-[(4-methoxy-1-naphthalenyl)methyl]-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- 331740-33-1P, Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-[[5-[2-nitro-4-(trifluoromethyl)phenyl]-2-furanyl]methyl)- 331740-34-2P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(2-pyridinyl)phenyl]methyl]- 331740-35-3P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-(phenylmethyl)phenyl]methyl]- 331740-36-4P, Glycine, N-heptyl-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- 331740-37-5P, Glycine, N-([1,1'-biphenyl]-4-ylmethyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- 331740-38-6P, Glycine, N-[(2-hydroxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- 331740-39-7P, Glycine, N-[[5-(2-chlorophenyl)-2-furanyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- 331740-40-0P, Glycine, N-[(3,5-dimethoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- 331740-41-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-[(3-phenoxyphenyl)methyl)- 331740-42-2P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl)- 331740-43-3P, Glycine, N-[[3-(4-chlorophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- 331740-44-4P, Glycine, N-[[3-(3,5-dichlorophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- 331740-45-5P, Glycine, N-[[3-(4-methylphenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- 331740-46-6P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-[[4-[(1E)-2-

phenylethenyl]phenyl)methyl]- 331740-47-7P, Glycine,
N-[[4-[(2-chloro-6-fluorophenyl)methoxy]phenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-48-8P,
Glycine, N-[(3-benzoyl-2,4-dichlorophenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-49-9P, Glycine,
N-[[3-[4-(1,1-dimethylethyl)phenoxy]phenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-50-2P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(phenylmethoxy)phenyl)methyl]- 331740-51-3P, Glycine,
N-[[4-[4-(1,1-dimethylethyl)-2-thiazolyl]phenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-52-4P,
Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[2-phenoxyphenyl)methyl]- 331740-53-5P, Glycine,
N-[[4-(3-methoxyphenoxy)phenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-54-6P, Glycine,
N-[[4-(4-bromophenoxy)phenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-55-7P, Glycine,
N-[[4-(4-chlorophenoxy)phenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-56-8P, Glycine,
N-[[4-(4-methylphenoxy)phenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-57-9P, Glycine,
N-[[4-(4-methoxyphenoxy)phenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-58-0P, Glycine,
N-[[4-(2-chlorophenoxy)phenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-59-1P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-[4-(trifluoromethyl)phenoxy]phenyl)methyl]- 331740-60-4P, Glycine,
N-[[4-(3,5-dichlorophenoxy)phenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-61-5P, Glycine,
N-[[4-(4-fluorophenoxy)phenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-62-6P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(3-thienyloxy)phenyl)methyl]- 331740-63-7P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-[4-(methylthio)phenoxy]phenyl)methyl]- 331740-64-8P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[3-phenoxy-2-thienyl)methyl]- 331740-65-9P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-[3-(trifluoromethyl)phenoxy]phenyl)methyl]- 331740-66-0P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(3-nitrophenoxy)phenyl)methyl]- 331740-67-1P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(phenylamino)phenyl)methyl]- 331740-68-2P, Glycine,
N-[[4-(1H-imidazol-1-yl)phenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-69-3P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(4-pyridinyl)phenyl)methyl]- 331740-70-6P, Glycine,
N-[[4'-(aminocarbonyl)[1,1'-biphenyl]-4-yl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-71-7P, Glycine,
N-[(3',5'-dichloro[1,1'-biphenyl]-4-yl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-72-8P, Glycine,
N-[(3'-methoxy[1,1'-biphenyl]-4-yl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-73-9P, Glycine,
N-[(3',4'-difluoro[1,1'-biphenyl]-4-yl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-74-0P, Glycine,
N-[(3'-fluoro[1,1'-biphenyl]-4-yl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-75-1P, Glycine,
N-[[4-(3-furanyl)phenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-76-2P, Glycine,

N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(2-thienyl)phenyl]methyl]- 331740-77-3P, Glycine,
N-[(3-methoxy-4-phenoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-78-4P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-nitro-4-phenoxyphenyl)methyl]- 331740-79-5P, Glycine,
N-[(3-methyl-4-phenoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-80-8P, Glycine,
N-[(3-chloro-4-phenoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-81-9P, Glycine,
N-[(2-methoxy-4-phenoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-82-0P, Glycine,
N-[(2-chloro-4-phenoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-83-1P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-nitro-3-phenoxyphenyl)methyl]- 331740-84-2P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-nitro-5-phenoxyphenyl)methyl]- 331740-85-3P, Glycine,
N-[(6-methoxy-2-naphthalenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-86-4P, Glycine,
N-[(4-methoxy-1-naphthalenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-87-5P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(2-pyrimidinyl)phenyl]methyl]- 331740-88-6P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(5-pyrimidinyl)phenyl]methyl]- 331740-89-7P, Glycine,
N-(1H-indol-2-yl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-90-0P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(1R)-1-phenylethyl]- 331740-91-1P, D-Alanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-92-2P, D-Phenylalanine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-93-3P, D-Alanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- 331740-94-4P, D-Phenylalanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- 331740-95-5P, L-Phenylalanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- 331740-96-6P, D-Valine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- 331740-97-7P, Acetic acid, (2,2-dimethylpropoxy)[[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)[(4-phenoxyphenyl)methyl]amino]-, (2R)- 331740-98-8P, D-Serine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- 331740-99-9P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy)carbonyl]- 331741-00-5P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy)carbonyl]- 331741-01-6P, Glycine, N-[(2-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-02-7P, Glycine, N-[(3,5-dichlorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-03-8P, Glycine, N-[[3-(3-methoxyphenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-04-9P, Glycine, N-[[4-(difluoromethoxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-05-0P, Glycine, N-[[4-(difluoromethoxy)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-06-1P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-

(phenylmethoxy)phenoxy]carbonyl]- 331741-07-2P, Glycine,
N-[(4-hydroxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-08-3P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenoxy)carbonyl]- 331741-09-4P, Glycine, N-[(4-chloro-3-fluorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-10-7P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-phenoxyphenyl]methoxy]carbonyl]- 331741-11-8P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-propynyloxy)carbonyl]- 331741-12-9P, Glycine,
N-[(4-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-13-0P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-14-1P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-nitrophenoxy)carbonyl]- 331741-15-2P, Glycine,
N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-16-3P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-nitrophenyl]methoxy]carbonyl]- 331741-17-4P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-nitrophenoxy)carbonyl]- 331741-18-5P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenoxy)carbonyl]- 331741-19-6P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-phenoxyphenyl)methoxy]carbonyl]- 331741-20-9P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-phenoxyphenyl]methoxy]carbonyl]- 331741-21-0P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-phenoxyphenoxy)carbonyl]- 331741-22-1P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-phenoxyphenoxy)carbonyl]- 331741-23-2P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-phenoxyethoxy)carbonyl]- 331741-24-3P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[(2E)-3-phenyl-2-propenyl]oxy]carbonyl]- 331741-25-4P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-phenyl-2-propynyl]oxy]carbonyl]- 331741-26-5P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-phenylethoxy)carbonyl]- 331741-27-6P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-phenylpropoxy)carbonyl]- 331741-28-7P
Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[(2Z)-3-phenyl-2-propenyl]oxy]carbonyl]- 331741-29-8P,
Glycine, N-[(4-fluoro-3-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-30-1P, Glycine,
N-[(3-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-31-2P, Glycine,
N-[(3,4-dimethoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-32-3P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3,4,5-trimethoxyphenoxy)carbonyl]- 331741-33-4P, Glycine,
N-[[3-(3-methoxyphenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-34-5P, Glycine,
N-[[4-(4-methoxyphenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-35-6P, Glycine,
N-[(1,3-benzodioxol-5-ylmethoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-36-7P, Glycine,

N-[(1,3-benzodioxol-5-yloxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-37-8P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(trifluoromethoxy)phenoxy]carbonyl]- 331741-38-9P, Glycine,
N-[[4-methoxy-1-naphthalenyl]oxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-39-0P, Glycine,
N-[(2,3-dimethoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-40-3P, Benzoic acid,
4-[[[(carboxymethyl)[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]carbonyl]oxy]-, 1-methyl ester 331741-41-4P, Glycine, N-[(4-bromo-3-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-42-5P, Glycine, N-[[4-(1,3-dithiolan-2-yl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-43-6P, Glycine, N-[(4-chloro-3-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-44-7P, Glycine, N-[(4-fluorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-45-8P, Glycine, N-[(4-chlorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-46-9P, Glycine, N-[(4-bromophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-47-0P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-(trifluoromethoxy)phenoxy]carbonyl]- 331741-48-1P, Glycine, N-[(3-fluorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-49-2P, Glycine, N-[(3-chlorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-50-5P, Glycine, N-[(3-bromophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-51-6P, Glycine, N-[[3-(acetyloxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-52-7P, Glycine, N-[(4-acetylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-53-8P, Glycine, N-[(3-acetylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-54-9P, Glycine, N-[[2,3-dihydro-3-oxo-6-benzofuranyl]oxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-55-0P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(1,2,3-thiadiazol-4-yl)phenoxy]carbonyl]- 331741-56-1P, Glycine, N-[(3-hydroxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-57-2P, Glycine, N-[(3-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-58-3P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3,4,5-trimethylphenoxy)carbonyl]- 331741-59-4P, Glycine, N-[(4-ethoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-60-7P, Glycine, N-[(3-ethoxy-4-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-61-8P, Glycine, N-[(4-cyclopentylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-63-0P, Glycine, N-[(4-ethenylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-64-1P, Glycine, N-[[4-(3-methylbutyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-65-2P, Glycine, N-[(4-butylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-66-3P, Glycine, N-[(4-hexylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]phenyl)methyl]- 331741-67-4P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[3-(4-morpholinyl)phenoxy]carbonyl]- 331741-68-5P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[5,6,7,8-tetrahydro-2-naphthalenyl)oxy]carbonyl]- 331741-69-6P, Glycine,
N-[[3-(1,1-dimethylethyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-70-9P, Glycine,
N-[[3-(1-methylethyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-71-0P, Glycine,
N-[[3-(4-dimethylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-72-1P, Glycine,
N-[[3-(5-dimethylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

IT 331741-73-2P, Glycine, N-[[3-(ethylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-74-3P, Glycine, N-[[4-(1,1-dimethylethyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-75-4P, Glycine, N-[[4-(1-methylethyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-76-5P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(phenylmethyl)phenoxy]carbonyl]- 331741-77-6P, Glycine, N-[[4-(ethylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-78-7P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(propylphenoxy)carbonyl]- 331741-79-8P, Glycine, N-[[2,3-dihydro-1H-inden-5-yl)oxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-80-1P, Glycine, N-[[3-(ethoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-81-2P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(pentylphenoxy)carbonyl]- 331741-82-3P, Glycine, N-[[4-(fluoro-3-(trifluoromethyl)phenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-83-4P, Glycine, N-[[3-(3-fluorophenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-84-5P, Glycine, N-[[3-(3-chlorophenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-85-6P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[3-(trifluoromethoxy)phenyl)methoxy]carbonyl]- 331741-86-7P, Glycine, N-[[4-(fluorophenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-87-8P, Glycine, N-[[4-(chlorophenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-88-9P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(trifluoromethoxy)phenyl)methoxy]carbonyl]- 331741-89-0P, Glycine, N-[[3-(3,5-dimethoxyphenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-90-3P, Glycine, N-[[3-(acetyloxy)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-91-4P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[3-(phenoxyphenyl)methoxy]carbonyl]- 331741-92-5P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[2-(propynyloxy)carbonyl]- 331741-93-6P, Glycine, N-[[4-(methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]phenyl)methyl]- 331741-94-7P, Glycine,
N-[[4-(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-95-8P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2-nitrophenoxy)carbonyl]- 331741-96-9P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(phenoxycarbonyl)- 331741-97-0P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-nitrophenyl)methoxy]carbonyl]- 331741-98-1P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-nitrophenoxy)carbonyl]- 331741-99-2P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-phenoxyphenoxy)carbonyl]- 331742-00-8P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[2-phenoxyphenyl)methoxy]carbonyl]- 331742-01-9P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-phenoxyphenyl)methoxy]carbonyl]- 331742-02-0P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3-phenoxyphenoxy)carbonyl]- 331742-03-1P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2-phenoxyphenoxy)carbonyl]- 331742-04-2P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2-phenoxyethoxy)carbonyl]- 331742-05-3P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[[(2E)-3-phenyl-2-propenyl]oxy]carbonyl]- 331742-06-4P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[[(3-phenyl-2-propynyl]oxy]carbonyl]- 331742-07-5P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2-phenylethoxy)carbonyl]- 331742-08-6P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3-phenylpropoxy)carbonyl]- 331742-09-7P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[[(2Z)-3-phenyl-2-propenyl]oxy]carbonyl]- 331742-10-0P, Glycine,
N-[(2-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-11-1P, Glycine,
N-[(3-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-12-2P, Glycine,
N-[(3,4-dimethoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-13-3P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3,4,5-trimethoxyphenoxy)carbonyl]- 331742-14-4P, Glycine,
N-[(3-acetylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-15-5P, Glycine,
N-[[4-(4-methoxyphenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-16-6P, Glycine,
N-[(1,3-benzodioxol-5-ylmethoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-17-7P, Glycine,
N-[(1,3-benzodioxol-5-yloxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-18-8P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(trifluoromethoxy)phenoxy]carbonyl]- 331742-19-9P, Glycine,
N-[[4-(4-methoxy-1-naphthalenyl)oxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-20-2P, Glycine,
N-[(2,3-dimethoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-21-3P, Benzoic acid,
4-[[[(carboxymethyl)[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]amino]carbonyl]oxy]-, 1-methyl ester 331742-22-4P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(phenylmethoxy)phenoxy]carbonyl]-

331742-23-5P, Glycine, N-[(4-hydroxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-24-6P, Glycine, N-[(4-bromo-3-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-25-7P, Glycine, N-[(4-fluorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-26-8P, Glycine, N-[(4-chlorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-27-9P, Glycine, N-[(4-bromophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-28-0P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-(trifluoromethoxy)phenoxy]carbonyl]- 331742-29-1P, Glycine, N-[(3-fluorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-30-4P, Glycine, N-[(3-chlorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-31-5P, Glycine, N-[(3-bromophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-32-6P, Glycine, N-[(3,5-difluorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-33-7P, Glycine, N-[(3-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-34-8P, Glycine, N-[(3-chloro-4-fluorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-35-9P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3,4,5-trimethylphenoxy)carbonyl]- 331742-36-0P, Glycine, N-[(4-chloro-3,5-dimethylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-37-1P, Glycine, N-[(3,4-difluorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-38-2P, Glycine, N-[(4-ethenylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-39-3P, Glycine, N-[(4-fluoro-3-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-40-6P, Glycine, N-[(4-chloro-3-fluorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-41-7P, Glycine, N-[[3-methyl-4-(methylthio)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-42-8P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(1H-pyrrol-1-yl)phenoxy]carbonyl]- 331742-43-9P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]carbonyl]- 331742-44-0P, Glycine, N-[[[1,1'-biphenyl]-3-yloxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-45-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-(trifluoromethyl)phenoxy]carbonyl]- 331742-46-2P, Glycine, N-[[3-(1,1-dimethylethyl)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-47-3P, Glycine, N-[[3-(1-methylethyl)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-48-4P, Glycine, N-[(3,4-dimethylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-49-5P, Glycine, N-[(3,5-dimethylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-50-8P, Glycine, N-[(3-ethylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-51-9P, Glycine, N-[(4-chloro-3-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-52-0P, Glycine, N-[[4-(1-methylethyl)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]phenyl)methyl]- 331742-53-1P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(phenylmethyl)phenoxy]carbonyl]- 331742-54-2P, Glycine,
N-[[4-(4-ethylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-55-3P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-propylphenoxy]carbonyl]- 331742-56-4P, Glycine,
N-[[[2,3-dihydro-1H-inden-5-yl]oxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-57-5P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[2-naphthalenyloxy]carbonyl]- 331742-58-6P, Glycine,
N-[[3-ethoxyphenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-59-7P, Glycine,
N-[[3,5-dichlorophenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-60-0P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(1,2,3-thiadiazol-4-yl)phenoxy]carbonyl]- 331742-61-1P, Glycine,
N-[[4-fluoro-3-(trifluoromethyl)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-62-2P, Glycine,
N-[[3-methoxy-5-methylphenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-63-3P, Glycine,
N-[[3-fluorophenyl]methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-64-4P, Glycine,
N-[[3-chlorophenyl]methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-65-5P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[3-(trifluoromethoxy)phenyl]methoxy]carbonyl]- 331742-66-6P, Glycine,
N-[[4-fluorophenyl]methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-67-7P, Glycine,
N-[[4-chlorophenyl]methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-68-8P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(trifluoromethoxy)phenyl]methoxy]carbonyl]- 331742-69-9P, Glycine,
N-[[3,5-dimethoxyphenyl]methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-70-2P, Glycine,
N-[[3-(difluoromethoxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-71-3P, Glycine,
N-[[3-(difluoromethoxy)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-72-4P, Glycine,
N-[[3-hydroxyphenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-73-5P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(phenoxythioxomethyl)- 331742-74-6P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(phenoxythioxomethyl)- 331742-75-7P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(4-phenoxybenzoyl)- 331742-76-8P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(2-naphthalenylcarbonyl)- 331742-77-9P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(2-thienylcarbonyl)- 331742-78-0P, Glycine,
N-(3,5-dimethoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-79-1P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(1-naphthalenylcarbonyl)- 331742-80-4P, Glycine,
N-(3,4-difluorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-81-5P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(3-phenoxybenzoyl)- 331742-82-6P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[4-(phenylmethyl)benzoyl]-

331742-83-7P, Glycine, N-(3,5-dimethylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-84-8P, Glycine, N-([2,2'-bithiophen]-5-ylcarbonyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-85-9P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(5-methyl-2-thienyl)carbonyl]- 331742-86-0P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(5-nitro-2-thienyl)carbonyl]- 331742-87-1P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-methyl-2-thienyl)carbonyl]- 331742-88-2P, Glycine, N-(4-butoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-89-3P, Glycine, N-(4-methoxy-3-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-90-6P, Glycine, N-(3-chloro-4-methoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-91-7P, Glycine, N-(3,4-dimethylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-92-8P, Glycine, N-(4-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-93-9P, Glycine, N-(3-fluoro-4-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-94-0P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[4-(methylthio)benzoyl]- 331742-95-1P, Glycine, N-[4-(1-methylethyl)benzoyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-96-2P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[4-(2-methylpropyl)benzoyl]- 331742-97-3P, Glycine, N-(4-chloro-3-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-98-4P, Glycine, N-(3-methoxy-4-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-99-5P, Glycine, N-(1,3-benzodioxol-5-ylcarbonyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-00-1P, Glycine, N-[4-(1-methylethoxy)benzoyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-02-3P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(3-thienylcarbonyl)- 331743-04-5P, Glycine, N-benzoyl-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-05-6P, Glycine, N-(3-methoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-06-7P, Glycine, N-(4-fluorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-07-8P, Glycine, N-(3,4-dichlorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-08-9P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(4-propoxybenzoyl)- 331743-09-0P, Glycine, N-(4-ethoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-10-3P, Glycine, N-(3-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-11-4P, Glycine, N-(4-methoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-12-5P, Glycine, N-(3-chlorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-13-6P, Glycine, N-(4-chlorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-14-7P, Glycine, N-(4-butylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-15-8P, Glycine, N-(3,5-dichlorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-16-9P, Glycine,

N-(3-fluorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-17-0P, Glycine,
N-(3-chloro-4-fluorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-18-1P, Glycine,
N-(3-ethoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-19-2P,
Glycine, N-[(5-chloro-2-thienyl)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-20-5P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(5-methylthio)-2-thienyl]carbonyl]- 331743-21-6P, Glycine,
N-[(4-methylphenyl)acetyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-22-7P, Glycine,
N-[(3-fluorophenyl)acetyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-23-8P, Glycine,
N-[(3,5-difluorophenyl)acetyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-24-9P, Glycine,
N-(1,3-benzodioxol-5-ylacetyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-25-0P, Glycine,
N-[(4-ethoxyphenyl)acetyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-26-1P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-nitrophenyl)acetyl]- 331743-27-2P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-nitrophenyl)acetyl]- 331743-28-3P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(1-oxo-3-phenylpropyl)- 331743-29-4P, Glycine, N-([1,1'-biphenyl]-2-ylcarbonyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-30-7P,
Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(4-phenoxybenzoyl)- 331743-31-8P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[2-(phenylmethyl)benzoyl]- 331743-32-9P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[3-(phenylsulfinyl)benzoyl]- 331743-33-0P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[2-[(4-methylphenyl)thio]benzoyl]- 331743-34-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[2-(phenylsulfinyl)benzoyl]- 331743-35-2P, Glycine, N-(5-chloro-2-phenoxybenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-36-3P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-phenoxybenzoyl)- 331743-37-4P, Glycine, N-([1,1'-biphenyl]-4-ylcarbonyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-38-5P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(3-phenoxybenzoyl)- 331743-39-6P,
Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-phenoxyphenyl)acetyl]- 331743-40-9P, Glycine, N-([1,1'-biphenyl]-4-ylacetyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-41-0P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[4-(phenylmethyl)benzoyl]- 331743-42-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[2-(1H-pyrrol-1-yl)benzoyl]- 331743-43-2P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)acetyl]- 331743-44-3P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-phenoxyphenyl)acetyl]- 331743-45-4P, Glycine, N-([2,2'-bithiophen]-5-ylcarbonyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-46-5P, Glycine, N-(3,4-dimethylbenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-47-6P, Glycine,

N-(4-chloro-3-methylbenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-48-7P, Glycine,
N-(3,4-difluorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-49-8P, Glycine,
N-(3,4-dichlorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-50-1P, Glycine,
N-(3-chlorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-51-2P, Glycine,
N-(4-chlorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-52-3P, Glycine,
N-(3-chloro-4-fluorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-53-4P, Glycine,
N-[4-(1-methylethyl)benzoyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-54-5P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[4-(2-methylpropyl)benzoyl]- 331743-55-6P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(4-propoxybenzoyl)- 331743-56-7P, Glycine, N-(4-butylbenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-57-8P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-(methylthio)-2-thienyl]carbonyl]-
331743-58-9P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[(phenylmethyl)amino]carbonyl]-
331743-59-0P, Glycine, N-[[4-(methoxyphenyl)amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-60-3P, Glycine, N-[[4-(methoxyphenyl)methylamino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-61-4P, Glycine, N-[[[1,1'-biphenyl]-4-ylamino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-62-5P, Glycine, N-[[[3,5-dimethoxyphenyl]amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-63-6P, Glycine, N-[[[3,5-dichlorophenyl]amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-64-7P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[3-(methylthio)phenyl]amino]carbonyl]-
331743-65-8P, Glycine, N-[[[2,4-difluorophenyl]amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-66-9P, Glycine, N-[[[2,4-dimethoxyphenyl]amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-67-0P, Glycine, N-[[[2-methoxyphenyl]amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-68-1P, Glycine, N-[[[1,1'-biphenyl]-4-ylamino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-69-2P, Glycine, N-[[[3,5-dimethoxyphenyl]amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-70-5P, Glycine, N-[[[3,5-dichlorophenyl]amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-71-6P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[3-(methylthio)phenyl]amino]carbonyl]-
331743-72-7P, Glycine, N-[[[2,4-difluorophenyl]amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-73-8P, Glycine, N-[[[2,4-dimethoxyphenyl]amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-74-9P, Glycine, N-[[[4-methoxyphenyl]amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-75-0P, Glycine, N-[[[2-methoxyphenyl]amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-76-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(1-naphthalenylsulfonyl)-

331743-77-2P, Glycine, N-[[[4-fluorophenyl)methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-
331743-78-3P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(phenylsulfonyl)- **331743-79-4P**, Glycine, N-[(2,5-dichlorophenyl)sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- **331743-80-7P**, Glycine, N-[[4-fluorophenyl)sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- **331743-81-8P**, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(phenylmethyl)sulfonyl]- **331743-82-9P**, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[1E]-2-phenylethenyl)sulfonyl]- **331743-83-0P**, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2,2,2-trifluoroethyl)sulfonyl]- **331743-84-1P**, Glycine, N-[(2,5-dimethylphenyl)sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

IT **331743-85-2P**, Glycine, N-[(3,4-dichlorophenyl)sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- **331743-86-3P**, Glycine, N-[(2,5-dichloro-3-thienyl)sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- **331743-87-4P**, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[5-(2-pyridinyl)sulfonyl]-2-thienyl)sulfonyl]- **331743-88-5P**, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[[3-(trifluoromethyl)phenyl)methyl]sulfonyl]- **331743-89-6P**, Glycine, N-[[[3-methylphenyl)methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- **331743-90-9P**, Glycine, N-[[[2-fluorophenyl)methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- **331743-91-0P**, Glycine, N-[[4-chlorophenyl)sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- **331743-92-1P**, Glycine, N-[[[3,4-dichlorophenyl)sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- **331743-93-2P**, Glycine, N-[[[2-chloro-6-fluorophenyl)methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- **331743-94-3P**, Glycine, N-[[[4-chlorophenyl)methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- **331743-95-4P**, Glycine, N-[[[2-chlorophenyl)methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- **331743-96-5P**, Glycine, N-[[[2,4-dichlorophenyl)methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- **331743-97-6P**, Glycine, N-[[[2-methylphenyl)methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- **331743-98-7P**, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[[4-(trifluoromethoxy)phenyl)methyl]sulfonyl]- **331743-99-8P**, Glycine, N-[[[4-(1,1-dimethylethyl)phenyl)methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- **331744-00-4P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-propylphenyl)sulfonyl]- **331744-01-5P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(2-naphthalenylsulfonyl)- **331744-02-6P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(phenylsulfonyl)- **331744-03-7P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2,4,6-trimethylphenyl)sulfonyl]- **331744-04-8P**, Glycine,

N-[(4-chlorophenyl)sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-05-9P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethyl)sulfonyl]- 331744-06-0P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(1E)-2-phenylethenyl]sulfonyl]- 331744-07-1P, Glycine,
N-[(2,5-dimethylphenyl)sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-08-2P, Glycine,
N-[(3,4-dichlorophenyl)sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-09-3P, Glycine,
N-[[4-(2-chloro-6-nitrophenoxy)phenyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-10-6P, Glycine,
N-(2-dibenzofuranylsulfonyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-11-7P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[3-(trifluoromethyl)phenyl]methyl]sulfonyl]- 331744-12-8P, Glycine,
N-[[[3-methylphenyl]methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-13-9P, Glycine,
N-[[[2-fluorophenyl]methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-14-0P, Glycine,
N-[[[4-fluorophenyl]methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-15-1P, Glycine,
N-[[[3,4-dichlorophenyl]methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-16-2P, Glycine,
N-[[[2-chloro-6-fluorophenyl]methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-17-3P, Glycine,
N-[[[4-chlorophenyl]methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-18-4P, Glycine,
N-[[[2-chlorophenyl]methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-19-5P, Glycine,
N-[[[2,4-dichlorophenyl]methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-20-8P, Glycine,
N-[[[2-methylphenyl]methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-21-9P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[4-(trifluoromethoxy)phenyl]methyl]sulfonyl]- 331744-22-0P, Glycine,
N-[[[4-(1,1-dimethylethyl)phenyl]methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-23-1P, Glycine,
N-[[[6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-3-pyridinyl]methyl]-N-[[4-(phenoxyphenyl)methyl]- 331744-24-2P, Glycine,
N-[[[6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-pyridinyl]methyl]-N-[[4-(phenoxyphenyl)methyl]- 331744-25-3P, Glycine,
N-[2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-N-[[4-(phenoxyphenyl)methyl]- 331744-26-4P, Glycine,
N-[[5-(2-chlorophenyl)-2-furanyl]methyl]-N-[2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331744-27-5P, Glycine,
N-[2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-N-[(phenylmethoxy)carbonyl]- 331744-28-6P, Glycine,
N-[2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-N-(phenylmethyl)- 331744-29-7P, Carbamic acid, [[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl](1H-tetrazol-5-ylmethyl)-, 4-methoxyphenyl ester 331744-30-0P, Glycine, N-[[4-(methoxyphenoxy)carbonyl]-N-[[2-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-31-1P, β -Alanine, N-[[3-(chlorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-32-2P, β -Alanine, N-[[3-(chlorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-33-3P, β -Alanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenoxy carbonyl)- 331744-34-4P

, β -Alanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]-**331744-35-5P**, β -Alanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy)carbonyl]-**331744-36-6P**, β -Alanine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenoxycarbonyl)-**331744-37-7P**, β -Alanine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]-**331744-38-8P**, β -Alanine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy)carbonyl]-**331744-39-9P**, Glycine, N-[(3-cyclopropylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-**331744-40-2P**, Glycine, N-[[3-(cyclopropyloxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-**331744-41-3P**, Glycine, N-[[3-(cyclopropyloxy)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-**331744-42-4P**, Glycine, N-[(3-fluoro-4-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-**331744-43-5P**, Glycine, N-[(3-chloro-4-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-**331744-44-6P**, Glycine, N-[(3-bromo-4-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-**331744-45-7P**, Glycine, N-[(3-fluoro-4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-**331744-46-8P**, Glycine, N-[(3-chloro-4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-**331744-47-9P**, Glycine, N-[(3-bromo-4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-**331744-48-0P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-propylphenoxy)carbonyl]-**331744-49-1P**, Glycine, N-[(4-cyclopropylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-**331744-50-4P**, Glycine, N-[[4-(cyclopropyloxy)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-**331744-51-5P**, Glycine, N-[(3-fluoro-4-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-**331744-52-6P**, Glycine, N-[(3-chloro-4-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-**331744-53-7P**, Glycine, N-[(3-bromo-4-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-**331744-54-8P**, Glycine, N-[(3-fluoro-4-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-**331744-55-9P**, Glycine, N-[(3-chloro-4-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-**331744-56-0P**, Glycine, N-[(3-bromo-4-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-**331744-57-1P**, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-propylphenoxy)carbonyl]-**331744-58-2P**, Glycine, N-[(3-cyclopropylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-**331744-59-3P**, Glycine, N-[(4-cyclopropylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-**331744-60-6P**, Glycine, N-[[4-(cyclopropyloxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-**331744-61-7P**, Benzoic acid, 2-(carboxymethyl)-2-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]hydrazide **331744-62-8P**, Benzoic acid, 2-(carboxymethyl)-2-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]hydrazide **331744-63-9P**, Glycine, N-[(4-methylphenoxy)carbonyl]-N-[1-[3-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]phenyl]ethyl]- 331744-64-0P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331744-65-1P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331744-66-2P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]pentyl]- 331744-67-3P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-3-butenyl]- 331744-68-4P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]butyl]- 331744-69-5P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]phenyl]ethyl]- 331744-70-8P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]phenyl]ethyl]- 331744-71-9P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]cyclopropyl]- 331744-72-0P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331744-73-1P, Glycine,
N-[(4-methylphenoxy)carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331744-74-2P, Glycine,
N-[(4-methylphenoxy)carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]pentyl]- 331744-75-3P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]propyl]- 331744-76-4P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]butyl]- 331744-77-5P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331744-78-6P, Glycine,
N-[(3-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331744-79-7P, Glycine,
N-[(3-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331744-80-0P, Glycine,
N-[(4-methylphenoxy)carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331744-81-1P, Glycine,
N-[(4-methylphenoxy)carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331744-82-2P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331744-83-3P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331744-84-4P, Alanine,
N-[(4-methoxyphenoxy)carbonyl]-2-methyl-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-85-5P, Cyclopropanecarboxylic acid, 1-[[4-methoxyphenoxy]carbonyl][4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]- 331744-86-6P,
Cyclopropanecarboxylic acid, 1-[[4-methylphenoxy]carbonyl][4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]- 331744-87-7P, L-Alanine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-88-8P,
L-Alanine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy)carbonyl]- 331744-89-9P, D-Alanine,
N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-90-2P, D-Alanine,
N-[(4-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-91-3P, D-Alanine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy)carbonyl]- 331744-92-4P, Cyclopropanecarboxylic acid, 1-[[4-methoxyphenoxy]carbonyl][3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]- 331744-93-5P,

Cyclopropanecarboxylic acid, 1-[[(4-methylphenoxy) carbonyl] [[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]-
331744-94-6P, Alanine, N-[(4-methoxyphenoxy) carbonyl]-2-methyl-N-
[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331744-95-7P, D-Alanine, N-[(4-methoxyphenoxy) carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-96-8P**
, D-Alanine, N-[(4-methylphenoxy) carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-97-9P**, D-Alanine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-
[(phenylmethoxy) carbonyl]- **331744-98-0P**, L-Alanine,
N-[(4-methoxyphenoxy) carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-99-1P**, L-Alanine,
N-[(4-methylphenoxy) carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331745-00-7P**, L-Alanine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-
[(phenylmethoxy) carbonyl]- **331745-01-8P**, L-Alanine,
N-[(4-methoxyphenoxy) carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- **331745-02-9P**, D-Alanine,
N-[(4-methoxyphenoxy) carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- **331745-03-0P**, L-Alanine,
N-[(4-methoxyphenoxy) carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- **331745-04-1P**, D-Alanine,
N-[(4-methoxyphenoxy) carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- **331745-05-2P**, Glycine,
N-[(4-methylphenoxy) carbonyl]-N-[[3-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]- **331745-06-3P**, Glycine,
N-[(4-methylphenoxy) carbonyl]-N-[[4-[4-(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- **331745-07-4P**, Glycine,
N-[(4-methoxyphenoxy) carbonyl]-N-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl]methyl]- **331745-08-5P**, Glycine,
N-[(4-methoxyphenoxy) carbonyl]-N-[[4-[2-methyl-2-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]- **331745-09-6P**, Glycine,
N-[(4-methoxyphenoxy) carbonyl]-N-[[4-[[(2Z)-3-(5-methyl-2-phenyl-4-oxazolyl)-2-propenyl]oxy]phenyl]methyl]- **331745-10-9P**, Glycine,
N-[(4-methoxyphenoxy) carbonyl]-N-[[3-[2-methyl-2-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]- **331745-11-0P**, Glycine,
N-[(4-methylphenoxy) carbonyl]-N-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]- **331745-12-1P**, Glycine,
N-[(4-methoxyphenoxy) carbonyl]-N-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]- **331745-13-2P**, Glycine,
N-[(4-methoxyphenoxy) carbonyl]-N-[[4-[4-(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- **331745-14-3P**, Glycine,
N-[[4-[2-methyl-2-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]-N-
[(4-methylphenoxy) carbonyl]- **331745-15-4P**, Glycine,
N-[(4-methoxyphenoxy) carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]- **331745-16-5P**, Glycine,
N-[(4-methylphenoxy) carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]- **331745-17-6P**, Glycine,
N-[(4-methoxyphenoxy) carbonyl]-N-[[3-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]- **331745-18-7P**, Glycine,
N-[(4-methylphenoxy) carbonyl]-N-[[3-[4-(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- **331745-19-8P**, Glycine,
N-[(4-methoxyphenoxy) carbonyl]-N-[[3-[4-(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- **331745-20-1P**, Glycine,
N-[(4-methoxyphenoxy) carbonyl]-N-[[3-[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl]methyl]- **331745-21-2P**, Glycine,
N-[(4-methylphenoxy) carbonyl]-N-[[3-[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl]methyl]- **331745-22-3P**, Glycine,
N-(5-methyl-2-benzoxazolyl)-N-[[3-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]phenyl)methyl]- 331745-23-4P, Glycine,
N-(5-methyl-2-benzoxazolyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331745-24-5P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl)methyl]- 331745-25-6P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl]ethyl]- 331745-26-7P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl]ethyl]- 331745-27-8P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)-1-propynyl]phenyl)methyl]- 331745-28-9P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)propyl]phenyl)methyl]- 331745-29-0P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)-1,2-propadienyl]phenyl)methyl]- 331745-30-3P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[(1Z)-3-(5-methyl-2-phenyl-4-oxazolyl)-1-propenyl]phenyl)methyl]- 331745-31-4P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[(1R,2R)-2-[(5-methyl-2-phenyl-4-oxazolyl)methyl]cyclopropyl]phenyl)methyl]-, rel- 331745-32-5P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[(1E)-3-(5-methyl-2-phenyl-4-oxazolyl)-1-propenyl]phenyl)methyl]- 331745-33-6P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]phenyl)methyl]-N-[(phenylmethoxy)carbonyl]- 331745-34-7P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]phenyl)methyl]-N-[(4-phenoxyphenyl)methyl]- 331745-35-8P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-[5-methyl-2-(4-pyridinyl)-4-thiazolyl]ethoxy]phenyl)methyl]- 331745-36-9P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[3-(5-methyl-2-phenyl-4-oxazolyl)-1,2-propadienyl]phenyl)methyl]- 331745-37-0P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[3-(5-methyl-2-phenyl-4-oxazolyl)propyl]phenyl)methyl]- 331745-38-1P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[3-(5-methyl-2-phenyl-4-oxazolyl)-1-propynyl]phenyl)methyl]- 331745-39-2P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[(1Z)-3-(5-methyl-2-phenyl-4-oxazolyl)-1-propenyl]phenyl)methyl]- 331745-40-5P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[(1E)-3-(5-methyl-2-phenyl-4-oxazolyl)-1-propenyl]phenyl)methyl]- 331745-41-6P, Glycine,
N-[[4-[2-[2-(4-chlorophenyl)-5-methyl-4-thiazolyl]ethoxy]phenyl)methyl]-N-[(4-methoxyphenoxy)carbonyl]- 331745-42-7P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-[2-(3-methoxyphenyl)-5-methyl-4-thiazolyl]ethoxy]phenyl)methyl]- 331745-43-8P, Glycine,
N-[[3-[2-[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl)methyl]-N-[(4-methylphenoxy)carbonyl]- 331745-44-9P, Glycine, N-[[3-[2-[2-(2-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl)methyl]-N-[(4-methylphenoxy)carbonyl]- 331745-45-0P, Glycine, N-[[4-[2-[2-(2-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl)methyl]-N-[(4-methoxyphenoxy)carbonyl]- 331745-46-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(oxophenylacetyl)- 331745-47-2P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(oxophenylacetyl)- 331745-48-3P, Glycine, N-[[6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-pyridinyl]methyl]-N-[(3-phenoxyphenyl)methyl]- 331745-49-4P, Glycine, N-[[4-(4-methoxyphenyl)thio]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331745-60-9P, Glycine, N-[(3-methylphenoxy)carbonyl]-N-[(1S)-1-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]ethyl]- 331745-69-8P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(1S)-1-phenylethyl]- 331745-80-3P, Glycine, N-[[6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-3-pyridinyl]methyl]-N-[(4-

phenoxyphenyl)methyl]-, mono(trifluoroacetate) **331745-86-9P**,
 Glycine, N-[[6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-
 pyridinyl)methyl]-N-[(4-phenoxyphenyl)methyl]-, mono(trifluoroacetate)
331746-91-9P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[3-methyl-
 1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-3-butenyl]-
331746-92-0P, Glycine, N-[[4-(4-methoxyphenyl)thio]carbonyl]-N-[[4-
 [2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-
331746-93-1P, L-Alanine, N-[[3-[2-(5-methyl-2-phenyl-4-
 oxazolyl)ethoxy]phenyl)methyl]-N-[(4-phenoxyphenyl)methyl]-
331746-95-3P, Glycine, N-(6-methyl-2-benzoxazolyl)-N-[[3-[2-(5-
 methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- **439276-48-9P**
439276-49-0P 439276-50-3P 439276-51-4P
439276-54-7P 439276-55-8P 439276-57-0P
439276-58-1P 439276-59-2P 439276-61-6P
439276-62-7P 439579-19-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related
 compds. as antidiabetic and antiobesity agents)

IT 65-85-0, Benzoic acid, reactions 66-99-9, 2-Naphthaldehyde 67-36-7,
 4-Phenoxybenzaldehyde 85-46-1, 1-Naphthalenesulfonyl chloride 90-05-1,
 2-Methoxyphenol 93-09-4, 2-Naphthalenecarboxylic acid 94-53-1,
 Piperonylic acid 96-32-2, Methyl bromoacetate 98-88-4, Benzoyl
 chloride 100-83-4, 3-Hydroxybenzaldehyde 102-29-4, Resorcinol
 monoacetate 103-16-2, 4-Benzyloxyphenol 105-36-2, Ethyl bromoacetate
 106-95-6, Allyl bromide, reactions 106-96-7, Propargyl bromide
 121-71-1, Ethanone, 1-(3-hydroxyphenyl)- 123-08-0, 4-Hydroxybenzaldehyde
 151-18-8, 2-Cyanoethylamine 455-91-4, 3'-Fluoro-4'-methoxyacetophenone
 501-53-1, Benzyl chloroformate 527-72-0, 2-Thiophenecarboxylic acid
 591-35-5, 3,5-Dichlorophenol 615-18-9, 2-Chlorobenzoxazole 621-84-1,
 Benzyl carbamate 623-33-6, Glycine ethyl ester hydrochloride 626-02-8,
 3-Iodophenol 626-55-1, 3-Bromopyridine 766-85-8, 3-Iodoanisole
 768-35-4, 3-Fluorophenylboronic acid 815-60-1, 2,4-Dibromo-3-pentanone
 937-62-2, 4-Methylphenyl chloroformate 1005-56-7, Phenyl
 chlorothionoformate 1066-54-2, Trimethylsilylacetylene 1132-21-4,
 3,5-Dimethoxybenzoic acid 1700-37-4, 3-Benzyloxybenzaldehyde
 2215-77-2, p-Phenoxybenzoic acid 2589-71-1, 1-Pentanone,
 1-(4-hydroxyphenyl)- 2627-86-3, (S)- α -Methylbenzylamine
 2835-98-5, Phenol, 2-amino-5-methyl- 3173-56-6, Benzyl isocyanate
 3403-25-6 3424-93-9, 4-Methoxybenzamide 3886-69-9, Benzenemethanamine,
 α -methyl-, (α R)- 4949-44-4, Ethyl propionylacetate
 5292-43-3, tert-Butyl bromoacetate 5345-54-0, 3-Chloro-4-methoxyaniline
 5416-93-3, 4-Methoxyphenyl isocyanate 5680-79-5, Glycine methyl ester
 hydrochloride 5961-59-1, N-Methyl-p-anisidine 6436-90-4,
 N-Benzylglycine ethyl ester 6945-92-2, Ethyl hydrazinoacetate
 hydrochloride 7693-41-6, 4-Methoxyphenyl chloroformate 7699-00-5,
 Propanoic acid, 2-hydroxy-, ethyl ester, (2R)- 7745-91-7,
 3-Bromo-4-methylaniline 15028-41-8, Methyl α -aminoisobutyrate
 hydrochloride 15894-04-9, 4-Fluorobenzyl mercaptan 16728-01-1,
 Cyclopropanecarboxylic acid, 1-(4-methoxyphenyl)- 19621-92-2,
 2-Hydroxypyridine-6-carboxylic acid 22038-86-4, (R)-1-(4-
 Methoxyphenyl)ethylamine 27492-46-2, Oxazole, 4,5-dimethyl-2-phenyl-,
 3-oxide 27532-96-3, Glycine tert-butyl ester hydrochloride 30414-53-0,
 Methyl propionylacetate 34035-03-5, 2-Furancarboxaldehyde,
 5-(4-chlorophenyl)- 41851-59-6, (S)-1-(4-Methoxyphenyl)ethylamine
 50428-03-0, 4-Pentynoic acid, 2-amino- 50868-72-9, Benzenamine,
 5-methoxy-2-methyl- 59531-86-1 64318-28-1, Carbamic acid,
 [2-(4-hydroxyphenyl)ethyl]-, 1,1-dimethylethyl ester 66171-50-4, Methyl

2-hydroxypyridine-5-carboxylate 81228-89-9, Carbonochloridic acid, (3-methoxyphenyl)methyl ester 87199-17-5, 4-Formylphenylboronic acid 103788-65-4, 4-Oxazoleethanol, 5-methyl-2-phenyl- 107367-98-6, 2-Phenyl-5-methyloxazole-4-acetic acid 164660-78-0, Phenol, 3-[(trimethylsilyl)ethynyl]-, acetate 175136-30-8, 4-Thiazoleethanol, 5-methyl-2-phenyl- 182913-11-7, Glycine, N-[(2-hydroxyphenyl)methyl]-, methyl ester 331746-63-5, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, 1,1-dimethylethyl ester 331746-64-6, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester 331746-65-7, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester 331746-66-8, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, mono(trifluoroacetate) 331746-68-0, Glycine, N-[[3-(difluoromethoxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, 1,1-dimethylethyl ester 331746-69-1, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(4-phenoxybenzoyl)-, 1,1-dimethylethyl ester 331746-70-4, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-naphthalenylcarbonyl)-, 1,1-dimethylethyl ester 331746-71-5, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(1-naphthalenylsulfonyl)-, 1,1-dimethylethyl ester 331746-72-6, 3-Pyridinemethanol, 6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- 331746-73-7, Benzenesulfonamide, N-[2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-2,4-dinitro- 331746-74-8, β -Alanine, N-[(3-chlorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester 331746-75-9, Glycine, N-(chlorocarbonyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester 331746-76-0, Glycine, N-[[3-(cyclopropyloxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester 331746-78-2, Glycine, N-[(1S)-1-(4-methoxyphenyl)ethyl]-, methyl ester 331746-80-6, Glycine, N-[(1R)-1-(4-hydroxyphenyl)ethyl]-N-[(4-methoxyphenoxy)carbonyl]-, ethyl ester 331746-81-7, Glycine, N-[(1S)-1-(4-hydroxyphenyl)ethyl]-N-[(4-methoxyphenoxy)carbonyl]-, ethyl ester 331746-82-8, Glycine, N-[(4-hydroxyphenyl)methyl]-, methyl ester 331746-83-9, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl]methyl]-, 1,1-dimethylethyl ester 331746-84-0, Glycine, N-[(4-iodophenyl)methyl]-, methyl ester 331746-85-1, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[(1Z)-3-(5-methyl-2-phenyl-4-oxazolyl)-1-propenyl]phenyl]methyl]-, methyl ester 331746-86-2, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[(1R,2R)-2-[(5-methyl-2-phenyl-4-oxazolyl)methyl]cyclopropyl]phenyl]methyl]-, methyl ester, rel- 331746-87-3, Glycine, N-[(4-hydroxyphenyl)methyl]-N-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester 331746-88-4, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester 331746-89-5, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]-, methyl ester 331746-90-8, Glycine, N-[(4-hydroxyphenyl)methyl]-N-[(4-phenoxyphenyl)methyl]-, methyl ester

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

IT 405-06-1P, Benzene, 2-fluoro-4-methoxy-1-methyl- 452-78-8P, Phenol, 3-fluoro-4-methyl- 621-27-2P, 3-Propylphenol 768-70-7P, Benzene, 1-ethynyl-3-methoxy- 2293-75-6P, 2-Methoxyphenyl chloroformate 2454-30-0P, Phenol, 3-ethenyl-, acetate 3621-83-8P, Benzoxazole, 2-chloro-6-methyl- 4847-94-3P, Piperonylamide 10401-12-4P, Phenol, 3-ethynyl-, acetate 18093-12-4P, 3-Chloro-4-methoxyphenol 23417-29-0P,

2(3H)-Benzoxazolethione, 6-methyl- 28857-88-7P, Phenol, 3-cyclopropyl-30062-34-1P, 2-Pyridinecarboxylic acid, 1,6-dihydro-6-oxo-, methyl ester 36187-69-6P, Ethyl 4-bromo-3-oxopentanoate 42861-71-2P, Phenol, 3-iodo-, acetate 52177-62-5P, 3-Methoxyphenyl chloroformate 52177-75-0P, Carbonochloridic acid, 4-(phenylmethoxy)phenyl ester 60710-39-6P, 3-Bromo-4-methylphenol 62103-69-9P, Benzene, 1-methoxy-3-propyl-68331-44-2P, Propanoic acid, 2-[(methylsulfonyl)oxy]-, ethyl ester, (2R)-70170-23-9P, 4-Oxazolecarboxaldehyde, 5-methyl-2-phenyl- 72934-40-8P, Cyclopropanamine, 1-(4-methoxyphenyl)- 74067-76-8P, 1-Penten-3-one, 4-bromo- 103360-04-9P, 4-Fluorobenzylsulfonyl chloride 103788-59-6P, Benzaldehyde, 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- 103788-61-0P, Oxazole, 4-(chloromethyl)-5-methyl-2-phenyl- 103788-64-3P, 4-Oxazoleacetic acid, 5-methyl-2-phenyl-, methyl ester 105983-77-5P, Pentanoic acid, 4-bromo-3-oxo-, methyl ester 136058-69-0P, 4-Oxazoleethanol, 2-(4-methoxyphenyl)-5-methyl- 137208-84-5P, Ethanol, 2-[3-(phenylmethoxy)phenoxy]- 140130-09-2P, Benzamide, N-(1-acetyl-3-butynyl)- 140130-10-5P, Oxazole, 5-methyl-2-phenyl-4-(2-propynyl)- 157169-61-4P, 3-Pyridinecarboxaldehyde, 6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- 174258-60-7P, Ethanone, 1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]- 196810-26-1P, 4-Oxazoleacetic acid, 2-(4-methoxyphenyl)-5-methyl-, methyl ester 223562-18-3P, Benzene, 1-methoxy-3-(1-propynyl)- 227029-27-8P, 4-Oxazoleethanol, 5-methyl-2-phenyl-, methanesulfonate (ester) 244152-94-1P, Benzaldehyde, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- 258346-53-1P, 4-Oxazolepropanol, 5-methyl-2-phenyl- 258346-54-2P, 4-Oxazolepropanenitrile, 5-methyl-2-phenyl- **331745-61-0P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenylmethyl)-, ethyl ester **331745-62-1P**, Glycine, N,N-bis[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester 331745-63-2P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester 331745-64-3P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, 1,1-dimethylethyl ester **331745-65-4P**, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]-, 1,1-dimethylethyl ester 331745-66-5P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331745-67-6P**, Glycine, N-[(4-hydroxyphenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, 1,1-dimethylethyl ester **331745-68-7P**, Glycine, N-[(4-boronophenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, 1-(1,1-dimethylethyl) ester 331745-70-1P, Benzenemethanamine, α -methyl-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, (α S)- **331745-71-2P**, Glycine, N-(chlorocarbonyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, 1,1-dimethylethyl ester **331745-72-3P**, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylmethoxy)phenoxy]carbonyl]-, 1,1-dimethylethyl ester **331745-73-4P**, Glycine, N-[(4-hydroxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, 1,1-dimethylethyl ester **331745-74-5P**, Carbonochloridic acid, 3-(acetyloxy)phenyl ester **331745-75-6P**, Glycine, N-[[3-(acetyloxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, 1,1-dimethylethyl ester **331745-76-7P**, Glycine, N-[[4-methoxyphenyl]amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester **331745-77-8P**, Glycine, N-[[4-methoxyphenyl]methylamino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester 331745-78-9P, 3-Pyridinecarboxylic acid, 6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester 331745-79-0P, Glycine, N-[[6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-3-pyridinyl]methyl]-,

methyl ester 331745-81-4P, 2-Pyridinecarboxylic acid, 6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester 331745-82-5P, 2-Pyridinemethanol, 6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- 331745-83-6P, 2-Pyridinecarboxaldehyde, 6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- 331745-84-7P, Glycine, N-[[6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-pyridinyl]methyl]-, methyl ester 331745-85-8P, Glycine, N-[[6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-pyridinyl]methyl]-N-[(4-phenoxyphenyl)methyl]-, methyl ester 331745-87-0P, Carbamic acid, [2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1,1-dimethylethyl ester 331745-88-1P, Glycine, N-[(2,4-dinitrophenyl)sulfonyl]-N-[2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1,1-dimethylethyl ester 331745-89-2P, Glycine, N-[2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1,1-dimethylethyl ester 331745-90-5P, Carbamic acid, [2-[(2-cyanoethyl)amino]-2-oxoethyl][4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, 4-methoxyphenyl ester 331745-91-6P, Carbamic acid, [[1-(2-cyanoethyl)-1H-tetrazol-5-yl]methyl][4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, 4-methoxyphenyl ester 331745-92-7P, Glycine, N-[(2-hydroxyphenyl)methyl]-N-[(4-methoxyphenoxy)carbonyl]-, methyl ester 331745-93-8P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[2-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester 331745-94-9P, Phenol, 3-cyclopropyl-, acetate 331745-95-0P, Glycine, N-[(3-cyclopropylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester 331745-96-1P, Acetic acid, [3-(phenylmethoxy)phenoxy]-, ethyl ester 331745-97-2P, Benzene, 1-(2-bromoethoxy)-3-(phenylmethoxy)- 331745-98-3P, Benzene, 1-(ethenylloxy)-3-(phenylmethoxy)- 331745-99-4P, Benzene, 1-(cyclopropyloxy)-3-(phenylmethoxy)- 331746-00-0P, Phenol, 3-(cyclopropyloxy)- 331746-01-1P, Carbonochloridic acid, 3-fluoro-4-methylphenyl ester 331746-02-2P, Carbonochloridic acid, 3-bromo-4-methylphenyl ester 331746-03-3P, Benzoic acid, 2-(carboxymethyl)hydrazide 331746-04-4P, Benzoic acid, 2-(2-ethoxy-2-oxoethyl)-2-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]hydrazide 331746-05-5P, Oxazole, 4-[2-[3-(bromomethyl)phenoxy]ethyl]-5-methyl-2-phenyl- 331746-06-6P, Glycine, N-[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, methyl ester 331746-07-7P, Glycine, N-[(4-methylphenoxy)carbonyl]-N-[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, methyl ester 331746-08-8P, Glycine, N-[(1S)-1-(4-hydroxyphenyl)ethyl]-, methyl ester 331746-09-9P, Glycine, N-[(1S)-1-(4-hydroxyphenyl)ethyl]-N-[(4-methoxyphenoxy)carbonyl]-, methyl ester 331746-10-2P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, methyl ester 331746-11-3P, 1-Pentanone, 1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]- 331746-12-4P, Glycine, N-[1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]pentyl]-, methyl ester 331746-13-5P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-3-butenyl]-, methyl ester 331746-14-6P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]butyl]-, methyl ester 331746-15-7P, 4-Thiazoleethanol, 5-methyl-2-phenyl-, methanesulfonate (ester) 331746-16-8P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]phenyl]ethyl]-, ethyl ester 331746-17-9P, Glycine, N-[1-(4-methoxyphenyl)cyclopropyl]-, methyl ester 331746-18-0P, Glycine, N-[1-(4-hydroxyphenyl)cyclopropyl]-, methyl ester 331746-19-1P, Glycine, N-[1-(4-hydroxyphenyl)cyclopropyl]-N-[(4-methoxyphenoxy)carbonyl]-, methyl ester 331746-20-4P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[1-[4-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]phenyl]cyclopropyl]-, methyl ester 331746-21-5P, Alanine, 2-methyl-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester 331746-22-6P, Alanine, 2-methyl-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331746-23-7P, L-Alanine, N-[(1R)-1-(4-methoxyphenyl)ethyl]-, methyl ester 331746-24-8P, L-Alanine, N-[(1R)-1-(4-hydroxyphenyl)ethyl]-, methyl ester 331746-25-9P, L-Alanine, N-[(1R)-1-(4-hydroxyphenyl)ethyl]-N-[(4-methoxyphenoxy)carbonyl]-, methyl ester 331746-26-0P, L-Alanine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, methyl ester 331746-27-1P, 4-Oxazolepropanoic acid, 5-methyl-2-phenyl-, ethyl ester 331746-28-2P, 4-Oxazolepropanol, 5-methyl-2-phenyl-, methanesulfonate (ester) 331746-29-3P, Benzaldehyde, 4-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]- 331746-30-6P, Glycine, N-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]-, methyl ester 331746-31-7P, Glycine, N-[(4-hydroxyphenyl)methyl]-N-[(4-methylphenoxy)carbonyl]-, methyl ester 331746-32-8P, Glycine, N-[(4-methylphenoxy)carbonyl]-N-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, methyl ester 331746-33-9P, Oxazole, 4-(2,2-dibromoethenyl)-5-methyl-2-phenyl- 331746-34-0P, 2-Propyn-1-ol, 3-(5-methyl-2-phenyl-4-oxazolyl)- 331746-35-1P, 2-Propyn-1-ol, 3-(5-methyl-2-phenyl-4-oxazolyl)-, methanesulfonate (ester) 331746-36-2P, Benzaldehyde, 4-[[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]- 331746-37-3P, Glycine, N-[[4-[[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl]methyl]-, methyl ester 331746-38-4P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl]methyl]-, methyl ester 331746-39-5P, 4-Oxazoleacetic acid, α ,5-dimethyl-2-phenyl-, methyl ester 331746-40-8P, 4-Oxazoleacetic acid, α , α ,5-trimethyl-2-phenyl-, methyl ester 331746-41-9P, 4-Oxazoleethanol, β , β ,5-trimethyl-2-phenyl- 331746-42-0P, Benzaldehyde, 4-[2-methyl-2-(5-methyl-2-phenyl-4-oxazolyl)propoxy]- 331746-43-1P, Glycine, N-[[4-[2-methyl-2-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]-, methyl ester 331746-44-2P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-methyl-2-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]-, methyl ester 331746-45-3P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[[[(2Z)-3-(5-methyl-2-phenyl-4-oxazolyl)-2-propenyl]oxy]phenyl]methyl]-, 1,1-dimethylethyl ester 331746-46-4P, Benzaldehyde, 3-[[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]- 331746-47-5P, Glycine, N-[[3-[[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl]methyl]-, methyl ester 331746-48-6P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl]methyl]-, methyl ester 331746-50-0P, 4-Oxazoleethanol, 2-(4-methoxyphenyl)-5-methyl-, methanesulfonate (ester) 331746-51-1P, Glycine, N-[(4-hydroxyphenyl)methyl]-N-[(4-methoxyphenoxy)carbonyl]-, methyl ester 331746-52-2P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, methyl ester 331746-53-3P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl]ethyl]-, ethyl ester 331746-54-4P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl]ethyl]-, ethyl ester 331746-55-5P, Glycine, N-[(4-iodophenyl)methyl]-N-[(4-methoxyphenoxy)carbonyl]-, methyl ester 331746-56-6P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)-1-propynyl]phenyl]methyl]-, methyl ester 331746-57-7P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)propyl]phenyl]methyl]-, methyl ester 331746-58-8P, Oxazole, 4-(3-bromo-2-propynyl)-5-methyl-2-phenyl- 331746-59-9P, Oxazole,

5-methyl-2-phenyl-4-[3-(tributylstannyl)-2-propenyl]- 331746-60-2P
Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[(1E)-3-(5-methyl-2-phenyl-4-oxazolyl)-1-propenyl]phenyl]methyl]-, methyl ester 331746-61-3P,
Glycine, N-[[4-[(4-bromo-3-oxopentyl)oxy]phenyl]methyl]-N-[(4-methoxyphenoxy)carbonyl]-, methyl ester 331746-62-4P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-(4-pyridinyl)-4-thiazolyl]ethoxy]phenyl]methyl]-, methyl ester 331746-67-9P,
Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester 331746-77-1P,
Carbonochloridic acid, 3-chloro-4-methylphenyl ester 331746-79-3P,
Glycine, N-[1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-3-butenyl]-, methyl ester 331746-94-2P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[(phenylmethyl)amino]carbonyl]-, ethyl ester 439276-63-8P
439573-59-8P 439573-60-1P 439573-63-4P 439573-65-6P 439573-66-7P
439573-67-8P 439573-68-9P 439573-69-0P 439573-70-3P
439573-71-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

IT 439573-86-1P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

IT 331739-67-4P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenylmethyl)- 331739-68-5P,
Glycine, N,N-bis[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-70-9P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-2-propynyl- 331739-71-0P,
Glycine, N-2-benzoxazolyl-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-72-1P, Glycine,
N-2-benzoxazolyl-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-73-2P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- 331739-74-3P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-naphthalenylmethyl)- 331739-75-4P, Glycine, N-[[3-(4-chlorophenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-76-5P, Glycine,
N-[[5-(4-chlorophenyl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-77-6P, Glycine,
N-[[4-(3-fluorophenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-78-7P, Glycine,
N-[[4-(3-methylphenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-79-8P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(3-pyridinyl)phenyl]methyl]- 331739-80-1P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenylmethyl)- 331739-81-2P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-phenylethyl)- 331739-82-3P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(3-phenylpropyl)- 331739-83-4P,
Glycine, N-[[3-(3,4-dichlorophenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-84-5P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-phenoxyphenyl)methyl]- 331739-85-6P, Glycine,
N-([1,1'-biphenyl]-4-ylmethyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-86-7P, Glycine,

N-[[5-(2-chlorophenyl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-87-8P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-[3-(trifluoromethyl)phenoxy]phenyl]methyl]- 331739-88-9P, Glycine,
N-[[3-(4-methylphenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-89-0P, Glycine,
N-[[3-(4-methoxyphenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-90-3P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[(1E)-2-phenylethenyl]phenyl]methyl]- 331739-91-4P, Glycine,
N-[[4-[(2-chloro-6-fluorophenyl)methoxy]phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-92-5P, Glycine,
N-[(2E)-3,7-dimethyl-2,6-octadienyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-93-6P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylmethoxy)phenyl]methyl]- 331739-94-7P, Glycine,
N-[[4-[4-(1,1-dimethylethyl)-2-thiazolyl]phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-95-8P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-phenoxy-2-thienyl]methyl]- 331739-96-9P, Glycine,
N-[(2Z)-3-(2-furanyl)-2-propenyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-97-0P, Glycine,
N-[[4-(fluorophenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-98-1P, Glycine,
N-[[2-[(4-chlorophenyl)thio]phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-99-2P, Glycine,
N-[[3-(3,5-dimethoxyphenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-00-2P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(1-naphthalenylmethyl)- 331740-01-3P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-naphthalenylmethyl)- 331740-02-4P, Glycine,
N-(1H-indol-2-ylmethyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-03-5P, Glycine,
N-[[3-(benzoyl-2,4-dichlorophenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-04-6P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-[2-(trifluoromethyl)phenyl]-2-furanyl]methyl]- 331740-05-7P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-(3-nitrophenyl)-2-furanyl]methyl]- 331740-06-8P, Glycine,
N-[[5-[2-chloro-5-(trifluoromethyl)phenyl]-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-07-9P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-[3-(trifluoromethyl)phenyl]-2-furanyl]methyl]- 331740-08-0P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-(2-nitrophenyl)-2-furanyl]methyl]- 331740-09-1P, 1H-Pyrrole-2-carboxylic acid,
5-[[[(carboxymethyl)[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]methyl]-4-ethyl-3-methyl-, 2-(phenylmethyl) ester 331740-10-4P, Glycine,
N-[[5-(4-bromophenyl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-11-5P, Glycine,
N-[[5-(3-chlorophenyl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-12-6P, Glycine,
N-[[5-(1,3-dioxolan-2-yl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-13-7P, Glycine,
N-[[1-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-1H-indol-3-yl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-14-8P, Glycine,
N-[[5-(2,4-dichlorophenyl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-15-9P, Glycine,

N-[[4-(2,6-difluorobenzoyl)-1-methyl-1H-pyrrol-2-yl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-16-0P, Glycine, N-[[4-benzoyl-1-methyl-1H-pyrrol-2-yl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-17-1P, Glycine, N-[[2,2'-bithiophen]-5-ylmethyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-18-2P, Glycine, N-[[5-bromo-3,4-dimethylthieno[2,3-b]thien-2-yl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-19-3P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-(phenylethynyl)-2-thienyl]methyl]- 331740-20-6P, Glycine, N-[[4-(2,4-dichlorobenzoyl)-1-methyl-1H-pyrrol-2-yl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-21-7P, Glycine, N-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-22-8P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylethynyl)-2-thienyl]methyl]- 331740-23-9P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-nitro-4-phenoxyphenyl)methyl]- 331740-24-0P, Glycine, N-[(3-methyl-4-phenoxyphenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-25-1P, Glycine, N-[(3-chloro-4-phenoxyphenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-26-2P, Glycine, N-[(2-chloro-4-phenoxyphenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-27-3P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-nitro-3-phenoxyphenyl)methyl]- 331740-28-4P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-nitro-5-phenoxyphenyl)methyl]- 331740-29-5P, Glycine, N-[(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-30-8P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-2-thienyl]methyl]- 331740-31-9P, Glycine, N-[(6-methoxy-2-naphthalenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-32-0P, Glycine, N-[(4-methoxy-1-naphthalenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-33-1P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-[2-nitro-4-(trifluoromethyl)phenyl]-2-furanyl]methyl]- 331740-34-2P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(2-pyridinyl)phenyl]methyl]- 331740-35-3P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-(phenylmethyl)phenyl]methyl]- 331740-36-4P, Glycine, N-heptyl-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-37-5P, Glycine, N-[[1,1'-biphenyl]-4-ylmethyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-38-6P, Glycine, N-[(2-hydroxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-39-7P, Glycine, N-[[5-(2-chlorophenyl)-2-furanyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-40-0P, Glycine, N-[(3,5-dimethoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-41-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-phenoxyphenyl)methyl]- 331740-42-2P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- 331740-43-3P, Glycine, N-[[3-(4-chlorophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-44-4P, Glycine, N-[[3-(3,5-dichlorophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]phenyl)methyl]- 331740-45-5P, Glycine,
N-[[3-(4-methylphenoxy)phenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-46-6P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-[(1E)-2-phenylethenyl]phenyl)methyl]- 331740-47-7P, Glycine,
N-[[4-[(2-chloro-6-fluorophenyl)methoxy]phenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-48-8P, Glycine,
N-[[3-(benzoyl-2,4-dichlorophenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-49-9P, Glycine,
N-[[3-[4-(1,1-dimethylethyl)phenoxy]phenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-50-2P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(phenylmethoxy)phenyl)methyl]- 331740-51-3P, Glycine,
N-[[4-[4-(1,1-dimethylethyl)-2-thiazolyl]phenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-52-4P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[2-(phenoxyphenyl)methyl]- 331740-53-5P, Glycine,
N-[[4-(3-methoxyphenoxy)phenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-54-6P, Glycine,
N-[[4-(4-bromophenoxy)phenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-55-7P, Glycine,
N-[[4-(4-chlorophenoxy)phenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-56-8P, Glycine,
N-[[4-(4-methylphenoxy)phenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-57-9P, Glycine,
N-[[4-(4-methoxyphenoxy)phenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-58-0P, Glycine,
N-[[4-(2-chlorophenoxy)phenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-59-1P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-[4-(trifluoromethyl)phenoxy]phenyl)methyl]- 331740-60-4P, Glycine,
N-[[4-(3,5-dichlorophenoxy)phenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-61-5P, Glycine,
N-[[4-(4-fluorophenoxy)phenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-62-6P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(3-thienyloxy)phenyl)methyl]- 331740-63-7P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-[4-(methylthio)phenoxy]phenyl)methyl]- 331740-64-8P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3-phenoxy-2-thienyl)methyl]- 331740-65-9P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-[3-(trifluoromethyl)phenoxy]phenyl)methyl]- 331740-66-0P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(3-nitrophenoxy)phenyl)methyl]- 331740-67-1P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(phenylamino)phenyl)methyl]- 331740-68-2P, Glycine,
N-[[4-(1H-imidazol-1-yl)phenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-69-3P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(4-pyridinyl)phenyl)methyl]- 331740-70-6P, Glycine,
N-[[4'-(aminocarbonyl)[1,1'-biphenyl]-4-yl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-71-7P, Glycine,
N-[(3',5'-dichloro[1,1'-biphenyl]-4-yl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-72-8P, Glycine,
N-[(3'-methoxy[1,1'-biphenyl]-4-yl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-73-9P, Glycine,
N-[(3',4'-difluoro[1,1'-biphenyl]-4-yl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331740-74-0P, Glycine,

N-[(3'-fluoro[1,1'-biphenyl]-4-yl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-75-1P, Glycine,
N-[[4-(3-furanyl)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-76-2P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(2-thienyl)phenyl]methyl]- 331740-77-3P, Glycine,
N-[(3-methoxy-4-phenoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-78-4P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-nitro-4-phenoxyphenyl)methyl]- 331740-79-5P, Glycine,
N-[(3-methyl-4-phenoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-80-8P, Glycine,
N-[(3-chloro-4-phenoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-81-9P, Glycine,
N-[(2-methoxy-4-phenoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-82-0P, Glycine,
N-[(2-chloro-4-phenoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-83-1P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-nitro-3-phenoxyphenyl)methyl]- 331740-84-2P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-nitro-5-phenoxyphenyl)methyl]- 331740-85-3P, Glycine,
N-[(6-methoxy-2-naphthalenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-86-4P, Glycine,
N-[(4-methoxy-1-naphthalenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-87-5P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(2-pyrimidinyl)phenyl]methyl]- 331740-88-6P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(5-pyrimidinyl)phenyl]methyl]- 331740-89-7P, Glycine,
N-(1H-indol-2-yl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-90-0P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(1R)-1-phenylethyl]- 331740-93-3P, D-Alanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- 331740-94-4P, D-Phenylalanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- 331740-95-5P

, L-Phenylalanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- 331740-96-6P, D-Valine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- 331740-97-7P, Acetic acid,
(2,2-dimethylpropoxy)[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl][(4-phenoxyphenyl)methyl]amino]-, (2R)- 331740-98-8P, D-Serine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- 331740-99-9P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy)carbonyl]- 331741-00-5P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy)carbonyl]- 331741-01-6P, Glycine, N-[(2-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-02-7P, Glycine, N-[(3,5-dichlorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-03-8P, Glycine, N-[[3-(3-methoxyphenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-04-9P, Glycine, N-[[4-(difluoromethoxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-05-0P, Glycine, N-[[4-(difluoromethoxy)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]phenyl)methyl]- 331741-06-1P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(phenylmethoxy)phenoxy]carbonyl]- 331741-07-2P, Glycine,
N-[[4-hydroxyphenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-08-3P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(phenoxycarbonyl)- 331741-09-4P, Glycine, N-[[4-chloro-3-fluorophenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-10-7P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[3-phenoxyphenyl)methoxy]carbonyl]- 331741-11-8P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2-propynyloxy)carbonyl]- 331741-12-9P, Glycine,
N-[[4-methylphenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-13-0P, Glycine,
N-[[4-methoxyphenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-14-1P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2-nitrophenoxy)carbonyl]- 331741-15-2P, Glycine,
N-[[9H-fluoren-9-ylmethoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-16-3P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-nitrophenyl)methoxy]carbonyl]- 331741-17-4P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-nitrophenoxy]carbonyl]- 331741-18-5P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-phenoxyphenoxy]carbonyl]- 331741-19-6P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[2-phenoxyphenyl)methoxy]carbonyl]- 331741-20-9P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-phenoxyphenyl)methoxy]carbonyl]- 331741-21-0P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3-phenoxyphenoxy)carbonyl]- 331741-22-1P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2-phenoxyphenoxy)carbonyl]- 331741-23-2P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2-phenoxyethoxy)carbonyl]- 331741-24-3P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[[(2E)-3-phenyl-2-propenyl]oxy]carbonyl]- 331741-25-4P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[3-phenyl-2-propynyl]oxy]carbonyl]- 331741-26-5P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2-phenylethoxy)carbonyl]- 331741-27-6P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3-phenylpropoxy)carbonyl]- 331741-28-7P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[[(2Z)-3-phenyl-2-propenyl]oxy]carbonyl]- 331741-29-8P, Glycine,
N-[[4-fluoro-3-methylphenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-30-1P, Glycine,
N-[(3-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-31-2P, Glycine,
N-[(3,4-dimethoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-32-3P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3,4,5-trimethoxyphenoxy)carbonyl]- 331741-33-4P, Glycine,
N-[[3-methoxyphenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-34-5P, Glycine,
N-[[4-methoxyphenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-35-6P, Glycine,


N-[(1,3-benzodioxol-5-ylmethoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-36-7P, Glycine,
N-[(1,3-benzodioxol-5-yloxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-37-8P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(trifluoromethoxy)phenoxy]carbonyl]- 331741-38-9P, Glycine,
N-[[4-methoxy-1-naphthalenyl]oxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-39-0P, Glycine,
N-[(2,3-dimethoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-40-3P, Benzoic acid,
4-[[[(carboxymethyl)[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]carbonyl]oxy]-, 1-methyl ester
331741-41-4P, Glycine, N-[(4-bromo-3-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331741-42-5P, Glycine, N-[[4-(1,3-dithiolan-2-yl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331741-43-6P, Glycine, N-[(4-chloro-3-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331741-44-7P, Glycine, N-[(4-fluorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-45-8P,
Glycine, N-[(4-chlorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-46-9P, Glycine,
N-[(4-bromophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-47-0P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-(trifluoromethoxy)phenoxy]carbonyl]- 331741-48-1P, Glycine,
N-[[3-(fluorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-49-2P, Glycine,
N-[[3-(chlorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-50-5P, Glycine,
N-[[3-(bromophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-51-6P, Glycine,
N-[[3-(acetyloxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-52-7P, Glycine,
N-[(4-acetylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-53-8P, Glycine,
N-[[3-(acetylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-54-9P, Glycine,
N-[[2,3-dihydro-3-oxo-6-benzofuranyl]oxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-55-0P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(1,2,3-thiadiazol-4-yl)phenoxy]carbonyl]- 331741-56-1P, Glycine,
N-[(3-hydroxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-57-2P, Glycine,
N-[(3-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-58-3P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3,4,5-trimethylphenoxy)carbonyl]- 331741-59-4P, Glycine,
N-[(4-ethoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-60-7P, Glycine,
N-[(3-ethoxy-4-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-61-8P, Glycine,
N-[(4-cyclopentylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-63-0P, Glycine,
N-[(4-ethenylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-64-1P, Glycine,
N-[[4-(3-methylbutyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-65-2P, Glycine,
N-[(4-butylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]phenyl)methyl]- 331741-66-3P, Glycine,
 N-[(4-hexylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-67-4P, Glycine,
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[3-(4-morpholinyl)phenoxy]carbonyl]- 331741-68-5P, Glycine,
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[5,6,7,8-tetrahydro-2-naphthalenyl]oxy]carbonyl]- 331741-69-6P, Glycine,
 N-[[3-(1,1-dimethylethyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-70-9P, Glycine,
 N-[[3-(1-methylethyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-71-0P, Glycine,
 N-[(3,4-dimethylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-72-1P, Glycine,
 N-[(3,5-dimethylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-73-2P, Glycine,
 N-[(3-ethylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-74-3P, Glycine,
 N-[[4-(1,1-dimethylethyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)


RN 331739-67-4 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 331739-68-5 HCAPLUS

CN Glycine, N,N-bis[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B




RN 331739-70-9 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-2-propynyl- (9CI) (CA INDEX NAME)




RN 331739-71-0 HCAPLUS

CN Glycine, N-2-benzoxazolyl-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331739-72-1 HCAPLUS

CN Glycine, N-2-benzoxazolyl-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331739-73-2 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-phenoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331739-74-3 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)




RN 331739-75-4 HCAPLUS

CN Glycine, N-[[3-(4-chlorophenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331739-76-5 HCAPLUS

CN Glycine, N-[[5-(4-chlorophenyl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331739-77-6 HCAPLUS

CN Glycine, N-[[4-(3-fluorophenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331739-78-7 HCAPLUS

CN Glycine, N-[[4-(3-methylphenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331739-79-8 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(3-pyridinyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331739-80-1 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 331739-81-2 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 331739-82-3 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 331739-83-4 HCAPLUS

CN Glycine, N-[[3-(3,4-dichlorophenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331739-84-5 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-(3-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331739-85-6 HCAPLUS

CN Glycine, N-([1,1'-biphenyl]-4-ylmethyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331739-86-7 HCAPLUS


CN Glycine, N-[[5-(2-chlorophenyl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331739-87-8 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-[3-(trifluoromethyl)phenoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CF3

RN 331739-88-9 HCAPLUS


CN Glycine, N-[[3-(4-methylphenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331739-89-0 HCAPLUS

CN Glycine, N-[[3-(4-methoxyphenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— OMe

RN 331739-90-3 HCAPLUS


CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[(1E)-2-phenylethenyl]phenyl]methyl]- (9CI) (CA INDEX NAME).

Double bond geometry as shown.



RN 331739-91-4 HCAPLUS


CN Glycine, N-[[4-[(2-chloro-6-fluorophenyl)methoxy]phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331739-92-5 HCAPLUS


CN Glycine, N-[(2E)-3,7-dimethyl-2,6-octadienyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331739-93-6 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331739-94-7 HCAPLUS

CN Glycine, N-[[4-[4-(1,1-dimethylethyl)-2-thiazolyl]phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331739-95-8 HCAPLUS


CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-phenoxy-2-thienyl]methyl]- (9CI) (CA INDEX NAME)



RN 331739-96-9 HCAPLUS


CN Glycine, N-[(2Z)-3-(2-furanyl)-2-propenyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331739-97-0 HCAPLUS

CN Glycine, N-[(4-fluorophenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331739-98-1 HCAPLUS


CN Glycine, N-[[2-[(4-chlorophenyl)thio]phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331739-99-2 HCAPLUS

CN Glycine, N-[[3-(3,5-dimethoxyphenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— OMe


RN 331740-00-2 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(1-naphthalenylmethyl)- (9CI) (CA INDEX NAME)




RN 331740-01-3 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)




RN 331740-02-4 HCAPLUS

CN Glycine, N-(1H-indol-2-ylmethyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-03-5 HCAPLUS

CN Glycine, N-[(3-benzoyl-2,4-dichlorophenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-04-6 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-[2-(trifluoromethyl)phenyl]-2-furanyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-05-7 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-(3-nitrophenyl)-2-furanyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-06-8 HCAPLUS

CN Glycine, N-[[5-[2-chloro-5-(trifluoromethyl)phenyl]-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-07-9 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-[3-(trifluoromethyl)phenyl]-2-furanyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-08-0 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-(2-nitrophenyl)-2-furanyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-09-1 HCAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 5-[[[(carboxymethyl)[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]methyl]-4-ethyl-3-methyl-, 2-(phenylmethyl) ester (9CI) (CA INDEX NAME)




RN 331740-10-4 HCAPLUS

CN Glycine, N-[[5-(4-bromophenyl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-11-5 HCAPLUS

CN Glycine, N-[[5-(3-chlorophenyl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-12-6 HCAPLUS

CN Glycine, N-[[5-(1,3-dioxolan-2-yl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-13-7 HCAPLUS

CN Glycine, N-[[1-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-1H-indol-3-yl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331740-14-8 HCAPLUS


CN Glycine, N-[[5-(2,4-dichlorophenyl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331740-15-9 HCAPLUS


CN Glycine, N-[[4-(2,6-difluorobenzoyl)-1-methyl-1H-pyrrol-2-yl]methyl]-N-[[3-

[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331740-16-0 HCAPLUS

CN Glycine, N-[(4-benzoyl-1-methyl-1H-pyrrol-2-yl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331740-17-1 HCAPLUS

CN Glycine, N-([2,2'-bithiophen]-5-ylmethyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331740-18-2 HCAPLUS

CN Glycine, N-[(5-bromo-3,4-dimethylthieno[2,3-b]thien-2-yl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331740-19-3 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-(phenylethynyl)-2-thienyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-20-6 HCAPLUS

CN Glycine, N-[[4-(2,4-dichlorobenzoyl)-1-methyl-1H-pyrrol-2-yl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-21-7 HCAPLUS

CN Glycine, N-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-22-8 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylethynyl)-2-thienyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-23-9 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-nitro-4-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331740-24-0 HCAPLUS

CN Glycine, N-[(3-methyl-4-phenoxyphenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-25-1 HCAPLUS

CN Glycine, N-[(3-chloro-4-phenoxyphenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-26-2 HCAPLUS

CN Glycine, N-[(2-chloro-4-phenoxyphenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-27-3 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-nitro-3-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331740-28-4 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-nitro-5-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331740-29-5 HCAPLUS


CN Glycine, N-[(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-30-8 HCAPLUS
 CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)



RN 331740-31-9 HCAPLUS
 CN Glycine, N-[(6-methoxy-2-naphthalenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-32-0 HCAPLUS
 CN Glycine, N-[(4-methoxy-1-naphthalenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-33-1 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-[2-nitro-4-(trifluoromethyl)phenyl]-2-furanyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-34-2 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(2-pyridinyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-35-3 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-(phenylmethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-36-4 HCAPLUS

CN Glycine, N-heptyl-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-37-5 HCAPLUS

CN Glycine, N-([1,1'-biphenyl]-4-ylmethyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-38-6 HCAPLUS

CN Glycine, N-[(2-hydroxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-39-7 HCAPLUS

CN Glycine, N-[[5-(2-chlorophenyl)-2-furanyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-40-0 HCAPLUS

CN Glycine, N-[(3,5-dimethoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-41-1 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331740-42-2 HCAPLUS


CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331740-43-3 HCAPLUS


CN Glycine, N-[[3-(4-chlorophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-

4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331740-44-4 HCAPLUS

CN Glycine, N-[[3-(3,5-dichlorophenoxy)phenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331740-45-5 HCAPLUS


CN Glycine, N-[[3-(4-methylphenoxy)phenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331740-46-6 HCAPLUS


CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-[(1E)-2-phenylethenyl]phenyl)methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331740-47-7 HCAPLUS

CN Glycine, N-[[4-[(2-chloro-6-fluorophenyl)methoxy]phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331740-48-8 HCAPLUS


CN Glycine, N-[(3-benzoyl-2,4-dichlorophenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331740-49-9 HCAPLUS

CN Glycine, N-[[3-[4-(1,1-dimethylethyl)phenoxy]phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Bu-t


RN 331740-50-2 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-51-3 HCAPLUS

CN Glycine, N-[[4-[4-(1,1-dimethylethyl)-2-thiazolyl]phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331740-52-4 HCAPLUS


CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-phenoxyphenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331740-53-5 HCAPLUS

CN Glycine, N-[[4-(3-methoxyphenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OMe


RN 331740-54-6 HCAPLUS

CN Glycine, N-[[4-(4-bromophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-55-7 HCAPLUS

CN Glycine, N-[[4-(4-chlorophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-56-8 HCAPLUS

CN Glycine, N-[[4-(4-methylphenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331740-57-9 HCAPLUS

CN Glycine, N-[[4-(4-methoxyphenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B

— OMe

RN 331740-58-0 HCAPLUS


CN Glycine, N-[[4-(2-chlorophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331740-59-1 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[4-(trifluoromethyl)phenoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

-CF₃


RN 331740-60-4 HCAPLUS

CN Glycine, N-[[4-(3,5-dichlorophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-61-5 HCAPLUS

CN Glycine, N-[[4-(4-fluorophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331740-62-6 HCAPLUS


CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(3-thienyloxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331740-63-7 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[4-(methylthio)phenoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— SMe

RN 331740-64-8 HCAPLUS


CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-phenoxy-2-thienyl]methyl]- (9CI) (CA INDEX NAME)



RN 331740-65-9 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[3-(trifluoromethyl)phenoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CF₃

RN 331740-66-0 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(3-nitrophenoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—NO₂


RN 331740-67-1 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylamino)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-68-2 HCAPLUS

CN Glycine, N-[[4-(1H-imidazol-1-yl)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-69-3 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(4-pyridinyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-70-6 HCAPLUS

CN Glycine, N-[[4'-(aminocarbonyl)[1,1'-biphenyl]-4-yl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-71-7 HCAPLUS

CN Glycine, N-[(3',5'-dichloro[1,1'-biphenyl]-4-yl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-72-8 HCAPLUS

CN Glycine, N-[(3'-methoxy[1,1'-biphenyl]-4-yl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-73-9 HCAPLUS

CN Glycine, N-[(3',4'-difluoro[1,1'-biphenyl]-4-yl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-74-0 HCAPLUS

CN Glycine, N-[(3'-fluoro[1,1'-biphenyl]-4-yl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-75-1 HCAPLUS

CN Glycine, N-[[4-(3-furanyl)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-76-2 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(2-thienyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-77-3 HCAPLUS

CN Glycine, N-[(3-methoxy-4-phenoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-78-4 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-nitro-4-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331740-79-5 HCAPLUS

CN Glycine, N-[(3-methyl-4-phenoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-80-8 HCAPLUS

CN Glycine, N-[(3-chloro-4-phenoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-81-9 HCAPLUS

CN Glycine, N-[(2-methoxy-4-phenoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-82-0 HCAPLUS

CN Glycine, N-[(2-chloro-4-phenoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-83-1 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-nitro-3-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331740-84-2 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-nitro-5-phenoxyphenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331740-85-3 HCAPLUS


CN Glycine, N-[(6-methoxy-2-naphthalenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-86-4 HCAPLUS

CN Glycine, N-[(4-methoxy-1-naphthalenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331740-87-5 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(2-pyrimidinyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-88-6 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(5-pyrimidinyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331740-89-7 HCAPLUS


CN Glycine, N-(1H-indol-2-ylmethyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331740-90-0 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331740-93-3 HCAPLUS

CN D-Alanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331740-94-4 HCAPLUS

CN D-Phenylalanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331740-95-5 HCAPLUS

CN L-Phenylalanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331740-96-6 HCAPLUS

CN D-Valine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331740-97-7 HCAPLUS

CN Acetic acid, (2,2-dimethylpropoxy)[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl][(4-phenoxyphenyl)methyl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331740-98-8 HCAPLUS


CN D-Serine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-phenoxyphenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331740-99-9 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-00-5 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-01-6 HCAPLUS

CN Glycine, N-[(2-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-02-7 HCAPLUS

CN Glycine, N-[(3,5-dichlorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-03-8 HCAPLUS

CN Glycine, N-[[4-(3-methoxyphenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-04-9 HCAPLUS


CN Glycine, N-[[4-(difluoromethoxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-05-0 HCAPLUS
 CN Glycine, N-[[4-(difluoromethoxy)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-06-1 HCAPLUS
 CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylmethoxy)phenoxy]carbonyl]- (9CI) (CA INDEX NAME)



RN 331741-07-2 HCAPLUS
 CN Glycine, N-[(4-hydroxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-08-3 HCAPLUS
 CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenoxycarbonyl)- (9CI) (CA INDEX NAME)




RN 331741-09-4 HCAPLUS

CN Glycine, N-[(4-chloro-3-fluorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-10-7 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-(phenoxyphenyl)methoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-11-8 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-propynyloxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-12-9 HCAPLUS

CN Glycine, N-[(4-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-13-0 HCAPLUS

CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-14-1 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-nitrophenoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-15-2 HCAPLUS

CN Glycine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-16-3 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-nitrophenyl]methoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-17-4 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-nitrophenoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-18-5 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-19-6 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-phenoxyphenyl]methoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-20-9 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-phenoxyphenyl]methoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-21-0 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-phenoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-22-1 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-phenoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)



RN 331741-23-2 HCAPLUS


CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-phenoxyethoxy)carbonyl]- (9CI) (CA INDEX NAME)



RN 331741-24-3 HCAPLUS


CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[(2E)-3-phenyl-2-propenyl]oxy]carbonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331741-25-4 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[(3-phenyl-2-propynyl)oxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-26-5 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-phenylethoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-27-6 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-
[(3-phenylpropoxy)carbonyl]- (9CI) (CA INDEX NAME)

RN 331741-28-7 HCAPLUS


CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-
[[[(2Z)-3-phenyl-2-propenyl]oxy]carbonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331741-29-8 HCAPLUS

CN Glycine, N-[(4-fluoro-3-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-30-1 HCAPLUS

CN Glycine, N-[(3-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-31-2 HCAPLUS

CN Glycine, N-[(3,4-dimethoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-32-3 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3,4,5-trimethoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-33-4 HCAPLUS

CN Glycine, N-[[3-methoxyphenyl]methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-34-5 HCAPLUS

CN Glycine, N-[[4-methoxyphenyl]methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-35-6 HCAPLUS

CN Glycine, N-[(1,3-benzodioxol-5-ylmethoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-36-7 HCAPLUS

CN Glycine, N-[(1,3-benzodioxol-5-yloxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-37-8 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(trifluoromethoxy)phenoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-38-9 HCAPLUS

CN Glycine, N-[[4-methoxy-1-naphthalenyl]oxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-39-0 HCAPLUS

CN Glycine, N-[(2,3-dimethoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-40-3 HCAPLUS

CN Benzoic acid, 4-[[[(carboxymethyl)[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]carbonyl]oxy]-, 1-methyl ester (9CI) (CA INDEX NAME)




RN 331741-41-4 HCAPLUS

CN Glycine, N-[(4-bromo-3-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-42-5 HCAPLUS

CN Glycine, N-[[4-(1,3-dithiolan-2-yl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-43-6 HCAPLUS

CN Glycine, N-[(4-chloro-3-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-44-7 HCAPLUS

CN Glycine, N-[(4-fluorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-45-8 HCAPLUS

CN Glycine, N-[(4-chlorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-46-9 HCAPLUS

CN Glycine, N-[(4-bromophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331741-47-0 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[3-(trifluoromethoxy)phenoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-48-1 HCAPLUS

CN Glycine, N-[(3-fluorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331741-49-2 HCAPLUS

CN Glycine, N-[(3-chlorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331741-50-5 HCAPLUS

CN Glycine, N-[(3-bromophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-51-6 HCAPLUS

CN Glycine, N-[[3-(acetyloxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-52-7 HCAPLUS

CN Glycine, N-[(4-acetylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-53-8 HCAPLUS

CN Glycine, N-[(3-acetylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-54-9 HCAPLUS

CN Glycine, N-[[[2,3-dihydro-3-oxo-6-benzofuranyl]oxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-55-0 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(1,2,3-thiadiazol-4-yl)phenoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-56-1 HCAPLUS

CN Glycine, N-[(3-hydroxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-57-2 HCAPLUS

CN Glycine, N-[(3-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-58-3 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3,4,5-trimethoxyphenyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-59-4 HCAPLUS

CN Glycine, N-[(4-ethoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-60-7 HCAPLUS

CN Glycine, N-[(3-ethoxy-4-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-61-8 HCAPLUS

CN Glycine, N-[(4-cyclopentylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331741-63-0 HCAPLUS


CN Glycine, N-[(4-ethenylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331741-64-1 HCAPLUS

CN Glycine, N-[[4-(3-methylbutyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CHMe₂


RN 331741-65-2 HCAPLUS

CN Glycine, N-[(4-butylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-66-3 HCAPLUS

CN Glycine, N-[(4-hexylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-67-4 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-(4-morpholinyl)phenoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-68-5 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5,6,7,8-tetrahydro-2-naphthalenyl]oxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-69-6 HCAPLUS

CN Glycine, N-[[3-(1,1-dimethylethyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-70-9 HCAPLUS

CN Glycine, N-[[3-(1-methylethyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-71-0 HCAPLUS

CN Glycine, N-[(3,4-dimethylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-72-1 HCAPLUS

CN Glycine, N-[(3,5-dimethylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-73-2 HCAPLUS

CN Glycine, N-[(3-ethylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331741-74-3 HCAPLUS

CN Glycine, N-[[4-(1,1-dimethylethyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



IT 331741-75-4P, Glycine, N-[[4-(1-methylethyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
 331741-76-5P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylmethyl)phenoxy]carbonyl]-
 331741-77-6P, Glycine, N-[[4-ethylphenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-78-7P,
 Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-propylphenoxy]carbonyl]- 331741-79-8P, Glycine,
 N-[[2,3-dihydro-1H-inden-5-yl]oxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-80-1P, Glycine,
 N-[[3-ethoxyphenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-81-2P, Glycine,
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-pentylphenoxy]carbonyl]- 331741-82-3P, Glycine,
 N-[[4-fluoro-3-(trifluoromethyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-83-4P, Glycine,
 N-[[3-(3-fluorophenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-84-5P, Glycine,
 N-[[3-(3-chlorophenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-85-6P, Glycine,
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-(trifluoromethoxy)phenyl]methoxy]carbonyl]- 331741-86-7P,
 Glycine, N-[[4-(3-fluorophenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-87-8P, Glycine,
 N-[[4-(3-chlorophenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-88-9P, Glycine,
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(trifluoromethoxy)phenyl]methoxy]carbonyl]- 331741-89-0P,
 Glycine, N-[[3-(3,5-dimethoxyphenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-90-3P, Glycine,
 N-[[3-(acetyloxy)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-91-4P, Glycine,
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-phenoxyphenyl]methoxy]carbonyl]- 331741-92-5P, Glycine,
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-propynyloxy]carbonyl]- 331741-93-6P, Glycine,
 N-[[4-(4-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-94-7P, Glycine,
 N-[[4-(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-95-8P, Glycine,
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-nitrophenoxy]carbonyl]- 331741-96-9P, Glycine,
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(3-phenoxyphenyl)methoxy]carbonyl]- 331741-97-0P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-nitrophenyl]methoxy]carbonyl]- 331741-98-1P, Glycine,
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-nitrophenoxy]carbonyl]- 331741-99-2P, Glycine,
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-phenoxyphenoxy]carbonyl]- 331742-00-8P, Glycine,

N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-phenoxyphenyl)methoxy]carbonyl]- **331742-01-9P**, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-phenoxyphenyl)methoxy]carbonyl]- **331742-02-0P**, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-phenoxyphenoxy]carbonyl]- **331742-03-1P**, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-phenoxyphenoxy]carbonyl]- **331742-04-2P**, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-phenoxyethoxy]carbonyl]- **331742-05-3P**, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[(2E)-3-phenyl-2-propenyl]oxy]carbonyl]- **331742-06-4P**, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-phenyl-2-propynyl]oxy]carbonyl]- **331742-07-5P**, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-phenylethoxy]carbonyl]- **331742-08-6P**, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-phenylpropoxy]carbonyl]- **331742-09-7P**, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[(2Z)-3-phenyl-2-propenyl]oxy]carbonyl]- **331742-10-0P**, Glycine,
N-[[2-methoxyphenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331742-11-1P**, Glycine,
N-[[3-methoxyphenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331742-12-2P**, Glycine,
N-[[3,4-dimethoxyphenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331742-13-3P**, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3,4,5-trimethoxyphenoxy]carbonyl]- **331742-14-4P**, Glycine,
N-[[3-acetylphenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331742-15-5P**, Glycine,
N-[[4-methoxyphenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331742-16-6P**, Glycine,
N-[[1,3-benzodioxol-5-ylmethoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331742-17-7P**, Glycine,
N-[[1,3-benzodioxol-5-yloxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331742-18-8P**, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(trifluoromethoxy)phenoxy]carbonyl]- **331742-19-9P**, Glycine,
N-[[4-methoxy-1-naphthalenyl]oxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331742-20-2P**, Glycine,
N-[[2,3-dimethoxyphenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331742-21-3P**, Benzoic acid,
4-[[[(carboxymethyl)[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]amino]carbonyl]oxy]-, 1-methyl ester
331742-22-4P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylmethoxy)phenoxy]carbonyl]-
331742-23-5P, Glycine, N-[[4-hydroxyphenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331742-24-6P**,
Glycine, N-[[4-bromo-3-methylphenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331742-25-7P**, Glycine,
N-[[4-fluorophenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331742-26-8P**, Glycine,
N-[[4-chlorophenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331742-27-9P**, Glycine,
N-[[4-bromophenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331742-28-0P**, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-(trifluoromethoxy)phenoxy]carbonyl]- **331742-29-1P**, Glycine,
N-[[3-fluorophenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]phenyl)methyl]- 331742-30-4P, Glycine,
N-[(3-chlorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-31-5P, Glycine,
N-[(3-bromophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-32-6P, Glycine,
N-[(3,5-difluorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-33-7P, Glycine,
N-[(3-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-34-8P, Glycine,
N-[(3-chloro-4-fluorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-35-9P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3,4,5-trimethylphenoxy)carbonyl]- 331742-36-0P, Glycine,
N-[(4-chloro-3,5-dimethylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-37-1P, Glycine,
N-[(3,4-difluorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-38-2P, Glycine,
N-[(4-ethenylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-39-3P, Glycine,
N-[(4-fluoro-3-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-40-6P, Glycine,
N-[(4-chloro-3-fluorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-41-7P, Glycine,
N-[[3-methyl-4-(methylthio)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-42-8P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(1H-pyrrol-1-yl)phenoxy]carbonyl]- 331742-43-9P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]carbonyl]- 331742-44-0P, Glycine,
N-[[[1,1'-biphenyl]-3-yloxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-45-1P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[3-(trifluoromethyl)phenoxy]carbonyl]- 331742-46-2P, Glycine,
N-[[3-(1,1-dimethylethyl)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-47-3P, Glycine,
N-[[3-(1-methylethyl)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-48-4P, Glycine,
N-[(3,4-dimethylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-49-5P, Glycine,
N-[(3,5-dimethylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-50-8P, Glycine,
N-[(3-ethylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-51-9P, Glycine,
N-[(4-chloro-3-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-52-0P, Glycine,
N-[[4-(1-methylethyl)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-53-1P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(phenylmethyl)phenoxy]carbonyl]- 331742-54-2P, Glycine,
N-[(4-ethylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-55-3P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-propylphenoxy)carbonyl]- 331742-56-4P, Glycine,
N-[[[2,3-dihydro-1H-inden-5-yl]oxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-57-5P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2-naphthalenyl)oxy]carbonyl]- 331742-58-6P, Glycine,
N-[(3-ethoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-59-7P, Glycine,

N-[(3,5-dichlorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-60-0P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(1,2,3-thiadiazol-4-yl)phenoxy]carbonyl]- 331742-61-1P, Glycine,
N-[[4-fluoro-3-(trifluoromethyl)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-62-2P, Glycine,
N-[(3-methoxy-5-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-63-3P, Glycine,
N-[[3-(fluorophenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-64-4P, Glycine,
N-[[3-(chlorophenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-65-5P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-(trifluoromethoxy)phenyl]methoxy]carbonyl]- 331742-66-6P, Glycine,
N-[[4-(fluorophenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-67-7P, Glycine,
N-[[4-(chlorophenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-68-8P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(trifluoromethoxy)phenyl]methoxy]carbonyl]- 331742-69-9P, Glycine,
N-[[3-(3,5-dimethoxyphenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-70-2P, Glycine,
N-[[3-(difluoromethoxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-71-3P, Glycine,
N-[[3-(difluoromethoxy)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-72-4P, Glycine,
N-[[3-(3-hydroxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-73-5P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenoxythioxomethyl)- 331742-74-6P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenoxythioxomethyl)- 331742-75-7P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(4-phenoxybenzoyl)- 331742-76-8P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-naphthalenylcarbonyl)- 331742-77-9P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-thienylcarbonyl)- 331742-78-0P, Glycine, N-(3,5-dimethoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-79-1P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(1-naphthalenylcarbonyl)- 331742-80-4P, Glycine,
N-(3,4-difluorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-81-5P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(3-phenoxybenzoyl)- 331742-82-6P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[4-(phenylmethyl)benzoyl]- 331742-83-7P, Glycine, N-(3,5-dimethylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-84-8P, Glycine, N-([2,2'-bithiophen]-5-ylcarbonyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-85-9P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(5-methyl-2-thienyl)carbonyl]- 331742-86-0P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(5-nitro-2-thienyl)carbonyl]- 331742-87-1P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-methyl-2-thienyl)carbonyl]- 331742-88-2P, Glycine, N-(4-butoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-89-3P, Glycine,
N-(4-methoxy-3-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-90-6P, Glycine,

N-(3-chloro-4-methoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-91-7P, Glycine,
N-(3,4-dimethylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-92-8P, Glycine,
N-(4-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-93-9P, Glycine,
N-(3-fluoro-4-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-94-0P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[4-(methylthio)benzoyl]- 331742-95-1P, Glycine,
N-[4-(1-methylethyl)benzoyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-96-2P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[4-(2-methylpropyl)benzoyl]- 331742-97-3P, Glycine,
N-(4-chloro-3-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-98-4P, Glycine,
N-(3-methoxy-4-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-99-5P, Glycine,
N-(1,3-benzodioxol-5-ylcarbonyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-00-1P, Glycine,
N-[4-(1-methylethoxy)benzoyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-02-3P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(3-thienylcarbonyl)- 331743-04-5P, Glycine, N-benzoyl-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-05-6P, Glycine, N-(3-methoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-06-7P, Glycine,
N-(4-fluorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-07-8P, Glycine,
N-(3,4-dichlorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-08-9P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(4-propoxybenzoyl)- 331743-09-0P, Glycine, N-(4-ethoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-10-3P, Glycine, N-(3-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-11-4P, Glycine,
N-(4-methoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-12-5P, Glycine,
N-(3-chlorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-13-6P, Glycine,
N-(4-chlorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-14-7P, Glycine,
N-(4-butylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-15-8P, Glycine,
N-(3,5-dichlorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-16-9P, Glycine,
N-(3-fluorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-17-0P, Glycine,
N-(3-chloro-4-fluorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-18-1P, Glycine,
N-(3-ethoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-19-2P, Glycine,
N-[(5-chloro-2-thienyl)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-20-5P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-(methylthio)-2-thienyl]carbonyl]- 331743-21-6P, Glycine,
N-[(4-methylphenyl)acetyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-22-7P, Glycine,
N-[(3-fluorophenyl)acetyl]-N-[[3-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]phenyl)methyl]- 331743-23-8P, Glycine,
N-[(3,5-difluorophenyl)acetyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331743-24-9P, Glycine,
N-(1,3-benzodioxol-5-ylacetyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331743-25-0P, Glycine,
N-[(4-ethoxyphenyl)acetyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331743-26-1P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3-nitrophenyl)acetyl]- 331743-27-2P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-nitrophenyl)acetyl]- 331743-28-3P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(1-oxo-3-phenylpropyl)- 331743-29-4P, Glycine, N-([1,1'-biphenyl]-2-ylcarbonyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331743-30-7P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(4-phenoxybenzoyl)- 331743-31-8P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[2-(phenylmethyl)benzoyl]- 331743-32-9P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[3-(phenylsulfinyl)benzoyl]- 331743-33-0P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[2-(4-methylphenyl)thio]benzoyl]- 331743-34-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[2-(phenylsulfinyl)benzoyl]- 331743-35-2P, Glycine, N-(5-chloro-2-phenoxybenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331743-36-3P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(2-phenoxybenzoyl)- 331743-37-4P, Glycine, N-([1,1'-biphenyl]-4-ylcarbonyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331743-38-5P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(3-phenoxybenzoyl)- 331743-39-6P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2-phenoxyphenyl)acetyl]- 331743-40-9P, Glycine, N-([1,1'-biphenyl]-4-ylacetyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331743-41-0P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[4-(phenylmethyl)benzoyl]- 331743-42-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[2-(1H-pyrrol-1-yl)benzoyl]- 331743-43-2P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-phenoxyphenyl)acetyl]- 331743-44-3P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3-phenoxyphenyl)acetyl]- 331743-45-4P, Glycine, N-([2,2'-bithiophen]-5-ylcarbonyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331743-46-5P, Glycine, N-(3,4-dimethylbenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331743-47-6P, Glycine, N-(4-chloro-3-methylbenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331743-48-7P, Glycine, N-(3,4-difluorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331743-49-8P, Glycine, N-(3,4-dichlorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331743-50-1P, Glycine, N-(3-chlorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331743-51-2P, Glycine, N-(4-chlorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331743-52-3P, Glycine, N-(3-chloro-4-fluorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331743-53-4P, Glycine,

N-[4-(1-methylethyl)benzoyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-54-5P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[4-(2-methylpropyl)benzoyl]- 331743-55-6P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(4-propoxybenzoyl)- 331743-56-7P, Glycine, N-(4-butylbenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-57-8P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-(methylthio)-2-thienyl]carbonyl]-
331743-58-9P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethyl)amino]carbonyl]-
331743-59-0P, Glycine, N-[[4-(methoxyphenyl)amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-60-3P, Glycine, N-[[4-(methoxyphenyl)methylamino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-61-4P, Glycine, N-[[1,1'-biphenyl]-4-ylamino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-62-5P, Glycine, N-[[3,5-dimethoxyphenyl]amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-63-6P, Glycine, N-[[3,5-dichlorophenyl]amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-64-7P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-(methylthio)phenyl]amino]carbonyl]-
331743-65-8P, Glycine, N-[[2,4-difluorophenyl]amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-66-9P, Glycine, N-[[2,4-dimethoxyphenyl]amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-67-0P, Glycine, N-[[2-methoxyphenyl]amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-68-1P, Glycine, N-[[1,1'-biphenyl]-4-ylamino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-69-2P, Glycine, N-[[3,5-dimethoxyphenyl]amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-70-5P, Glycine, N-[[3,5-dichlorophenyl]amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-71-6P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-(methylthio)phenyl]amino]carbonyl]-
331743-72-7P, Glycine, N-[[2,4-difluorophenyl]amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-73-8P, Glycine, N-[[2,4-dimethoxyphenyl]amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-74-9P, Glycine, N-[[4-(methoxyphenyl)amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-75-0P, Glycine, N-[[2-methoxyphenyl]amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-76-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(1-naphthalenylsulfonyl)-
331743-77-2P, Glycine, N-[[4-(fluorophenyl)methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
331743-78-3P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenylsulfonyl)- 331743-79-4P,
Glycine, N-[[2,5-dichlorophenyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-80-7P, Glycine,
N-[[4-(fluorophenyl)sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-81-8P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethyl)sulfonyl]- 331743-82-9P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[1E)-2-phenylethenyl]sulfonyl]- 331743-83-0P, Glycine,

N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2,2,2-trifluoroethyl)sulfonyl]- **331743-84-1P**, Glycine,

N-[(2,5-dimethylphenyl)sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331743-85-2P**, Glycine,

N-[(3,4-dichlorophenyl)sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331743-86-3P**, Glycine,


N-[(2,5-dichloro-3-thienyl)sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)


RN 331741-75-4 HCAPLUS

CN Glycine, N-[[4-(1-methylethyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-76-5 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylmethyl)phenoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-77-6 HCAPLUS

CN Glycine, N-[(4-ethylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-78-7 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-propylphenoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-79-8 HCAPLUS

CN Glycine, N-[[[2,3-dihydro-1H-inden-5-yl]oxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-80-1 HCAPLUS

CN Glycine, N-[(3-ethoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-81-2 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-pentylphenoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-82-3 HCAPLUS

CN Glycine, N-[[4-fluoro-3-(trifluoromethyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-83-4 HCAPLUS

CN Glycine, N-[[[(3-fluorophenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-84-5 HCAPLUS

CN Glycine, N-[[[(3-chlorophenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-85-6 HCAPLUS

CN Glycine, N-[[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[3-(trifluoromethoxy)phenyl]methoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-86-7 HCAPLUS

CN Glycine, N-[[[(4-fluorophenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-87-8 HCAPLUS

CN Glycine, N-[[[4-chlorophenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331741-88-9 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[[4-(trifluoromethoxy)phenyl)methoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-89-0 HCAPLUS

CN Glycine, N-[[[3,5-dimethoxyphenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331741-90-3 HCAPLUS


CN Glycine, N-[[3-(acetyloxy)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331741-91-4 HCAPLUS


CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-
[[3-phenoxyphenyl)methoxy]carbonyl]- (9CI) (CA INDEX NAME)

RN 331741-92-5 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-
[(2-propynyloxy)carbonyl]- (9CI) (CA INDEX NAME)


RN 331741-93-6 HCAPLUS

CN Glycine, N-[(4-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-94-7 HCAPLUS

CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-95-8 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-nitrophenoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-96-9 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenoxycarbonyl)- (9CI) (CA INDEX NAME)




RN 331741-97-0 HCAPLUS


CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[4-nitrophenyl]methoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-98-1 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-
[[4-nitrophenoxy]carbonyl]- (9CI) (CA INDEX NAME)

RN 331741-99-2 HCAPLUS


CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-
[[4-phenoxyphenoxy]carbonyl]- (9CI) (CA INDEX NAME)

RN 331742-00-8 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-
[[2-phenoxyphenyl]methoxy]carbonyl]- (9CI) (CA INDEX NAME)


RN 331742-01-9 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-
[[4-phenoxyphenyl]methoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331742-02-0 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-phenoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331742-03-1 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-phenoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)



RN 331742-04-2 HCAPLUS


CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-phenoxyethoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331742-05-3 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-
[[[(2E)-3-phenyl-2-propenyl]oxy]carbonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331742-06-4 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-
[[[3-phenyl-2-propynyl]oxy]carbonyl]- (9CI) (CA INDEX NAME)


RN 331742-07-5 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-
[(2-phenylethoxy)carbonyl]- (9CI) (CA INDEX NAME)



RN 331742-08-6 HCAPLUS


CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-phenylpropoxy]carbonyl]- (9CI) (CA INDEX NAME)



RN 331742-09-7 HCAPLUS


CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[(2Z)-3-phenyl-2-propenyl]oxy]carbonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331742-10-0 HCAPLUS

CN Glycine, N-[(2-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-11-1 HCAPLUS

CN Glycine, N-[(3-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-12-2 HCAPLUS

CN Glycine, N-[(3,4-dimethoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-13-3 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3,4,5-trimethoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331742-14-4 HCAPLUS

CN Glycine, N-[(3-acetylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-15-5 HCAPLUS

CN Glycine, N-[[4-methoxyphenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331742-16-6 HCAPLUS

CN Glycine, N-[(1,3-benzodioxol-5-ylmethoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331742-17-7 HCAPLUS

CN Glycine, N-[(1,3-benzodioxol-5-yloxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331742-18-8 HCAPLUS


CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(trifluoromethoxy)phenoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331742-19-9 HCAPLUS

CN Glycine, N-[[4-methoxy-1-naphthalenyl]oxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 331742-20-2 HCAPLUS


KATHLEEN FULLER EIC 1700 REMSEN 4B28 571/272-2505

CN Glycine, N-[(2,3-dimethoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331742-21-3 HCAPLUS

CN Benzoic acid, 4-[[[(carboxymethyl)[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]amino]carbonyl]oxy]-, 1-methyl ester (9CI) (CA INDEX NAME)




RN 331742-22-4 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(phenylmethoxy)phenoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331742-23-5 HCAPLUS

CN Glycine, N-[(4-hydroxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331742-24-6 HCAPLUS

CN Glycine, N-[(4-bromo-3-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-25-7 HCAPLUS

CN Glycine, N-[(4-fluorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-26-8 HCAPLUS

CN Glycine, N-[(4-chlorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-27-9 HCAPLUS

CN Glycine, N-[(4-bromophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-28-0 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-(trifluoromethoxy)phenoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331742-29-1 HCAPLUS

CN Glycine, N-[(3-fluorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-30-4 HCAPLUS

CN Glycine, N-[(3-chlorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-31-5 HCAPLUS

CN Glycine, N-[(3-bromophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-32-6 HCAPLUS

CN Glycine, N-[(3,5-difluorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-33-7 HCAPLUS

CN Glycine, N-[(3-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331742-34-8 HCAPLUS


CN Glycine, N-[(3-chloro-4-fluorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331742-35-9 HCAPLUS


CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-

[(3,4,5-trimethoxyphenyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 331742-36-0 HCAPLUS

CN Glycine, N-[(4-chloro-3,5-dimethoxyphenyl)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-37-1 HCAPLUS

CN Glycine, N-[(3,4-difluorophenyl)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-38-2 HCAPLUS

CN Glycine, N-[(4-ethenylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-39-3 HCAPLUS

CN Glycine, N-[(4-fluoro-3-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-40-6 HCAPLUS

CN Glycine, N-[(4-chloro-3-fluorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-41-7 HCAPLUS

CN Glycine, N-[[3-methyl-4-(methylthio)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-42-8 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(1H-pyrrol-1-yl)phenoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331742-43-9 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[5,6,7,8-tetrahydro-2-naphthalenyl]oxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331742-44-0 HCAPLUS

CN Glycine, N-[[[1,1'-biphenyl]-3-yloxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-45-1 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-(trifluoromethyl)phenoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331742-46-2 HCAPLUS

CN Glycine, N-[[3-(1,1-dimethylethyl)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-47-3 HCAPLUS

CN Glycine, N-[[3-(1-methylethyl)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-48-4 HCAPLUS

CN Glycine, N-[(3,4-dimethylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-49-5 HCAPLUS

CN Glycine, N-[(3,5-dimethylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-50-8 HCAPLUS

CN Glycine, N-[(3-ethylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-51-9 HCAPLUS

CN Glycine, N-[(4-chloro-3-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-52-0 HCAPLUS

CN Glycine, N-[[4-(1-methylethyl)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-53-1 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylmethyl)phenoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331742-54-2 HCAPLUS

CN Glycine, N-[(4-ethylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-55-3 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-propylphenoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331742-56-4 HCAPLUS

CN Glycine, N-[[2,3-dihydro-1H-inden-5-yl]oxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331742-57-5 HCAPLUS


CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-naphthalenyloxy)carbonyl]- (9CI) (CA INDEX NAME)



RN 331742-58-6 HCAPLUS


CN Glycine, N-[(3-ethoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331742-59-7 HCAPLUS

CN Glycine, N-[(3,5-dichlorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331742-60-0 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(1,2,3-thiadiazol-4-yl)phenoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331742-61-1 HCAPLUS

CN Glycine, N-[[4-fluoro-3-(trifluoromethyl)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331742-62-2 HCAPLUS

CN Glycine, N-[(3-methoxy-5-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-63-3 HCAPLUS

CN Glycine, N-[[[(3-fluorophenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-64-4 HCAPLUS

CN Glycine, N-[[[(3-chlorophenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-65-5 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[3-(trifluoromethoxy)phenyl]methoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331742-66-6 HCAPLUS

CN Glycine, N-[[[4-(4-fluorophenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-67-7 HCAPLUS

CN Glycine, N-[[[4-(4-chlorophenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-68-8 HCAPLUS

CN Glycine, N-[[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methoxy]carbonyl]-N-[[[4-(trifluoromethoxy)phenyl]methoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331742-69-9 HCAPLUS

CN Glycine, N-[[[3,5-dimethoxyphenyl]methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-70-2 HCAPLUS

CN Glycine, N-[[3-(difluoromethoxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-71-3 HCAPLUS

CN Glycine, N-[[3-(difluoromethoxy)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-72-4 HCAPLUS

CN Glycine, N-[(3-hydroxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-73-5 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenoxythioxomethyl)- (9CI) (CA INDEX NAME)




RN 331742-74-6 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenoxythioxomethyl)- (9CI) (CA INDEX NAME)




RN 331742-75-7 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(4-phenoxybenzoyl)- (9CI) (CA INDEX NAME)




RN 331742-76-8 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-naphthalenylcarbonyl)- (9CI) (CA INDEX NAME)




RN 331742-77-9 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-thienylcarbonyl)- (9CI) (CA INDEX NAME)




RN 331742-78-0 HCAPLUS

CN Glycine, N-(3,5-dimethoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-79-1 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(1-naphthalenylcarbonyl)- (9CI) (CA INDEX NAME)




RN 331742-80-4 HCAPLUS

CN Glycine, N-(3,4-difluorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-81-5 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(3-phenoxybenzoyl)- (9CI) (CA INDEX NAME)




RN 331742-82-6 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[4-(phenylmethyl)benzoyl]- (9CI) (CA INDEX NAME)




RN 331742-83-7 HCAPLUS

CN Glycine, N-(3,5-dimethylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-84-8 HCAPLUS

CN Glycine, N-([2,2'-bithiophen]-5-ylcarbonyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-85-9 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(5-methyl-2-thienyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 331742-86-0 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(5-nitro-2-thienyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 331742-87-1 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-methyl-2-thienyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 331742-88-2 HCAPLUS

CN Glycine, N-(4-butoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-89-3 HCAPLUS

CN Glycine, N-(4-methoxy-3-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-90-6 HCAPLUS

CN Glycine, N-(3-chloro-4-methoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-91-7 HCAPLUS

CN Glycine, N-(3,4-dimethylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-92-8 HCAPLUS

CN Glycine, N-(4-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-93-9 HCAPLUS

CN Glycine, N-(3-fluoro-4-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-94-0 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[4-(methylthio)benzoyl]- (9CI) (CA INDEX NAME)




RN 331742-95-1 HCAPLUS

CN Glycine, N-[4-(1-methylethyl)benzoyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-96-2 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[4-(2-methylpropyl)benzoyl]- (9CI) (CA INDEX NAME)




RN 331742-97-3 HCAPLUS

CN Glycine, N-(4-chloro-3-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-98-4 HCAPLUS

CN Glycine, N-(3-methoxy-4-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-99-5 HCAPLUS

CN Glycine, N-(1,3-benzodioxol-5-ylcarbonyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-00-1 HCAPLUS

CN Glycine, N-[4-(1-methylethoxy)benzoyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-02-3 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(3-thienylcarbonyl)- (9CI) (CA INDEX NAME)




RN 331743-04-5 HCAPLUS

CN Glycine, N-benzoyl-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-05-6 HCAPLUS

CN Glycine, N-(3-methoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-06-7 HCAPLUS

CN Glycine, N-(4-fluorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-07-8 HCAPLUS

CN Glycine, N-(3,4-dichlorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-08-9 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(4-propoxybenzoyl)- (9CI) (CA INDEX NAME)




RN 331743-09-0 HCAPLUS

CN Glycine, N-(4-ethoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-10-3 HCAPLUS

CN Glycine, N-(3-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-11-4 HCAPLUS

CN Glycine, N-(4-methoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-12-5 HCAPLUS

CN Glycine, N-(3-chlorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-13-6 HCAPLUS

CN Glycine, N-(4-chlorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-14-7 HCAPLUS

CN Glycine, N-(4-butylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-15-8 HCAPLUS

CN Glycine, N-(3,5-dichlorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-16-9 HCAPLUS

CN Glycine, N-(3-fluorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-17-0 HCAPLUS

CN Glycine, N-(3-chloro-4-fluorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-18-1 HCAPLUS

CN Glycine, N-(3-ethoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-19-2 HCAPLUS

CN Glycine, N-[(5-chloro-2-thienyl)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-20-5 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-(methylthio)-2-thienyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 331743-21-6 HCAPLUS

CN Glycine, N-[(4-methylphenyl)acetyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-22-7 HCAPLUS

CN Glycine, N-[(3-fluorophenyl)acetyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-23-8 HCAPLUS

CN Glycine, N-[(3,5-difluorophenyl)acetyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-24-9 HCAPLUS

CN Glycine, N-(1,3-benzodioxol-5-ylacetyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-25-0 HCAPLUS

CN Glycine, N-[[4-ethoxyphenyl]acetyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-26-1 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-nitrophenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 331743-27-2 HCAPLUS

CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-nitrophenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 331743-28-3 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(1-oxo-3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 331743-29-4 HCAPLUS

CN Glycine, N-([1,1'-biphenyl]-2-ylcarbonyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-30-7 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(4-phenoxybenzoyl)- (9CI) (CA INDEX NAME)




RN 331743-31-8 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[2-(phenylmethyl)benzoyl]- (9CI) (CA INDEX NAME)




RN 331743-32-9 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[3-(phenylsulfinyl)benzoyl]- (9CI) (CA INDEX NAME)




RN 331743-33-0 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[2-[(4-methylphenyl)thio]benzoyl]- (9CI) (CA INDEX NAME)




RN 331743-34-1 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[2-(phenylsulfinyl)benzoyl]- (9CI) (CA INDEX NAME)




RN 331743-35-2 HCAPLUS

CN Glycine, N-(5-chloro-2-phenoxybenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-36-3 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-phenoxybenzoyl)- (9CI) (CA INDEX NAME)




RN 331743-37-4 HCAPLUS

CN Glycine, N-([1,1'-biphenyl]-4-ylcarbonyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-38-5 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(3-phenoxybenzoyl)- (9CI) (CA INDEX NAME)




RN 331743-39-6 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-phenoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 331743-40-9 HCAPLUS

CN Glycine, N-([1,1'-biphenyl]-4-ylacetyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-41-0 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[4-(phenylmethyl)benzoyl]- (9CI) (CA INDEX NAME)




RN 331743-42-1 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[2-(1H-pyrrol-1-yl)benzoyl]- (9CI) (CA INDEX NAME)




RN 331743-43-2 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 331743-44-3 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-phenoxyphenyl]acetyl]- (9CI) (CA INDEX NAME)




RN 331743-45-4 HCAPLUS

CN Glycine, N-([2,2'-bithiophen]-5-ylcarbonyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-46-5 HCAPLUS

CN Glycine, N-(3,4-dimethylbenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-47-6 HCAPLUS

CN Glycine, N-(4-chloro-3-methylbenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-48-7 HCAPLUS

CN Glycine, N-(3,4-difluorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-49-8 HCAPLUS

CN Glycine, N-(3,4-dichlorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-50-1 HCAPLUS

CN Glycine, N-(3-chlorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-51-2 HCAPLUS

CN Glycine, N-(4-chlorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-52-3 HCAPLUS

CN Glycine, N-(3-chloro-4-fluorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-53-4 HCAPLUS

CN Glycine, N-[4-(1-methylethyl)benzoyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331743-54-5 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[4-(2-methylpropyl)benzoyl]- (9CI) (CA INDEX NAME)



RN 331743-55-6 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(4-